

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/010956 A2

(51) International Patent Classification⁷: **A61K**

(74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, PA 19103 (US).

(21) International Application Number:
PCT/US2003/023994

(22) International Filing Date: 31 July 2003 (31.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/210,838 31 July 2002 (31.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MONIA, Brett, P.** [US/US]; 2306 Casa Hermosa Ct., Encinitas, CA 92024 (US). **BHANOT, Sanjay** [CA/US]; 7975 Paseo Aliso, Carlsbad, CA 92009 (US). **DOBIE, Kenneth, W.** [GB/US]; 703 Stratford Ct. #4, Del Mar, CA 92014 (US). **FREIER, Susan, M.** [US/US]; 2946 Renault Street, San Diego, CA 92122 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF LAR EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of LAR. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids LAR. Methods of using these compounds for modulation of LAR expression and for treatment of diseases associated with expression of LAR are provided.



WO 2004/010956 A2

5

ANTISENSE MODULATION OF LAR EXPRESSION**FIELD OF THE INVENTION**

10 The present invention provides compositions and methods
for modulating the expression of LAR. In particular, this
invention relates to compounds, particularly
oligonucleotides, specifically hybridizable with nucleic
acids encoding LAR. Such compounds have been shown to
15 modulate the expression of LAR.

BACKGROUND OF THE INVENTION

 The process of phosphorylation, defined as the
attachment of a phosphate moiety to a biological molecule
20 through the action of enzymes called kinases, represents one
course by which intracellular signals are propagated
resulting finally in a cellular response. Within the cell,
proteins can be phosphorylated on serine, threonine or
tyrosine residues and the extent of phosphorylation is
25 regulated by the opposing action of phosphatases, which
remove the phosphate moieties. While the majority of protein
phosphorylation within the cell is on serine and threonine
residues, tyrosine phosphorylation is modulated to the
greatest extent during oncogenic transformation and growth
30 factor stimulation (Zhang, *Critical Review in Biochemistry
and Molecular Biology*, **1998**, 33, 1-52).

-2-

Because phosphorylation is such a ubiquitous process within cells and because cellular phenotypes are largely influenced by the activity of these pathways, it is currently believed that a number of disease states and/or disorders are a result of either aberrant activation of, or functional mutations in, kinases and phosphatases. Consequently, considerable attention has been devoted recently to the characterization of tyrosine kinases and tyrosine phosphatases.

10 Leukocyte antigen-related phosphatase (LAR, also known as protein tyrosine phosphatase, receptor type F; PTPRF and LCA-homolog) is a prototype for a family of transmembrane phosphatases whose extracellular regions are composed of a combination of immunoglobulin-like domains and fibronectin type III (Fn-III) domains (Streuli et al., *Embo J.*, **1992**, 11, 897-907.; Streuli et al., *J. Exp. Med.*, **1988**, 168, 1523-1530). LAR was first cloned in 1988 and mapped to chromosome 1p32-33 in 1992 (Streuli et al., *Embo J.*, **1992**, 11, 897-907.; Streuli et al., *J. Exp. Med.*, **1988**, 168, 1523-1530). It is expressed in cells of many different lineages including epithelial cells, smooth muscle cells and cardiac myocytes (Streuli et al., *Embo J.*, **1992**, 11, 897-907.). It is synthesized as a precursor with a molecular weight above 200 kDa which is cleaved by an endogenous protease into two subunits (150 and 85 kDa) that remain non-covalently attached (Streuli et al., *Embo J.*, **1992**, 11, 897-907.).

Alternative splicing of LAR has been observed in sections of mRNA encoding the FN-III domains 4,5,6 and 7 in various combinations (O'Grady et al., *J. Biol. Chem.*, **1994**, 269, 25193-25199). An alternatively-spliced 11 amino acid proximal membrane segment of LAR (LAR alternatively spliced element-a; LASE-a) has been shown to contribute to regulation of LAR expression and function during neurite development

-3-

(Honkaniemi et al., *Brain Res. Mol. Brain Res.*, **1998**, 60, 1-12). Increased levels of LAR expression and differential patterns of extracellular alternative splicing were found in breast cancer cell lines and pheochromocytoma tumor tissue
5 (Yang et al., *Carcinogenesis*, **2000**, 21, 125-131; Yang et al., *Mol. Carcinog.*, **1999**, 25, 139-149).

LAR has emerged as an important candidate enzyme for the regulation of the insulin receptor because it is widely expressed in insulin-sensitive tissues and its cytoplasmic
10 domain has a catalytic preference for the regulatory phosphotyrosines of the insulin receptor kinase domain *in vitro* (Goldstein et al., *Mol. Cell. Biochem.*, **1998**, 182, 91-99).

Overexpression of LAR in a variety of mammalian cells
15 induces cell death without affecting cell adhesion. This suggests that LAR may activate the caspase pathway and induce cell death directly (Weng et al., *Curr. Biol.*, **1998**, 8, 247-256).

Enhanced expression of LAR has been observed in corneal
20 cells with keratoconus, a corneal thinning disorder that leads to irregular astigmatism and corneal distortion (Chiplunkar et al., *Exp. Eye Res.*, **1999**, 68, 283-293).

The involvement of LAR in cell signaling events make it a potentially useful therapeutic target for intervention in
25 hyperproliferative disorders, metabolic disorders and disorders arising from aberrant apoptosis.

Small molecule inhibitors of tyrosine phosphatases exist in the art. For example, disclosed and claimed in US patent 6,169,087 are small molecule inhibitors of protein tyrosine
30 phosphatases for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and a number of other diseases (Andersen et al., **2001**).

-4-

Disclosed and claimed in PCT publication WO 00/61180 is a method for identifying indolinones, quinazolines, quinoxalines and tyrphostins that modulate LAR activity (Ullrich and Muller, 2000).

5 O'Grady et al. have shown that anti-LAR antibodies inhibit the interaction of LAR with the laminin-nidogen complex and have determined that binding of LAR to laminin-nidogen may play a role in regulating cell signaling because inhibition of this interaction causes cell morphological
10 changes (O'Grady et al., *J. Cell Biol.*, **1998**, 141, 1675-1684).

LAR antisense vectors have been used to inhibit LAR in investigations of the effects of LAR expression on insulin receptor signaling and apolipoprotein B metabolism in rat
15 hepatoma cells (Kulas et al., *J. Biol. Chem.*, **1995**, 270, 2435-2438.; Mooney et al., *Biochem. Biophys. Res. Commun.*, **1997**, 235, 709-712; Phung et al., *Biochem. Biophys. Res. Commun.*, **1997**, 237, 367-371) and apoptosis in rat PC12 cells (Tisi et al., *J. Neurobiol.*, **2000**, 42, 477-486).

20 To date, investigative strategies aimed at modulating LAR function have involved the use of small molecule inhibitors, antibodies and antisense LAR vectors. However, these strategies have yet to be tested as therapeutic protocols. Consequently, there remains a long felt need for
25 agents capable of effectively inhibiting LAR function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the
30 modulation of LAR expression.

The present invention provides compositions and methods for modulating LAR expression.

-5-

SUMMARY OF THE INVENTION

The present invention is directed to compounds,
5 particularly antisense oligonucleotides, which are targeted
to a nucleic acid encoding LAR, and which modulate the
expression of LAR. Pharmaceutical and other compositions
comprising the compounds of the invention are also provided.
Further provided are methods of modulating the expression of
10 LAR in cells or tissues comprising contacting said cells or
tissues with one or more of the antisense compounds or
compositions of the invention. Further provided are methods
of treating an animal, particularly a human, suspected of
having or being prone to a disease or condition associated
15 with expression of LAR by administering a therapeutically or
prophylactically effective amount of one or more of the
antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention employs oligomeric compounds,
particularly antisense oligonucleotides, for use in
modulating the function of nucleic acid molecules encoding
LAR, ultimately modulating the amount of LAR produced. This
is accomplished by providing antisense compounds which
25 specifically hybridize with one or more nucleic acids
encoding LAR. As used herein, the terms "target nucleic
acid" and "nucleic acid encoding LAR" encompass DNA encoding
LAR, RNA (including pre-mRNA and mRNA) transcribed from such
DNA, and also cDNA derived from such RNA. The specific
30 hybridization of an oligomeric compound with its target
nucleic acid interferes with the normal function of the
nucleic acid. This modulation of function of a target
nucleic acid by compounds which specifically hybridize to it

-6-

is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of LAR. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding LAR. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the

-7-

translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding LAR, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon

-8-

region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

5 The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region
10 (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region
15 (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an
20 N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target
25 region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions
30 are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is

-9-

implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". It has also been found that introns can be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

10 It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic regions.

Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop

-10-

codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the
5 "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently
10 well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary
15 nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain
20 position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are
25 complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of
30 complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100%

-11-

complementary to that of its target nucleic acid to be specifically hybridizable.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed. It is preferred that the antisense compounds of the present invention comprise at least 80% sequence complementarity to a target region within the target nucleic acid, moreover that they comprise 90% sequence complementarity and even more comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., *J. Mol. Biol.*, **1990**, 215, 403-410; Zhang and Madden, *Genome Res.*, **1997**, 7, 649-656).

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The sites to which these preferred antisense compounds are specifically

-12-

hybridizable are hereinbelow referred to as "preferred target regions" and are therefore preferred sites for targeting. As used herein the term "preferred target region" is defined as at least an 8-nucleobase portion of a target region to which
5 an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target regions represent regions of the target nucleic acid which are accessible for hybridization.

While the specific sequences of particular preferred
10 target regions are set forth below, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred target regions may be identified by one having ordinary skill.

15 Target regions 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target regions are considered to be suitable preferred target regions as well.

20 Exemplary good preferred target regions include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning
25 immediately upstream of the 5'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly good preferred target regions are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of
30 the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target region and continuing until the DNA or RNA

-13-

contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred target regions illustrated herein will be able, without undue experimentation, to identify further preferred target regions. In addition, one having ordinary skill in the art will also be able to identify additional compounds, including oligonucleotide probes and primers, that specifically hybridize to these preferred target regions using techniques available to the ordinary practitioner in the art.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or

-14-

unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, **2000**, 480, 17-24; Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, **2000**, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, **1999**, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, **2000**, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Jungblut, et al., *Electrophoresis*, **1999**, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Larsson, et al., *J. Biotechnol.*, **2000**, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, **2000**, 286, 91-98; Larson, et al., *Cytometry*, **2000**, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, **2000**, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, **1998**, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, **1999**, 35, 1895-904) and mass spectrometry methods (reviewed in To, *Comb. Chem. High Throughput Screen*, **2000**, 3, 235-41).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus

-15-

established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

5 In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and
10 covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example,
15 enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

 While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not
20 limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). Particularly preferred antisense compounds are
25 antisense oligonucleotides from about 8 to about 50 nucleobases, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic
30 oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

 Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive

-16-

nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are herein identified as preferred embodiments of the invention. While specific sequences of the antisense compounds are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the

-17-

scope of the present invention. Additional preferred antisense compounds may be identified by one having ordinary skill.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. In addition, linear structures may also have internal nucleobase complementarity and may therefore fold in a manner as to produce a double stranded structure. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom

-18-

in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, 5 phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, 10 thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' 15 to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed 20 salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 25 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are 30 commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are

-19-

formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These
5 include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene
10 containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the
15 preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
20 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

25 In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such
30 oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an

-20-

amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States
5 patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

10 Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-
15 N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino
20 backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-,
25 S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are
O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂,
30 and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl,

-21-

O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909;

-22-

5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873;
5,670,633; 5,792,747; and 5,700,920, certain of which are
commonly owned with the instant application, and each of
which is herein incorporated by reference in its entirety.

5 A further preferred modification includes Locked Nucleic
Acids (LNAs) in which the 2'-hydroxyl group is linked to the
3' or 4' carbon atom of the sugar ring thereby forming a
bicyclic sugar moiety. The linkage is preferably a methylene
(-CH₂-)_n group bridging the 2' oxygen atom and the 4' carbon
10 atom wherein n is 1 or 2. LNAs and preparation thereof are
described in WO 98/39352 and WO 99/14226.

Oligonucleotides may also include nucleobase (often
referred to in the art simply as "base") modifications or
substitutions. As used herein, "unmodified" or "natural"
15 nucleobases include the purine bases adenine (A) and guanine
(G), and the pyrimidine bases thymine (T), cytosine (C) and
uracil (U). Modified nucleobases include other synthetic and
natural nucleobases such as 5-methylcytosine (5-me-C), 5-
hydroxymethyl cytosine, xanthine, hypoxanthine, 2-
20 aminoadenine, 6-methyl and other alkyl derivatives of adenine
and guanine, 2-propyl and other alkyl derivatives of adenine
and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine,
5-halouracil and cytosine, 5-propynyl (-C≡C-CH₃) uracil and
cytosine and other alkynyl derivatives of pyrimidine bases,
25 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil),
4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-
hydroxyl and other 8-substituted adenines and guanines, 5-
halo particularly 5-bromo, 5-trifluoromethyl and other 5-
substituted uracils and cytosines, 7-methylguanine and 7-
30 methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and
8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-
deazaguanine and 3-deazaadenine. Further modified
nucleobases include tricyclic pyrimidines such as phenoxazine

-23-

cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),
phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-
2(3H)-one), G-clamps such as a substituted phenoxazine
cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-
5 b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-
pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-
pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified
nucleobases may also include those in which the purine or
pyrimidine base is replaced with other heterocycles, for
10 example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine
and 2-pyridone. Further nucleobases include those disclosed
in United States Patent No. 3,687,808, those disclosed in *The
Concise Encyclopedia Of Polymer Science And Engineering*,
pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, **1990**,
15 those disclosed by Englisch *et al.*, *Angewandte Chemie*,
International Edition, **1991**, 30, 613, and those disclosed by
Sanghvi, Y.S., Chapter 15, *Antisense Research and
Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. ,
ed., CRC Press, **1993**. Certain of these nucleobases are
20 particularly useful for increasing the binding affinity of
the oligomeric compounds of the invention. These include 5-
substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-
6 substituted purines, including 2-aminopropyladenine, 5-
propynyluracil and 5-propynylcytosine. 5-methylcytosine
25 substitutions have been shown to increase nucleic acid duplex
stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and
Lebleu, B., eds., *Antisense Research and Applications*, CRC
Press, Boca Raton, **1993**, pp. 276-278) and are presently
preferred base substitutions, even more particularly when
30 combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the
preparation of certain of the above noted modified
nucleobases as well as other modified nucleobases include,

-24-

but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent

-25-

Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference.

Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al.,
5 *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a
10 thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a
15 phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al.,
20 *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937). Oligonucleotides
25 of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic
30 acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepam, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug

-26-

conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to

-27-

confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide
5 may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the
10 efficiency of oligonucleotide inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as interferon-induced RNaseL which cleaves both cellular and viral RNA. Consequently, comparable results can often be
15 obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid
20 hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such
25 compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065;
30 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this

-28-

invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other
5 means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The compounds of the invention may also be admixed,
10 encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative
15 United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556;
20 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

25 The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite
30 or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

-29-

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin *et al.*, published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach *et al.*

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge *et al.*, "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free

-30-

acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those

-31-

skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of
5 pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with
10 inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid,
15 palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

20 The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of LAR is
25 treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the
30 antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for

-32-

research and diagnostics, because these compounds hybridize to nucleic acids encoding LAR, enabling sandwich and other assays to easily be constructed to exploit this fact.

Hybridization of the antisense oligonucleotides of the

5 invention with a nucleic acid encoding LAR can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of LAR in
10 a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of
15 ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including
20 by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular,
25 administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments,
30 lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like

-33-

may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

-34-

Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include

5 fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid,

10 taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid,

15 dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for

20 example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the

25 invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates;

30 cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred

-35-

complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino),
5 poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-
10 lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed
15 February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include
20 sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention
25 include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

30 The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques

-36-

include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in

-37-

diameter (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 301).

10 Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as

15 minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w)

20 emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-

25 oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often

30 provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed

-38-

in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., **1988**, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in

-39-

Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion
5 formulations include lanolin, beeswax, phosphatides, lecithin
and acacia. Absorption bases possess hydrophilic properties
such that they can soak up water to form w/o emulsions yet
retain their semisolid consistencies, such as anhydrous
lanolin and hydrophilic petrolatum. Finely divided solids
10 have also been used as good emulsifiers especially in
combination with surfactants and in viscous preparations.
These include polar inorganic solids, such as heavy metal
hydroxides, nonswelling clays such as bentonite, attapulgite,
hectorite, kaolin, montmorillonite, colloidal aluminum
15 silicate and colloidal magnesium aluminum silicate, pigments
and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also
included in emulsion formulations and contribute to the
properties of emulsions. These include fats, oils, waxes,
20 fatty acids, fatty alcohols, fatty esters, humectants,
hydrophilic colloids, preservatives and antioxidants (Block,
in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker
(Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1,
p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman,
25 Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New
York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally
occurring gums and synthetic polymers such as polysaccharides
(for example, acacia, agar, alginic acid, carrageenan, guar
30 gum, karaya gum, and tragacanth), cellulose derivatives (for
example, carboxymethylcellulose and carboxypropylcellulose),
and synthetic polymers (for example, carbomers, cellulose
ethers, and carboxyvinyl polymers). These disperse or swell

-40-

in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

5 Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include
10 methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as
15 tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via
20 dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery
25 have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in
30 *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins

-41-

and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system.

Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., **1989**, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*,

-42-

Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, 5 p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions 10 include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), 15 decaglycerol monocaprates (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to 20 increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying 25 microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, 30 materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated

-43-

polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers

-44-

to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

-45-

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been

-46-

administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

-47-

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of
5 interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, **1992**, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon
10 using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, **1992**, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin,
15 in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to
20 deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, **1994**, 4, 6, 466).

25 Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized
30 lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as

-48-

monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least
5 for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*,
10 **1987**, 223, 42; Wu et al., *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and
15 phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the
20 ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

25 Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety.
30 Illum et al. (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of

-49-

carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising
5 phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the
10 combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and
15 methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No.
20 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further
25 derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to
30 Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in

-50-

liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general

-51-

their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

10 If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

20 If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

25 If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

30 The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical*

-52-

Dosage Forms, Marcel Dekker, Inc., New York, NY, **1988**, p. 285).

Penetration Enhancers

5 In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or
10 lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration
15 enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug*
20 *Carrier Systems*, **1991**, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention,
25 surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the
30 mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews*

-53-

in *Therapeutic Drug Carrier Systems*, **1991**, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, **1988**, 40, 252).

Fatty acids: Various fatty acids and their derivatives
5 which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid,
10 arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate,
15 etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, **1992**, 44, 651-654).

20 Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, **1996**, pp. 934-935).
25 Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its
30 pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid

-54-

(sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, **1990**, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25; Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

15 Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With
20 regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*,
25 **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and
30 *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic*

-55-

Drug Carrier Systems, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-
5 chelating non-surfactant penetration enhancing compounds can
be defined as compounds that demonstrate insignificant
activity as chelating agents or as surfactants but that
nonetheless enhance absorption of oligonucleotides through
the alimentary mucosa (Muranishi, *Critical Reviews in*
10 *Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class
of penetration enhancers include, for example, unsaturated
cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone
derivatives (Lee et al., *Critical Reviews in Therapeutic Drug*
Carrier Systems, **1991**, page 92); and non-steroidal anti-
15 inflammatory agents such as diclofenac sodium, indomethacin
and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*,
1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the
cellular level may also be added to the pharmaceutical and
20 other compositions of the present invention. For example,
cationic lipids, such as lipofectin (Junichi et al, U.S.
Patent No. 5,705,188), cationic glycerol derivatives, and
polycationic molecules, such as polylysine (Lollo et al., PCT
Application WO 97/30731), are also known to enhance the
25 cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration
of the administered nucleic acids, including glycols such as
ethylene glycol and propylene glycol, pyrrols such as 2-
pyrrol, azones, and terpenes such as limonene and menthone.

30

Carriers

Certain compositions of the present invention also
incorporate carrier compounds in the formulation. As used

-56-

herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (*e.g.*, pregelatinized maize starch, polyvinylpyrrolidone or

-57-

hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g.,
5 magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium
10 lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention.
15 Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

20 Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other
25 suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include,
30 but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin,

-58-

hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

5 The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible,
10 pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes,
15 flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and,
20 if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the
25 formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

30 Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense

-59-

mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine
5 arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil,
10 methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramidate, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine,
15 taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. **1987**, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with
20 the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-
25 FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir,
30 may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., **1987**, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense

-60-

chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance

-61-

doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred
5 embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

-62-

EXAMPLES**Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. ChemGenes, Needham MA or Glen Research, Inc. Sterling VA).

10 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, optimized synthesis cycles were developed that incorporate multiple steps coupling longer
15 wait times relative to standard synthesis cycles.

The following abbreviations are used in the text: thin layer chromatography (TLC), melting point (MP), high pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), argon (Ar), methanol (MeOH), dichloromethane (CH₂Cl₂),
20 triethylamine (TEA), dimethyl formamide (DMF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF).

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-dC) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21,
25 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) or prepared as follows:

**Preparation of 5'-O-Dimethoxytrityl-thymidine intermediate
30 for 5-methyl dC amidite**

To a 50 L glass reactor equipped with air stirrer and Ar gas line was added thymidine (1.00 kg, 4.13 mol) in anhydrous pyridine (6 L) at ambient temperature. Dimethoxytrityl (DMT)

-63-

chloride (1.47 kg, 4.34 mol, 1.05 eq) was added as a solid in four portions over 1 h. After 30 min, TLC indicated approx. 95% product, 2% thymidine, 5% DMT reagent and by-products and 2 % 3',5'-bis DMT product (R_f in EtOAc 0.45, 0.05, 0.98, 0.95 respectively). Saturated sodium bicarbonate (4 L) and CH_2Cl_2 were added with stirring (pH of the aqueous layer 7.5). An additional 18 L of water was added, the mixture was stirred, the phases were separated, and the organic layer was transferred to a second 50 L vessel. The aqueous layer was extracted with additional CH_2Cl_2 (2 x 2 L). The combined organic layer was washed with water (10 L) and then concentrated in a rotary evaporator to approx. 3.6 kg total weight. This was redissolved in CH_2Cl_2 (3.5 L), added to the reactor followed by water (6 L) and hexanes (13 L). The mixture was vigorously stirred and seeded to give a fine white suspended solid starting at the interface. After stirring for 1 h, the suspension was removed by suction through a 1/2" diameter teflon tube into a 20 L suction flask, poured onto a 25 cm Coors Buchner funnel, washed with water (2 x 3 L) and a mixture of hexanes- CH_2Cl_2 (4:1, 2x3 L) and allowed to air dry overnight in pans (1" deep). This was further dried in a vacuum oven (75°C, 0.1 mm Hg, 48 h) to a constant weight of 2072 g (93%) of a white solid, (mp 122-124°C). TLC indicated a trace contamination of the bis DMT product. NMR spectroscopy also indicated that 1-2 mole percent pyridine and about 5 mole percent of hexanes was still present.

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal

-64-

thermometer and an Ar gas line was added 5'-O-dimethoxytrityl-thymidine (3.00 kg, 5.51 mol), anhydrous acetonitrile (25 L) and TEA (12.3 L, 88.4 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (2.1 L, 16.5 mol, 3.0 eq) was added over 30 minutes while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition. The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc-hexanes 4:1; R_f 0.43 to 0.84 of starting material and silyl product, respectively). Upon completion, triazole (3.05 kg, 44 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (1035 mL, 11.1 mol, 2.01 eq) was added over 60 min so as to maintain the temperature between -20°C and -10°C during the strongly exothermic process, followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h. TLC indicated a complete conversion to the triazole product (R_f 0.83 to 0.34 with the product spot glowing in long wavelength UV light). The reaction mixture was a peach-colored thick suspension, which turned darker red upon warming without apparent decomposition. The reaction was cooled to -15°C internal temperature and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The combined water layers were back-extracted with EtOAc (6 L). The water layer was discarded and the organic

-65-

layers were concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The second half of the reaction was treated in the same way. Each residue was dissolved in dioxane (3 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight (although the reaction is complete within 1 h).

TLC indicated a complete reaction (product R_f 0.35 in EtOAc-MeOH 4:1). The reaction solution was concentrated on a rotary evaporator to a dense foam. Each foam was slowly redissolved in warm EtOAc (4 L; 50°C), combined in a 50 L glass reactor vessel, and extracted with water (2 x 4L) to remove the triazole by-product. The water was back-extracted with EtOAc (2 L). The organic layers were combined and concentrated to about 8 kg total weight, cooled to 0°C and seeded with crystalline product. After 24 hours, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc (3 x 3L) until a white powder was left and then washed with ethyl ether (2 x 3L). The solid was put in pans (1" deep) and allowed to air dry overnight. The filtrate was concentrated to an oil, then redissolved in EtOAc (2 L), cooled and seeded as before. The second crop was collected and washed as before (with proportional solvents) and the filtrate was first extracted with water (2 x 1L) and then concentrated to an oil. The residue was dissolved in EtOAc (1 L) and yielded a third crop which was treated as above except that more washing was required to remove a yellow oily layer.

After air-drying, the three crops were dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to a constant weight (1750, 600

-66-

and 200 g, respectively) and combined to afford 2550 g (85%) of a white crystalline product (MP 215-217°C) when TLC and NMR spectroscopy indicated purity. The mother liquor still contained mostly product (as determined by TLC) and a small amount of triazole (as determined by NMR spectroscopy), bis DMT product and unidentified minor impurities. If desired, the mother liquor can be purified by silica gel chromatography using a gradient of MeOH (0-25%) in EtOAc to further increase the yield.

10

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-N4-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite

Crystalline 5'-O-dimethoxytrityl-5-methyl-2'-deoxycytidine (2000 g, 3.68 mol) was dissolved in anhydrous DMF (6.0 kg) at ambient temperature in a 50 L glass reactor vessel equipped with an air stirrer and argon line. Benzoic anhydride (Chem Impex not Aldrich, 874 g, 3.86 mol, 1.05 eq) was added and the reaction was stirred at ambient temperature for 8 h. TLC (CH₂Cl₂-EtOAc; CH₂Cl₂-EtOAc 4:1; R_f 0.25) indicated approx. 92% complete reaction. An additional amount of benzoic anhydride (44 g, 0.19 mol) was added. After a total of 18 h, TLC indicated approx. 96% reaction completion. The solution was diluted with EtOAc (20 L), TEA (1020 mL, 7.36 mol, ca 2.0 eq) was added with stirring, and the mixture was extracted with water (15 L, then 2 x 10 L). The aqueous layer was removed (no back-extraction was needed) and the organic layer was concentrated in 2 x 20 L rotary evaporator flasks until a foam began to form. The residues were coevaporated with acetonitrile (1.5 L each) and dried (0.1 mm Hg, 25°C, 24 h) to 2520 g of a dense foam. High pressure liquid chromatography (HPLC) revealed a

-67-

contamination of 6.3% of N⁴, 3'-O-dibenzoyl product, but very little other impurities.

The product was purified by Biotage column chromatography (5 kg Biotage) prepared with 65:35:1 hexanes-EtOAc-TEA (4L). The crude product (800 g), dissolved in CH₂Cl₂ (2 L), was applied to the column. The column was washed with the 65:35:1 solvent mixture (20 kg), then 20:80:1 solvent mixture (10 kg), then 99:1 EtOAc:TEA (17kg). The fractions containing the product were collected, and any fractions containing the product and impurities were retained to be resubjected to column chromatography. The column was re-equilibrated with the original 65:35:1 solvent mixture (17 kg). A second batch of crude product (840 g) was applied to the column as before. The column was washed with the following solvent gradients: 65:35:1 (9 kg), 55:45:1 (20 kg), 20:80:1 (10 kg), and 99:1 EtOAc:TEA (15 kg). The column was reequilibrated as above, and a third batch of the crude product (850 g) plus impure fractions recycled from the two previous columns (28 g) was purified following the procedure for the second batch. The fractions containing pure product combined and concentrated on a 20L rotary evaporator, co-evaporated with acetone (3 L) and dried (0.1 mm Hg, 48 h, 25°C) to a constant weight of 2023 g (85%) of white foam and 20 g of slightly contaminated product from the third run. HPLC indicated a purity of 99.8% with the balance as the diBenzoyl product.

[5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidine (998 g, 1.5 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (300

-68-

ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (15 ml) was added and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2.5 L) and water (600 ml), and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (7.5 L) and hexane (6 L). The two layers were separated, the upper layer was washed with DMF-water (7:3 v/v, 3 x 2 L) and water (3 x 2 L), and the phases were separated. The organic layer was dried (Na₂SO₄), filtered and rotary evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried to a constant weight (25 °C, 0.1mm Hg, 40 h) to afford 1250 g an off-white foam solid (96%).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. The preparation of 2'-fluoropyrimidines containing a 5-methyl substitution are described in US Patent 5,861,493. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-triflate group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the

-69-

THP and N6-benzoyl groups was accomplished using standard methodologies to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

5 **2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate isobutyryl-arabinofuranosylguanosine. Alternatively, isobutyryl-arabinofuranosylguanosine was prepared as described by Ross *et al.*, (Nucleosides & Nucleosides, 16, 1645, **1997**). Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give isobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

20

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

-70-

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites (otherwise known as MOE amidites) are prepared as follows, or alternatively, as per the methods of Martin, P., (Helvetica Chimica Acta, **1995**, 78, 486-504).

Preparation of 2'-O-(2-methoxyethyl)-5-methyluridine intermediate

10 2,2'-Anhydro-5-methyl-uridine (2000 g, 8.32 mol),
tris(2-methoxyethyl)borate (2504 g, 10.60 mol), sodium
bicarbonate (60 g, 0.70 mol) and anhydrous 2-methoxyethanol
(5 L) were combined in a 12 L three necked flask and heated
to 130 °C (internal temp) at atmospheric pressure, under an
15 argon atmosphere with stirring for 21 h. TLC indicated a
complete reaction. The solvent was removed under reduced
pressure until a sticky gum formed (50-85°C bath temp and
100-11 mm Hg) and the residue was redissolved in water (3 L)
and heated to boiling for 30 min in order to hydrolyze the
20 borate esters. The water was removed under reduced pressure
until a foam began to form and then the process was repeated.
HPLC indicated about 77% product, 15% dimer (5' of product
attached to 2' of starting material) and unknown derivatives,
and the balance was a single unresolved early eluting peak.

25 The gum was redissolved in brine (3 L), and the flask
was rinsed with additional brine (3 L). The combined aqueous
solutions were extracted with chloroform (20 L) in a heavier-
than continuous extractor for 70 h. The chloroform layer was
concentrated by rotary evaporation in a 20 L flask to a
30 sticky foam (2400 g). This was coevaporated with MeOH (400
mL) and EtOAc (8 L) at 75°C and 0.65 atm until the foam
dissolved at which point the vacuum was lowered to about 0.5
atm. After 2.5 L of distillate was collected a precipitate

-71-

began to form and the flask was removed from the rotary evaporator and stirred until the suspension reached ambient temperature. EtOAc (2 L) was added and the slurry was filtered on a 25 cm table top Buchner funnel and the product was washed with EtOAc (3 x 2 L). The bright white solid was air dried in pans for 24 h then further dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to afford 1649 g of a white crystalline solid (mp 115.5-116.5°C).

The brine layer in the 20 L continuous extractor was further extracted for 72 h with recycled chloroform. The chloroform was concentrated to 120 g of oil and this was combined with the mother liquor from the above filtration (225 g), dissolved in brine (250 mL) and extracted once with chloroform (250 mL). The brine solution was continuously extracted and the product was crystallized as described above to afford an additional 178 g of crystalline product containing about 2% of thymine. The combined yield was 1827 g (69.4%). HPLC indicated about 99.5% purity with the balance being the dimer.

Preparation of 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate

In a 50 L glass-lined steel reactor, 2'-O-(2-methoxyethyl)-5-methyl-uridine (MOE-T, 1500 g, 4.738 mol), lutidine (1015 g, 9.476 mol) were dissolved in anhydrous acetonitrile (15 L). The solution was stirred rapidly and chilled to -10°C (internal temperature).

Dimethoxytriphenylmethyl chloride (1765.7 g, 5.21 mol) was added as a solid in one portion. The reaction was allowed to warm to -2°C over 1 h. (Note: The reaction was monitored closely by TLC (EtOAc) to determine when to stop the reaction so as to not generate the undesired bis-DMT substituted side product). The reaction was allowed to warm from -2 to 3°C

-72-

over 25 min. then quenched by adding MeOH (300 mL) followed after 10 min by toluene (16 L) and water (16 L). The solution was transferred to a clear 50 L vessel with a bottom outlet, vigorously stirred for 1 minute, and the layers
5 separated. The aqueous layer was removed and the organic layer was washed successively with 10% aqueous citric acid (8 L) and water (12 L). The product was then extracted into the aqueous phase by washing the toluene solution with aqueous sodium hydroxide (0.5N, 16 L and 8 L). The combined aqueous
10 layer was overlaid with toluene (12 L) and solid citric acid (8 moles, 1270 g) was added with vigorous stirring to lower the pH of the aqueous layer to 5.5 and extract the product into the toluene. The organic layer was washed with water (10 L) and TLC of the organic layer indicated a trace of DMT-
15 O-Me, bis DMT and dimer DMT.

The toluene solution was applied to a silica gel column (6 L sintered glass funnel containing approx. 2 kg of silica gel slurried with toluene (2 L) and TEA(25 mL)) and the fractions were eluted with toluene (12 L) and EtOAc (3 x 4 L)
20 using vacuum applied to a filter flask placed below the column. The first EtOAc fraction containing both the desired product and impurities were resubjected to column chromatography as above. The clean fractions were combined, rotary evaporated to a foam, coevaporated with acetonitrile
25 (6 L) and dried in a vacuum oven (0.1 mm Hg, 40 h, 40°C) to afford 2850 g of a white crisp foam. NMR spectroscopy indicated a 0.25 mole % remainder of acetonitrile (calculates to be approx. 47 g) to give a true dry weight of 2803 g (96%). HPLC indicated that the product was 99.41% pure, with
30 the remainder being 0.06 DMT-O-Me, 0.10 unknown, 0.44 bis DMT, and no detectable dimer DMT or 3'-O-DMT.

-73-

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine (1237 g, 2.0 mol) was dissolved in anhydrous DMF (2.5 L). The solution was co-evaporated with toluene (200 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (70 g, 1.0 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (20 ml) was added and the solution was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (3.5 L) and water (600 ml) and extracted with hexane (3 x 3L). The mixture was diluted with water (1.6 L) and extracted with the mixture of toluene (12 L) and hexanes (9 L). The upper layer was washed with DMF-water (7:3 v/v, 3x3 L) and water (3x3 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25°C, 0.1mm Hg, 40 h) to afford 1526 g of an off-white foamy solid (95%).

Preparation of 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and argon gas line was added 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-uridine (2.616 kg, 4.23 mol, purified by base extraction only and no scrub column), anhydrous acetonitrile (20 L), and TEA (9.5 L, 67.7 mol, 16 eq). The mixture was chilled with stirring to -10°C

-74-

internal temperature (external -20°C).

Trimethylsilylchloride (1.60 L, 12.7 mol, 3.0 eq) was added over 30 min. while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L).

- 5 (Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition). The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc, R_f 0.68 and 0.87 for starting material and silyl product, respectively).
- 10 Upon completion, triazole (2.34 kg, 33.8 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (793 mL, 8.51 mol, 2.01 eq) was added slowly over 60 min so as to maintain the temperature between -20°C and -10°C (note: strongly
- 15 exothermic), followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h, at which point it was an off-white thick suspension. TLC indicated a complete conversion to the triazole product (EtOAc, R_f 0.87 to 0.75 with the product spot glowing in long
- 20 wavelength UV light). The reaction was cooled to -15°C and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half
- 25 of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The second half of the reaction was treated in the same way. The combined aqueous layers were back-extracted with EtOAc (8 L) The organic layers were combined
- 30 and concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The residue

-75-

was dissolved in dioxane (2 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight

5 TLC indicated a complete reaction (CH_2Cl_2 -acetone-MeOH, 20:5:3, R_f 0.51). The reaction solution was concentrated on a rotary evaporator to a dense foam and slowly redissolved in warm CH_2Cl_2 (4 L, 40°C) and transferred to a 20 L glass extraction vessel equipped with a air-powered stirrer. The
10 organic layer was extracted with water (2 x 6 L) to remove the triazole by-product. (Note: In the first extraction an emulsion formed which took about 2 h to resolve). The water layer was back-extracted with CH_2Cl_2 (2 x 2 L), which in turn was washed with water (3 L). The combined organic layer was
15 concentrated in 2 x 20 L flasks to a gum and then recrystallized from EtOAc seeded with crystalline product. After sitting overnight, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc until a white free-flowing powder was left (about 3 x 3 L).
20 The filtrate was concentrated to an oil recrystallized from EtOAc, and collected as above. The solid was air-dried in pans for 48 h, then further dried in a vacuum oven (50°C, 0.1mm Hg, 17 h) to afford 2248 g of a bright white, dense solid (86%). An HPLC analysis indicated both crops to be
25 99.4% pure and NMR spectroscopy indicated only a faint trace of EtOAc remained.

Preparation of 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N4-benzoyl-5-methyl-cytidine penultimate intermediate:

30 Crystalline 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-cytidine (1000 g, 1.62 mol) was suspended in anhydrous DMF (3 kg) at ambient temperature and stirred under an Ar atmosphere. Benzoic anhydride (439.3 g, 1.94 mol) was

-76-

added in one portion. The solution clarified after 5 hours and was stirred for 16 h. HPLC indicated 0.45% starting material remained (as well as 0.32% N⁴, 3'-O-bis Benzoyl). An additional amount of benzoic anhydride (6.0 g, 0.0265 mol) was added and after 17 h, HPLC indicated no starting material was present. TEA (450 mL, 3.24 mol) and toluene (6 L) were added with stirring for 1 minute. The solution was washed with water (4 x 4 L), and brine (2 x 4 L). The organic layer was partially evaporated on a 20 L rotary evaporator to remove 4 L of toluene and traces of water. HPLC indicated that the bis benzoyl side product was present as a 6% impurity. The residue was diluted with toluene (7 L) and anhydrous DMSO (200 mL, 2.82 mol) and sodium hydride (60% in oil, 70 g, 1.75 mol) was added in one portion with stirring at ambient temperature over 1 h. The reaction was quenched by slowly adding then washing with aqueous citric acid (10%, 100 mL over 10 min, then 2 x 4 L), followed by aqueous sodium bicarbonate (2%, 2 L), water (2 x 4 L) and brine (4 L). The organic layer was concentrated on a 20 L rotary evaporator to about 2 L total volume. The residue was purified by silica gel column chromatography (6 L Buchner funnel containing 1.5 kg of silica gel wetted with a solution of EtOAc-hexanes-TEA(70:29:1)). The product was eluted with the same solvent (30 L) followed by straight EtOAc (6 L). The fractions containing the product were combined, concentrated on a rotary evaporator to a foam and then dried in a vacuum oven (50°C, 0.2 mm Hg, 8 h) to afford 1155 g of a crisp, white foam (98%). HPLC indicated a purity of >99.7%.

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite)

-77-

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidine (1082 g, 1.5 mol) was dissolved in anhydrous DMF (2 L) and co-evaporated with toluene (300 ml) at 50 °C under reduced pressure. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40 v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1336 g of an off-white foam (97%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amdite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosine (purchased from Reliable Biopharmaceutical, St. Lois, MO), 1098 g, 1.5 mol) was dissolved in anhydrous DMF (3 L) and co-evaporated with toluene (300 ml) at 50 °C. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (78.8 g, 1.24 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and mixture was left at room temperature for 5 hours. TEA (300 ml) was

-78-

added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (1.4 L) and extracted with the mixture of toluene (9 L) and hexanes (6 L). The two layers were
5 separated and the upper layer was washed with DMF-water (60:40, v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to a sticky foam. The residue was co-evaporated with acetonitrile (2.5 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg,
10 40 h) to afford 1350 g of an off-white foam solid (96%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite)

15 5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosine (purchased from Reliable Biopharmaceutical, St. Louis, MO, 1426 g, 2.0 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (200 ml) at 50 °C, cooled to room
20 temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (68 g, 0.97 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the
25 mixture was diluted with DMF (2 L) and water (600 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (2 L) and extracted with a mixture of toluene (10 L) and hexanes (5 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3x3 L).
30 EtOAc (4 L) was added and the solution was washed with water (3 x 4 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to approx. 4 kg. Hexane (4 L) was added, the mixture was shaken for 10 min, and the supernatant liquid was

-79-

decanted. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1660 g of an off-white foamy solid (91%).

5

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

15

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

20 O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 25 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, EtOAc) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between CH₂Cl₂ (1 L) and saturated sodium bicarbonate (2 x 1 L) and brine (1 L). The organic layer was 30 dried over sodium sulfate, filtered, and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of EtOAc and ethyl ether (600mL) and cooling the

-80-

solution to -10°C afforded a white crystalline solid which was collected by filtration, washed with ethyl ether (3 x 200 mL) and dried (40°C, 1mm Hg, 24 h) to afford 149g of white solid (74.8%). TLC and NMR spectroscopy were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In the fume hood, ethylene glycol (350 mL, excess) was added cautiously with manual stirring to a 2 L stainless steel pressure reactor containing borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). (Caution : evolves hydrogen gas). 5'-O-tert-Butyldiphenylsilyl-0²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient temperature and opened. TLC (EtOAc, R_f 0.67 for desired product and R_f 0.82 for ara-T side product) indicated about 70% conversion to the product. The solution was concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. (Alternatively, once the THF has evaporated the solution can be diluted with water and the product extracted into EtOAc). The residue was purified by column chromatography (2kg silica gel, EtOAc-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, evaporated and dried to afford 84 g of a white crisp foam (50%), contaminated starting material (17.4g, 12% recovery) and pure reusable starting material (20g, 13% recovery). TLC and NMR spectroscopy were consistent with 99% pure product.

-81-

2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine

5'-O-*tert*-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with
5 triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol) and dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dissolved in dry THF (369.8mL, Aldrich, sure seal bottle). Diethyl-azodicarboxylate
10 (6.98mL, 44.36mmol) was added dropwise to the reaction mixture with the rate of addition maintained such that the resulting deep red coloration is just discharged before adding the next drop. The reaction mixture was stirred for 4 hrs., after which time TLC (EtOAc:hexane, 60:40) indicated
15 that the reaction was complete. The solvent was evaporated in vacuo and the residue purified by flash column chromatography (eluted with 60:40 EtOAc:hexane), to yield 2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%) upon rotary
20 evaporation.

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-
25 methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate washed with ice cold CH₂Cl₂, and the combined organic phase was washed with water and brine and dried
30 (anhydrous Na₂SO₄). The solution was filtered and evaporated to afford 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). Formaldehyde (20% aqueous

- 82 -

solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. The solvent was removed under vacuum and the residue was purified by column chromatography to yield 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%) upon rotary evaporation.

5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL) and cooled to 10°C under inert atmosphere. Sodium cyanoborohydride (0.39g, 6.13mmol) was added and the reaction mixture was stirred. After 10 minutes the reaction was warmed to room temperature and stirred for 2 h. while the progress of the reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and the product was extracted with EtOAc (2 x 20 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated to dryness. This entire procedure was repeated with the resulting residue, with the exception that formaldehyde (20% w/w, 30 mL, 3.37 mol) was added upon dissolution of the residue in the PPTS/MeOH solution. After the extraction and evaporation, the residue was purified by flash column chromatography and (eluted with 5% MeOH in CH₂Cl₂) to afford 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%) upon rotary evaporation.

2'-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and TEA (1.67mL, 12mmol, dry, stored

- 83 -

over KOH) and added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol). The reaction was stirred at room temperature for 24 hrs and monitored by TLC (5% MeOH in CH₂Cl₂). The solvent was removed under vacuum and the residue purified by flash column chromatography (eluted with 10% MeOH in CH₂Cl₂) to afford 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%) upon rotary evaporation of the solvent.

10 **5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine**
2'-O-(dimethylaminoxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P₂O₅ under high vacuum overnight at 40°C, co-evaporated with anhydrous pyridine (20 mL), and dissolved in pyridine (11 mL) under argon atmosphere. 4-
15 dimethylaminopyridine (26.5 mg, 2.60 mmol) and 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) were added to the pyridine solution and the reaction mixture was stirred at room temperature until all of the starting material had reacted. Pyridine was removed under vacuum and the residue
20 was purified by column chromatography (eluted with 10% MeOH in CH₂Cl₂ containing a few drops of pyridine) to yield 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%) upon rotary evaporation.

25 **5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL),
30 N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and the mixture was dried over P₂O₅ under high vacuum overnight at 40°C. This was dissolved in anhydrous

-84-

acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 h under inert atmosphere. The progress of the reaction was
5 monitored by TLC (hexane:EtOAc 1:1). The solvent was evaporated, then the residue was dissolved in EtOAc (70mL) and washed with 5% aqueous NaHCO₃ (40mL). The EtOAc layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue obtained was purified by column chromatography (EtOAc
10 as eluent) to afford 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%) upon rotary evaporation.

15 **2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared
20 similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

25 The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount
30 of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501

-85-

A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to
5 provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-
10 dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

15 2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

20

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) was slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL
25 bomb. (Caution: Hydrogen gas evolves as the solid dissolves). O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) were added and the bomb was sealed, placed in an oil bath and heated to 155°C for 26 h. then cooled to room temperature. The crude solution was
30 concentrated, the residue was diluted with water (200 mL) and extracted with hexanes (200 mL). The product was extracted from the aqueous layer with EtOAc (3 x 200 mL) and the combined organic layers were washed once with water, dried

-86-

over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (eluted with 5:100:2 MeOH/CH₂Cl₂/TEA) as the eluent. The appropriate fractions were combined and evaporated to afford the product as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), was added TEA (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) and the reaction was stirred for 1 h. The reaction mixture was poured into water (200 mL) and extracted with CH₂Cl₂ (2 x 200 mL). The combined CH₂Cl₂ layers were washed with saturated NaHCO₃ solution, followed by saturated NaCl solution, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was purified by silica gel column chromatography (eluted with 5:100:1 MeOH/CH₂Cl₂/TEA) to afford the product.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) were added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture was stirred overnight and the solvent evaporated. The resulting residue was purified by silica gel column chromatography with EtOAc as the eluent to afford the title compound.

-87-

Example 2**Oligonucleotide synthesis**

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard
5 phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v
10 solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide
15 at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

20 Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050,
25 herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as
30 described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are

-88-

prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by
5 reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

10 **Example 3**

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethyl-
hydrazo linked oligonucleosides, also identified as MDH
15 linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for
20 instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides
25 are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

30

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance

-89-

with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, **1996**, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully

-90-

protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at 55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric

-91-

oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

5 **Example 6**

Oligonucleotide Isolation

After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides
10 are recovered by precipitation out of 1 M NH₄OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative
15 amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of correct molecular weight relative to the -16 amu product (+/- 32 +/-48). For some studies oligonucleotides were purified by HPLC, as described by Chiang *et al.*, *J. Biol. Chem.* **1991**,
20 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

25 **Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were
30 afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected

-92-

beta-cyanoethyl-diiso-propyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature ($55\text{--}60^\circ\text{C}$) for 12-16 hours and the released product then dried *in vacuo*. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

15

Example 8**Oligonucleotide Analysis - 96-Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACETM MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACETM 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

30

Example 9

-93-

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas,

- 94 -

VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

25

HEPA 1-6 cells:

The mouse hepatoma cell line HEPA 1-6 is a derivative of the BW7756 mouse hepatoma that arose in a C57/L mouse and is supplied by the American Type Culture Collection (Manassas, VA). The cells are propagated in Dulbecco's minimal essential medium with 10% fetal bovine serum. Cells are subcultured by removing the medium, adding fresh 0.25% trypsin, 0.03% EDTA solution and letting the culture sit at room temperature for

-95-

3 minutes. Trypsin is then removed and the culture allowed to sit an additional 5 minutes until the cells begin to detach, at which point, fresh medium is added.

Treatment with antisense compounds:

5 When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEM™-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL
10 LIPOFECTIN™ (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

 The concentration of oligonucleotide used varies from
15 cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920
20 (**TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1) which is targeted to human H-ras, or ISIS 18078, (**GTGCGCGAGCCCGAAATC**, SEQ ID NO: 2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold) with a phosphorothioate
25 backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCAAGGA**, SEQ ID NO: 3, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive
30 control oligonucleotide that results in 80% inhibition of c-H-ras (for ISIS 13920), JNK2 (for ISIS 18078) or c-raf (for ISIS 15770) mRNA is then utilized as the screening

-96-

concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras, JNK2 or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

Example 10**Analysis of oligonucleotide inhibition of LAR expression**

Antisense modulation of LAR expression can be assayed in a variety of ways known in the art. For example, LAR mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., **1993**. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., **1996**. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's

-97-

instructions.

Protein levels of LAR can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or
5 fluorescence-activated cell sorting (FACS). Antibodies directed to LAR can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for
10 preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997). Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., (*Current*
15 *Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997).

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-
20 10.16.11, John Wiley & Sons, Inc., 1998). Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997). Enzyme-linked immunosorbent assays
25 (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

30 **Example 11**

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., (*Clin. Chem.*, 1996, 42, 1758-1764). Other methods for

-98-

poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993). Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C, was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 150 μ L Buffer RLT was added to each well and the plate vigorously

- 99 -

agitated for 20 seconds. 150 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96TM well plate attached to a QIAVACTM manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 μ L of Buffer RW1 was added to each well of the RNEASY 96TM plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500 μ L of Buffer RW1 was added to each well of the RNEASY 96TM plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96TM plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVACTM manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVACTM manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 μ L water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of LAR mRNA Levels

-100-

Quantitation of LAR mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by

-101-

laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to
5 quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification
10 reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for
15 GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of
20 the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

25 PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 µL PCR cocktail (2.5x PCR buffer (-MgCl₂), 6.6 mM MgCl₂, 375 µM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units
30 RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 µL total RNA solution. The RT reaction was

-102-

carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 µL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human LAR were designed to hybridize to a human LAR sequence, using published sequence information (GenBank accession number NM_002840.1, incorporated herein as SEQ ID NO:4). For human LAR the PCR primers were:

forward primer: CATCGCCATCCTCTTGTTCA (SEQ ID NO: 5)

reverse primer: CCGATCGACTGCTCATCCTT (SEQ ID NO: 6) and the PCR probe was: FAM-AAGGAAAAGGACCCACTCTCCGTCCTC-TAMRA

(SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)

-103-

reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO:9) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

5 Probes and primers to mouse LAR were designed to hybridize to a mouse LAR sequence, using published sequence information (a consensus sequence constructed from Gen Bank accession numbers AW823294, AA510577, BE375498, Z37988, the complement of BE456924, AI529033, AW495458, and BE284685, 10 AW909842 and AI385919, incorporated herein as SEQ ID NO:11). For mouse LAR the PCR primers were:
forward primer: CTCCTGCACGGATGCTGTT (SEQ ID NO:12)
reverse primer: GTTCCCCGAAATGCTGTGAT (SEQ ID NO: 13) and the PCR probe was: FAM-CGGCAGAGCACAGCCCACTGG-TAMRA 15 (SEQ ID NO: 14) where FAM is the fluorescent reporter dye and TAMRA is the quencher dye. For mouse GAPDH the PCR primers were:
forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO:15)
reverse primer: GGGTCTCGCTCCTGGAAGAT (SEQ ID NO:16) and the 20 PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTCATC-TAMRA 3' (SEQ ID NO: 17) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

25 **Example 14**

Northern blot analysis of LAR mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was 30 prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon,

-104-

OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).

5 RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent
10 conditions.

To detect human LAR, a human LAR specific probe was prepared by PCR using the forward primer CATCGCCATCCTCTTGTTCA (SEQ ID NO: 5) and the reverse primer CCGATCGACTGCTCATCCTT (SEQ ID NO: 6). To normalize for variations in loading and
15 transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse LAR, a mouse LAR specific probe was prepared by PCR using the forward primer CTCCTGCACGGATGCTGTT (SEQ ID NO: 12) and the reverse primer GTTCCCCGAAATGCTGTGAT (SEQ ID NO: 13). To normalize for variations in loading and
20 transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

25 Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

30

Example 15**Antisense inhibition of human LAR expression by chimeric**

-105-

phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human LAR RNA, using published sequences (GenBank accession number NM_002840.1, incorporated herein as SEQ ID NO: 4, a sequence constructed from GenBank accession number NM_002840 and the complement of GenBank accession number AI246688.1, incorporated herein as SEQ ID NO: 18, GenBank accession number BE620748.1, the complement of which is incorporated herein as SEQ ID NO: 19, and residues 2606000-2700000 from GenBank accession number NT_004852.4, incorporated herein as SEQ ID NO: 20). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human LAR mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which T-24 cells were treated with the oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

Table 1**Inhibition of human LAR mRNA levels by chimeric**

-106-

**phosphorothioate oligonucleotides having 2'-MOE wings and a
deoxy gap**

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
147319	Coding	4	540	gacttttcttcccttcttca	54	21	2
147322	Coding	4	764	ttctccaccaccttcagctg	44	22	2
147323	Coding	4	1027	tggagaaacgaggagccacg	61	23	2
147324	Coding	4	2194	cccggaccgtgggtggagccc	86	24	2
147327	Coding	4	2253	cacggagtactgggtgataa	87	25	2
147328	Coding	4	2309	ctgatgccatccaccacatg	18	26	2
147330	Coding	4	2385	tgtgtgtgcccgcacccaca	86	27	2
147331	Coding	4	2423	accagcacggggtgctctc	43	28	2
147333	Coding	4	2498	tgcacagcagtgaggttcag	84	29	2
147335	Coding	4	3346	gcatgggtccgggactggatg	80	30	2
147337	Coding	4	3452	aagggcacagctgacttata	51	31	2
147338	Coding	4	3509	agcttccgcacgagtgccc	57	32	2
147339	Coding	4	3605	gtgcggatggacaccaggtg	83	33	2
147340	Coding	4	3725	acaatgtagaaccacctgac	54	34	2
147343	Coding	4	4029	gcgcttctggtccatgggtt	79	35	2
147344	Coding	4	4167	gaggatggcgatgacaatga	60	36	2
147345	Coding	4	4309	ggtggtctcgatacctggg	80	37	2
147346	Coding	4	4367	ccatcggtggctttgaggcg	85	38	2
147348	Coding	4	4619	tcgcccacgtgctcgggcag	72	39	2
147352	Coding	4	5042	accgtcttctcggtcttcac	65	40	2
147354	Coding	4	5537	gtcagcatgacgatgatggt	86	41	2
147357	Coding	4	5703	tgtccttgactgcccacccc	72	42	2
147359	Coding	4	5844	agcactgcagtgacccgtga	82	43	2
147360	Coding	4	5904	atagcgcatgcgctccagga	85	44	2
147361	Coding	4	6005	gccgcacggtagcacagctg	87	45	2
147364	3'UTR	4	6111	gctcagaggagctgggtccc	85	46	2
147368	3'UTR	4	6312	aacagagagcttgaagcggg	74	47	2
147375	3'UTR	4	6861	acctttgcaaacacgatggt	87	48	2
147378	3'UTR	4	7163	gccccgcttggccctgagg	73	49	2
147379	3'UTR	4	7202	ctaccaggcccactggcctg	28	50	2
147383	3'UTR	4	7327	tagcttgccacattggttt	83	51	2
147386	3'UTR	4	7434	ccacttacctatctagatag	75	52	2
147388	3'UTR	4	7514	atcttgacttagcctagcta	84	53	2
147389	3'UTR	4	7562	gtaaaaatgaatgtttcatc	65	54	2
147391	3'UTR	4	7584	ctacagcactagcatccaca	78	55	2
147393	3'UTR	4	7629	gtttttcttaacaaatagaa	37	56	2
195463	Start Codon	18	360	gggcaccatcgctcctcctg	85	57	2
195464	Coding	18	631	tggcttcatctcgctgcacc	84	58	2
195465	Coding	18	1171	cgttgcgccaaactggcatc	72	59	2
195466	Exon: Exon Junction	18	1280	tttgaagagctttcactgt	59	60	2
195467	Coding	18	2013	ggttgggtcgaaggtgacct	64	61	2
195468	Coding	18	2087	Cccatatccgagcgtgcagc	44	62	2
195469	Coding	18	2722	Tataggcagcaacagtaacg	66	63	2
195470	Coding	18	3237	Gcgggtgtctgtcgtgatgt	69	64	2
195471	Coding	18	3310	cagagccttctgctggccat	76	65	2

-107-

195472	Exon: Exon Junction	18	3466	tgtacagaatcttaaagggc	33	66	2
195473	Coding	18	3955	ggttgtagaagccccggtag	72	67	2
195474	Coding	18	3986	cactggtagctcaagtccgg	75	68	2
195476	Exon: Exon Junction	18	4188	ggtccttttcccttttgaaca	79	69	2
195478	Coding	18	4654	tggccgtgcgctgttccac	77	70	2
195480	Coding	18	4754	gtcacctgaataaggccaca	81	71	2
195482	Coding	18	5026	tcatccgctccaacatggca	72	72	2
195484	Coding	18	5074	atcgcatgcaggtcacgtgg	74	73	2
195486	Coding	18	5080	tctgtgatcgcatgcaggtc	74	74	2
195488	Coding	18	5830	ccgtgataggcccatcctgt	74	75	2
195490	Stop Codon	18	6053	agcggtagttacgttgcata	85	76	2
195492	3'UTR	18	6556	caatgttctgtccttcagca	77	77	2
195494	3'UTR	18	7061	aagccaggctctgtgggccc	72	78	2
195496	Exon: Exon Junction	19	328	agccacgccctcatagcgca	82	79	2
195498	Exon: Intron Junction	20	495	ggtcactcaccgcctatcca	58	80	2
195500	Intron	20	19735	aactccccgggtaactccctt	61	81	2
195502	Intron	20	22222	agaggcccagagaggtaag	55	82	2
195504	Intron: Exon Junction	20	22761	actcaatgacctgtcagagg	51	83	2
195506	Intron	20	60763	ttgatcctcccaagagcccc	27	84	2
195508	Exon: Intron Junction	20	67551	gcactgcctaccgtcctcat	81	85	2
195510	Coding	20	90640	tccaggacgatgctcagagt	60	86	2
195512	Exon: Intron Junction	20	90673	aacatgtcgaccacgccctc	55	87	2
195514	Exon: Intron Junction	20	90735	tctgcgttacctctgtctgc	39	88	2
195516	Intron: Exon Junction	20	91437	gatactggtcctgccaggat	25	89	2
195518	Coding	20	92000	ctgtccttcagcagaagtca	85	90	2
195520	Intron: Exon Junction	20	92648	tgaaaggccagccacgcccc	62	91	2

As shown in Table 1, SEQ ID NOs 23, 24, 25, 27, 29, 30, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 57, 58, 59, 61, 63, 64, 65, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 81, 85, 86, 90 and 91 demonstrated at least 60% inhibition of human LAR

-108-

expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present invention. These preferred target regions are shown in Table 3. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 3 is the species in which each of the preferred target regions was found.

Example 16

Antisense inhibition of mouse LAR expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.

In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse LAR RNA, using published sequences (a consensus sequence was constructed from GenBank accession numbers AW823294, AA510577, BE375498, Z37988, the complement of BE456924, AI529033, AW495458, and BE284685, AW909842 and AI385919, incorporated herein as SEQ ID NO:11). The oligonucleotides are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The

-109-

internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse LAR mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which HEPA 1-6 cells were treated with the oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

Table 2

Inhibition of mouse LAR mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
147320	Coding	11	85	gctgggagctgactttcttc	0	92	1
147321	Coding	11	154	gctgcactcgtaatggctgg	33	93	1
147325	Coding	11	1104	acttaccgggaccgtggtgg	26	94	1
147326	Coding	11	1109	acccaacttaccgggaccgt	62	95	1
147329	Coding	11	1223	tgctcacggctgatgccatc	35	96	1
147334	Coding	11	1408	agacatgcacagcagtggag	25	97	1
147336	Coding	11	1740	cttggcaaacacttgctcca	43	98	1
147341	Coding	11	2125	tcccgccacacgggtcaatg	58	99	1
147342	Coding	11	2313	gcggtagctcttcttgtccc	36	100	1
147347	Coding	11	2897	ccaggaacaccatcaatgga	23	101	1
147349	Coding	11	2999	ctccagaaatcgcccatggt	11	102	1
147350	Coding	11	3073	cacacttcacccgggatttc	23	103	1
147351	Coding	11	3193	tggagccactcttatggagg	20	104	1
147353	Coding	11	3434	gtcacgtggccatagatgtc	10	105	1
147355	Coding	11	3919	cccgaagcttggtcagcatg	29	106	1
147356	Coding	11	3929	ctgcccatctcccgaagctt	44	107	1
147358	Coding	11	4079	cggattgtccttgactgcc	52	108	1
147362	Coding	11	4382	tccagggccgcacggtagca	0	109	1
147363	Stop Codon	11	4424	agcagtagttacgttgcata	48	110	1
147365	3'UTR	11	4484	ggtatggctcagaggagctg	41	111	1
147366	3'UTR	11	4585	ggctctctgactggtgtggc	40	112	1
147367	3'UTR	11	4651	cacttggcccggtggacgag	21	113	1
147369	3'UTR	11	4699	gagaagcatgagaacgcgga	48	114	1

-110-

147370	3'UTR	11	4895	tccttccgcagaagttgtac	50	115	1
147371	3'UTR	11	4921	cacaaggaaggcgagttact	34	116	1
147372	3'UTR	11	4976	agtcacgctgcctcccgggc	30	117	1
147373	3'UTR	11	4986	ggacagcaggagtcacgctg	12	118	1
147374	3'UTR	11	5179	cccagacacgtctgtggtt	30	119	1
147376	3'UTR	11	5436	cccgagggtggccagaacca	40	120	1
147377	3'UTR	11	5455	tcacctgtgccattcatttc	16	121	1
147380	3'UTR	11	5546	cagacatgtgctaccaggcc	21	122	1
147381	3'UTR	11	5553	ctgaggacagacatgtgcta	38	123	1
147382	3'UTR	11	5586	agctgcaaaccaggagagaa	36	124	1
147384	3'UTR	11	5667	aagtccagtagtcttgccac	44	125	1
147385	3'UTR	11	5742	tgccagaggaagagaccct	62	126	1
147387	3'UTR	11	5790	aacagctatgcacccttccc	30	127	1
147390	3'UTR	11	5899	gcatccacaaggtaaaaatg	29	128	1
147392	3'UTR	11	5920	acagtgaactctacagcact	59	129	1
147394	3'UTR	11	5968	catgatcgctgtagtttttc	0	130	1
147395	3'UTR	11	6044	agatacagagctgagacaga	5	131	1
147396	3'UTR	11	6103	ggctcaccccttgggagga	0	132	1

As shown in Table 2, SEQ ID NOS 95, 98, 99, 107, 108, 110, 111, 112, 114, 115, 120, 125, 126 and 129 demonstrated at least 40% inhibition of mouse LAR expression in this experiment and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present invention. These preferred target regions are shown in Table 3. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 3 is the species in which each of the preferred target regions was found.

Table 3
Sequence and position of preferred target regions identified
in LAR.

-111-

SITEID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
62564	4	1027	Cgtggctcctcgtttctcca	23	<i>H. sapiens</i>	133
62565	4	2194	Gggctccaccacggtccggg	24	<i>H. sapiens</i>	134
62568	4	2253	Ttaccaccagtagtccgtg	25	<i>H. sapiens</i>	135
62571	4	2385	tgtgggtgcgggcacacaca	27	<i>H. sapiens</i>	136
62574	4	2498	ctgaactccactgctgtgca	29	<i>H. sapiens</i>	137
62576	4	3346	catccagtcgccgaccatgc	30	<i>H. sapiens</i>	138
62580	4	3605	cacctgggtgtccatccgcac	33	<i>H. sapiens</i>	139
62584	4	4029	aaccatggaccagaagcgc	35	<i>H. sapiens</i>	140
62585	4	4167	tcattgtcatcgccatcctc	36	<i>H. sapiens</i>	141
62586	4	4309	cccaggtatgcgagaccacc	37	<i>H. sapiens</i>	142
62587	4	4367	cgctcaaagccaacgatgg	38	<i>H. sapiens</i>	143
62589	4	4619	ctgcccagagaccatggcgga	39	<i>H. sapiens</i>	144
62593	4	5042	atgaagcacgagaagacggt	40	<i>H. sapiens</i>	145
62595	4	5537	accatcatcgatcatgctgac	41	<i>H. sapiens</i>	146
62598	4	5703	gggatgggcagtcaggaca	42	<i>H. sapiens</i>	147
62600	4	5844	tcacggtgcactgcagtgtc	43	<i>H. sapiens</i>	148
62601	4	5904	tcctggagcgcgtgcgtat	44	<i>H. sapiens</i>	149
62602	4	6005	cagctgtgtctaccgtgcggc	45	<i>H. sapiens</i>	150
62605	4	6111	gggaccagctcctctgagc	46	<i>H. sapiens</i>	151
62609	4	6312	cccgttcaagctctctgtt	47	<i>H. sapiens</i>	152
62616	4	6861	accatcggtttgcaaagg	48	<i>H. sapiens</i>	153
62619	4	7163	cctcagggccaagcgggggc	49	<i>H. sapiens</i>	154
62624	4	7327	aaaccaatgtggcaagacta	51	<i>H. sapiens</i>	155
62627	4	7434	ctatctagataggttaagtgg	52	<i>H. sapiens</i>	156
62629	4	7514	tagctaggctaagtcaagat	53	<i>H. sapiens</i>	157
62630	4	7562	gatgaaacattcatttttac	54	<i>H. sapiens</i>	158
62632	4	7584	tgtggatgctagtgtgttag	55	<i>H. sapiens</i>	159
113695	18	360	cagggaggacgatggtgcc	57	<i>H. sapiens</i>	160
113696	18	631	ggtgcagcgagatgaagcca	58	<i>H. sapiens</i>	161
113697	18	1171	gatgccagttggccgaacg	59	<i>H. sapiens</i>	162
113699	18	2013	aggtcaccttcgacccaacc	61	<i>H. sapiens</i>	163
113701	18	2722	cgttactgttgctgcctata	63	<i>H. sapiens</i>	164
113702	18	3237	acatcacgacagacaccgc	64	<i>H. sapiens</i>	165
113703	18	3310	atggaccagcaaaggctctg	65	<i>H. sapiens</i>	166
113705	18	3955	ctaccggggcttctacaacc	67	<i>H. sapiens</i>	167
113706	18	3986	ccggacttgagctaccagtg	68	<i>H. sapiens</i>	168
113707	18	4188	tgttcaaaaggaaaaggacc	69	<i>H. sapiens</i>	169
113708	18	4654	gtgggaacagcgcacggcca	70	<i>H. sapiens</i>	170
113709	18	4754	tgtggccttattcaggtgac	71	<i>H. sapiens</i>	171
113710	18	5026	tgccatgttgagcggatga	72	<i>H. sapiens</i>	172
113711	18	5074	ccacgtgacctgcatgcat	73	<i>H. sapiens</i>	173
113712	18	5080	gacctgcatgcatcacaga	74	<i>H. sapiens</i>	174
113713	18	5830	acaggatgggcctatcacgg	75	<i>H. sapiens</i>	175
113714	18	6053	tatgcaacgtaactaccgct	76	<i>H. sapiens</i>	176
113715	18	6556	tgctgaaggacagaacattg	77	<i>H. sapiens</i>	177
113716	18	7061	gggcccacagagcctggctt	78	<i>H. sapiens</i>	178
113717	19	328	tgcgctatgagggcggtgct	79	<i>H. sapiens</i>	179
113719	20	19735	aaggaggttaccgggaggtt	81	<i>H. sapiens</i>	180
113723	20	67551	atgaggacggtaggcagtgc	85	<i>H. sapiens</i>	181
113724	20	90640	actctgagcatcgctcctgga	86	<i>H. sapiens</i>	182
113728	20	92000	tgacttctgctgaaggacag	90	<i>H. sapiens</i>	183

-112-

113729	20	92648	ggggcgtggctggcctttca	91	<i>H. sapiens</i>	184
62567	11	1109	acgggccgggtaagttgggt	95	<i>M. musculus</i>	185
62577	11	1740	tggagcaagtgtttgccaag	98	<i>M. musculus</i>	186
62582	11	2125	cattgaccgtgtgggcggga	99	<i>M. musculus</i>	187
62597	11	3929	aagcttcgggagatgggcag	107	<i>M. musculus</i>	188
62599	11	4079	gggcagtcaaggacaatccg	108	<i>M. musculus</i>	189
62604	11	4424	tatgcaacgtaactactgct	110	<i>M. musculus</i>	190
62606	11	4484	cagctcctctgagccatacc	111	<i>M. musculus</i>	191
62607	11	4585	gccacaccagtcagagagcc	112	<i>M. musculus</i>	192
62610	11	4699	tccgcgttctcatgcttctc	114	<i>M. musculus</i>	193
62611	11	4895	gtacaacttctgcggaagga	115	<i>M. musculus</i>	194
62617	11	5436	tgggttctggccacctcggg	120	<i>M. musculus</i>	195
62625	11	5667	gtggcaagactactggactt	125	<i>M. musculus</i>	196
62626	11	5742	agggctctctcctctgggca	126	<i>M. musculus</i>	197
62633	11	5920	agtgtgtagagttcactgt	129	<i>M. musculus</i>	198

As these "preferred target regions" have been found by
 5 experimentation to be open to, and accessible for,
 hybridization with the antisense compounds of the present
 invention, one of skill in the art will recognize or be able
 to ascertain, using no more than routine experimentation,
 further embodiments of the invention that encompass other
 10 compounds that specifically hybridize to these sites and
 consequently inhibit the expression of LAR.

In one embodiment, the "preferred target region" may be
 employed in screening candidate antisense compounds.
 "Candidate antisense compounds" are those that inhibit the
 15 expression of a nucleic acid molecule encoding LAR and which
 comprise at least an 8-nucleobase portion which is
 complementary to a preferred target region. The method
 comprises the steps of contacting a preferred target region
 of a nucleic acid molecule encoding LAR with one or more
 20 candidate antisense compounds, and selecting for one or more
 candidate antisense compounds which inhibit the expression of
 a nucleic acid molecule encoding LAR. Once it is shown that
 the candidate antisense compound or compounds are capable of
 inhibiting the expression of a nucleic acid molecule encoding

-113-

LAR, the candidate antisense compound may be employed as an antisense compound in accordance with the present invention.

According to the present invention, antisense compounds include ribozymes, external guide sequence (EGS)

5 oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

10 **Example 17**

Western blot analysis of LAR protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, 15 suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to LAR is used, with a radiolabeled or fluorescently labeled secondary 20 antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

-114-

What is claimed is:

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding LAR, wherein said compound specifically hybridizes with said nucleic acid molecule encoding LAR and inhibits the expression of LAR.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding LAR.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
12. The composition of claim 11 further comprising a colloidal dispersion system.

-115-

13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of LAR in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of LAR is inhibited.

15. A method of treating an animal having a disease or condition associated with LAR comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of LAR is inhibited.

16. A method of screening for an antisense compound, the method comprising the steps of:

- a. contacting a preferred target region of a nucleic acid molecule encoding LAR with one or more candidate antisense compounds, said candidate antisense compounds comprising at least an 8-nucleobase portion which is complementary to said preferred target region, and
- b. selecting for one or more candidate antisense compounds which inhibit the expression of a nucleic acid molecule encoding LAR.

17. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 17 wherein the hyperproliferative disorder is cancer.

19. The method of claim 15 wherein the disease or condition is a metabolic disorder.

20. The method of claim 15 wherein the disease or condition arises from aberrant apoptosis.

ISPT-1006-Seq.txt
SEQUENCE LISTING

<110> ISIS Pharmaceuticals, inc.
<120> ANTISENSE MODULATION OF LAR EXPRESSION
<130> ISPT-1006
<150> 10/210,838
<151> 2002-07-31
<160> 198
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Antisense Oligonucleotide
<400> 1
tccgtcatcg ctcctcaggg 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Antisense Oligonucleotide
<400> 2
gtgcgcgcga gcccgaaatc 20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Antisense Oligonucleotide
<400> 3
atgcattctg cccccaagga 20

<210> 4
<211> 7702
<212> DNA
<213> H. sapiens
<220>
<220>
<221> CDS
<222> (371) ... (6064)
<400> 4
cgggagcggc gggagcggtg gcggcgagcaggcggcggc tccagcttcg gctccggctc 60

ISPT-1006-Seq.txt

```

gggctcgggc tccggctccg gctccggctc cggctccagc tcgggtggcg gtggcgggag 120
cgggaccagg tggaggcggc ggcggcagag gagtgggagc agcggcccta gcggcttgcg 180
gggggacatg cggaccgacg gcccctggat aggcggaagg agtggaggcc ctggtgcccg 240
gcccttggtg ctgagtatcc agcaagagtg accgggggtga agaagcaaag actcggttga 300
ttgtcctggg ctgtggctgg ctgtggagct agagccctgg atggcccctg agccagcccc 360
agggaggacg atg gtg ccc ctt gtg cct gca ctg gtg atg ctt ggt ttg 409
      Met Val Pro Leu Val Pro Ala Leu Val Met Leu Gly Leu
          1             5             10

gtg gca ggc gcc cat ggt gac agc aaa cct gtc ttc att aaa gtc cct 457
Val Ala Gly Ala His Gly Asp Ser Lys Pro Val Phe Ile Lys Val Pro
      15             20             25

gag gac cag act ggg ctg tca gga ggg gta gcc tcc ttc gtg tgc caa 505
Glu Asp Gln Thr Gly Leu Ser Gly Gly Val Ala Ser Phe Val Cys Gln
      30             35             40             45

gct aca gga gaa ccc aag ccg cgc atc aca tgg atg aag aag ggg aag 553
Ala Thr Gly Glu Pro Lys Pro Arg Ile Thr Trp Met Lys Lys Gly Lys
      50             55             60

aaa gtc agc tcc cag cgc ttc gag gtc att gag ttt gat gat ggg gca 601
Lys Val Ser Ser Gln Arg Phe Glu Val Ile Glu Phe Asp Asp Gly Ala
      65             70             75

ggg tca gtg ctt cgg atc cag cca ttg cgg gtg cag cga gat gaa gcc 649
Gly Ser Val Leu Arg Ile Gln Pro Leu Arg Val Gln Arg Asp Glu Ala
      80             85             90

atc tat gag tgt aca gct act aac agc ctg ggt gag atc aac act agt 697
Ile Tyr Glu Cys Thr Ala Thr Asn Ser Leu Gly Glu Ile Asn Thr Ser
      95             100             105

gcc aag ctc tca gtg ctc gaa gag gaa cag ctg ccc cct ggg ttc cct 745
Ala Lys Leu Ser Val Leu Glu Glu Glu Gln Leu Pro Pro Gly Phe Pro
      110             115             120             125

tcc atc gac atg ggg cct cag ctg aag gtg gtg gag aag gca cgc aca 793
Ser Ile Asp Met Gly Pro Gln Leu Lys Val Val Glu Lys Ala Arg Thr
      130             135             140

gcc acc atg cta tgt gcc gca ggc gga aat cca gac cct gag att tct 841
Ala Thr Met Leu Cys Ala Ala Gly Gly Asn Pro Asp Pro Glu Ile Ser
      145             150             155

tgg ttc aag gac ttc ctt cct gta gac cct gcc acg agc aac ggc cgc 889
Trp Phe Lys Asp Phe Leu Pro Val Asp Pro Ala Thr Ser Asn Gly Arg
      160             165             170

atc aag cag ctg cgt tca ggt gcc ttg cag ata gag agc agt gag gaa 937
Ile Lys Gln Leu Arg Ser Gly Ala Leu Gln Ile Glu Ser Ser Glu Glu
      175             180             185

tcc gac caa ggc aag tac gag tgt gtg gcg acc aac tcg gca ggc aca 985
Ser Asp Gln Gly Lys Tyr Glu Cys Val Ala Thr Asn Ser Ala Gly Thr
      190             195             200             205

cgt tac tca gcc cct gcg aac ctg tat gtg cga gtg cgc cgc gtg gct 1033
Arg Tyr Ser Ala Pro Ala Asn Leu Tyr Val Arg Val Arg Arg Val Ala

```

ISPT-1006-Seq.txt

210	215	220	
cct cgt ttc tcc atc cct ccc agc agc cag gag gtg atg cca ggc ggc Pro Arg Phe Ser Ile Pro Pro Ser Ser Gln Glu Val Met Pro Gly Gly 225 230 235			1081
agc gtg aac ctg aca tgc gtg gca gtg ggt gca ccc atg ccc tac gtg Ser Val Asn Leu Thr Cys Val Ala Val Gly Ala Pro Met Pro Tyr Val 240 245 250			1129
aag tgg atg atg ggg gcc gag gag ctc acc aag gag gat gag atg cca Lys Trp Met Met Gly Ala Glu Glu Leu Thr Lys Glu Asp Glu Met Pro 255 260 265			1177
gtt ggc cgc aac gtc ctg gag ctc agc aat gtc gta cgc tct gcc aac Val Gly Arg Asn Val Leu Glu Leu Ser Asn Val Val Arg Ser Ala Asn 270 275 280 285			1225
tac acc tgt gtg gcc atc tcc tcg ctg ggc atg atc gag gcc aca gcc Tyr Thr Cys Val Ala Ile Ser Ser Leu Gly Met Ile Glu Ala Thr Ala 290 295 300			1273
cag gtc aca gtg aaa gct ctt cca aag cct ccg att gat ctt gtg gtg Gln Val Thr Val Lys Ala Leu Pro Lys Pro Pro Ile Asp Leu Val Val 305 310 315			1321
aca gag aca act gcc acc agt gtc acc ctc acc tgg gac tct ggg aac Thr Glu Thr Thr Ala Thr Ser Val Thr Leu Thr Trp Asp Ser Gly Asn 320 325 330			1369
tcg gag cct gta acc tac tat ggc atc cag tac cgc gca gcg ggc acg Ser Glu Pro Val Thr Tyr Tyr Gly Ile Gln Tyr Arg Ala Ala Gly Thr 335 340 345			1417
gag ggc ccc ttt cag gag gtg gat ggt gtg gcc acc acc cgc tac agc Glu Gly Pro Phe Gln Glu Val Asp Gly Val Ala Thr Thr Arg Tyr Ser 350 355 360 365			1465
att ggc ggc ctc agc cct ttc tcg gaa tat gcc ttc cgc gtg ctg gcg Ile Gly Gly Leu Ser Pro Phe Ser Glu Tyr Ala Phe Arg Val Leu Ala 370 375 380			1513
gtg aac agc atc ggg cga ggg ccg ccc agc gag gca gtg cgg gca cgc Val Asn Ser Ile Gly Arg Gly Pro Pro Ser Glu Ala Val Arg Ala Arg 385 390 395			1561
acg gga gaa cag gcg ccc tcc agc cca ccg cgc cgc gtg cag gca cgc Thr Gly Glu Gln Ala Pro Ser Ser Pro Pro Arg Arg Val Gln Ala Arg 400 405 410			1609
atg ctg agc gcc agc acc atg ctg gtg cag tgg gag cct ccc gag gag Met Leu Ser Ala Ser Thr Met Leu Val Gln Trp Glu Pro Pro Glu Glu 415 420 425			1657
ccc aac ggc ctg gtg cgg gga tac cgc gtc tac tat act ccg gac tcc Pro Asn Gly Leu Val Arg Gly Tyr Arg Val Tyr Tyr Thr Pro Asp Ser 430 435 440 445			1705
cgc cgc ccc ccg aac gcc tgg cac aag cac aac acc gac gcg ggg ctc Arg Arg Pro Pro Asn Ala Trp His Lys His Asn Thr Asp Ala Gly Leu 450 455 460			1753
ctc acg acc gtg ggc agc ctg ctg cct ggc atc acc tac agc ctg cgc Leu Thr Thr Val Gly Ser Leu Leu Pro Gly Ile Thr Tyr Ser Leu Arg 465 470 475			1801

ISPT-1006-Seq.txt

gtg ctt gcc ttc acc gcc gtg ggc gat ggc cct ccc agc ccc acc atc Val Leu Ala Phe Thr Ala Val Gly Asp Gly Pro Pro Ser Pro Thr Ile 480 485 490	1849
cag gtc aag acg cag cag gga gtg cct gcc cag ccc gcg gac ttc cag Gln Val Lys Thr Gln Gln Gly Val Pro Ala Gln Pro Ala Asp Phe Gln 495 500 505	1897
gcc gag gtg gag tcg gac acc agg atc cag ctc tcg tgg ctg ctg ccc Ala Glu Val Glu Ser Asp Thr Arg Ile Gln Leu Ser Trp Leu Leu Pro 510 515 520 525	1945
cct cag gag cgg atc atc atg tat gaa ctg gtg tac tgg gcg gca gag Pro Gln Glu Arg Ile Ile Met Tyr Glu Leu Val Tyr Trp Ala Ala Glu 530 535 540	1993
gac gaa gac caa cag cac aag gtc acc ttc gac cca acc tcc tcc tac Asp Glu Asp Gln Gln His Lys Val Thr Phe Asp Pro Thr Ser Ser Tyr 545 550 555	2041
aca cta gag gac ctg aag cct gac aca ctc tac cgc ttc cag ctg gct Thr Leu Glu Asp Leu Lys Pro Asp Thr Leu Tyr Arg Phe Gln Leu Ala 560 565 570	2089
gca cgc tcg gat atg ggg gtg ggc gtc ttc acc ccc acc att gag gcc Ala Arg Ser Asp Met Gly Val Gly Val Phe Thr Pro Thr Ile Glu Ala 575 580 585	2137
cgc aca gcc cag tcc acc ccc tcc gcc cct ccc cag aag gtg atg tgt Arg Thr Ala Gln Ser Thr Pro Ser Ala Pro Pro Gln Lys Val Met Cys 590 595 600 605	2185
gtg agc atg ggc tcc acc acg gtc cgg gta agt tgg gtc ccg ccg cct Val Ser Met Gly Ser Thr Thr Val Arg Val Ser Trp Val Pro Pro Pro 610 615 620	2233
gcc gac agc cgc aac ggc gtt atc acc cag tac tcc gtg gcc cac gag Ala Asp Ser Arg Asn Gly Val Ile Thr Gln Tyr Ser Val Ala His Glu 625 630 635	2281
gcg gtg gac ggc gag gac cgc ggg cgg cat gtg gtg gat ggc atc agc Ala Val Asp Gly Glu Asp Arg Gly Arg His Val Val Asp Gly Ile Ser 640 645 650	2329
cgt gag cac tcc agc tgg gac ctg gtg ggc ctg gag aag tgg acg gag Arg Glu His Ser Ser Trp Asp Leu Val Gly Leu Glu Lys Trp Thr Glu 655 660 665	2377
tac cgg gtg tgg gtg cgg gca cac aca gac gtg ggc ccc ggc ccc gag Tyr Arg Val Trp Val Arg Ala His Thr Asp Val Gly Pro Gly Pro Glu 670 675 680 685	2425
agc agc ccg gtg ctg gtg cgc acc gat gag gac gtg ccc agc ggg cct Ser Ser Pro Val Leu Val Arg Thr Asp Glu Asp Val Pro Ser Gly Pro 690 695 700	2473
ccg cgg aag gtg gag gtg gag cca ctg aac tcc act gct gtg cat gtc Pro Arg Lys Val Glu Val Glu Pro Leu Asn Ser Thr Ala Val His Val 705 710 715	2521
tac tgg aag ctg cct gtc ccc agc aag cag cat ggc cag atc cgc ggc Tyr Trp Lys Leu Pro Val Pro Ser Lys Gln His Gly Gln Ile Arg Gly 720 725 730	2569

ISPT-1006-Seq.txt

tac cag gtc acc tac gtg cgg ctg gag aat ggc gag ccc cgt gga ctc Tyr Gln Val Thr Tyr Val Arg Leu Glu Asn Gly Glu Pro Arg Gly Leu 735 740 745	2617
ccc atc atc caa gac gtc atg cta gcc gag gcc cag tgg cgg cca gag Pro Ile Ile Gln Asp Val Met Leu Ala Glu Ala Gln Trp Arg Pro Glu 750 755 760 765	2665
gag tcc gag gac tat gaa acc act atc agc ggc ctg acc ccg gag acc Glu Ser Glu Asp Tyr Glu Thr Thr Ile Ser Gly Leu Thr Pro Glu Thr 770 775 780	2713
acc tac tcc gtt act gtt gct gcc tat acc acc aag ggg gat ggt gcc Thr Tyr Ser Val Thr Val Ala Ala Tyr Thr Thr Lys Gly Asp Gly Ala 785 790 795	2761
cgc agc aag ccc aaa att gtc act aca aca ggt gca gtc cca ggc cgg Arg Ser Lys Pro Lys Ile Val Thr Thr Thr Gly Ala Val Pro Gly Arg 800 805 810	2809
ccc acc atg atg atc agc acc acg gcc atg aac act gcg ctg ctc cag Pro Thr Met Met Ile Ser Thr Thr Ala Met Asn Thr Ala Leu Leu Gln 815 820 825	2857
tgg cac cca ccc aag gaa ctg cct ggc gag ctg ctg ggc tac cgg ctg Trp His Pro Pro Lys Glu Leu Pro Gly Glu Leu Leu Gly Tyr Arg Leu 830 835 840 845	2905
cag tac tgc cgg gcc gac gag gcg cgg ccc aac acc ata gat ttc ggc Gln Tyr Cys Arg Ala Asp Glu Ala Arg Pro Asn Thr Ile Asp Phe Gly 850 855 860	2953
aag gat gac cag cac ttc aca gtc acc ggc ctg cac aag ggg acc acc Lys Asp Asp Gln His Phe Thr Val Thr Gly Leu His Lys Gly Thr Thr 865 870 875	3001
tac atc ttc cgg ctt gct gcc aag aac cgg gct ggc ttg ggt gag gag Tyr Ile Phe Arg Leu Ala Ala Lys Asn Arg Ala Gly Leu Gly Glu Glu 880 885 890	3049
ttc gag aag gag atc agg acc ccc gag gac ctg ccc agc ggc ttc ccc Phe Glu Lys Glu Ile Arg Thr Pro Glu Asp Leu Pro Ser Gly Phe Pro 895 900 905	3097
caa aac ctg cat gtg aca gga ctg acc acg tct acc aca gaa ctg gcc Gln Asn Leu His Val Thr Gly Leu Thr Thr Ser Thr Thr Glu Leu Ala 910 915 920 925	3145
tgg gac ccg cca gtg ctg gcg gag agg aac ggg cgc atc atc agc tac Trp Asp Pro Pro Val Leu Ala Glu Arg Asn Gly Arg Ile Ile Ser Tyr 930 935 940	3193
acc gtg gtg ttc cga gac atc aac agc caa cag gag ctg cag aac atc Thr Val Val Phe Arg Asp Ile Asn Ser Gln Gln Glu Leu Gln Asn Ile 945 950 955	3241
acg aca gac acc cgc ttt acc ctt act ggc ctc aag cca gac acc act Thr Thr Asp Thr Arg Phe Thr Leu Thr Gly Leu Lys Pro Asp Thr Thr 960 965 970	3289
tac gac atc aag gtc cgc gca tgg acc agc aaa ggc tct ggc cca ctc Tyr Asp Ile Lys Val Arg Ala Trp Thr Ser Lys Gly Ser Gly Pro Leu 975 980 985	3337
agc ccc agc atc cag tcc cgg acc atg ccg gtg gag caa gtg ttt gcc	3385

ISPT-1006-Seq.txt

Ser	Pro	Ser	Ile	Gln	Ser	Arg	Thr	Met	Pro	Val	Glu	Gln	Val	Phe	Ala		
990					995				1000						1005		
aag	aac	ttc	cgg	gtg	gcg	gct	gca	atg	aag	acg	tct	gtg	ctg	ctc	agc		3433
Lys	Asn	Phe	Arg	Val	Ala	Ala	Ala	Met	Lys	Thr	Ser	Val	Leu	Leu	Ser		
			1010						1015					1020			
tgg	gag	gtt	ccc	gac	tcc	tat	aag	tca	gct	gtg	ccc	ttt	aag	att	ctg		3481
Trp	Glu	Val	Pro	Asp	Ser	Tyr	Lys	Ser	Ala	Val	Pro	Phe	Lys	Ile	Leu		
			1025						1030					1035			
tac	aat	ggg	cag	agt	gtg	gag	gtg	gac	ggg	cac	tcg	atg	cgg	aag	ctg		3529
Tyr	Asn	Gly	Gln	Ser	Val	Glu	Val	Asp	Gly	His	Ser	Met	Arg	Lys	Leu		
			1040						1045					1050			
atc	gca	gac	ctg	cag	ccc	aac	aca	gag	tac	tcg	ttt	gtg	ctg	atg	aac		3577
Ile	Ala	Asp	Leu	Gln	Pro	Asn	Thr	Glu	Tyr	Ser	Phe	Val	Leu	Met	Asn		
			1055											1065			
cgt	ggc	agc	agc	gca	ggg	ggc	ctg	cag	cac	ctg	gtg	tcc	atc	cgc	aca		3625
Arg	Gly	Ser	Ser	Ala	Gly	Gly	Leu	Gln	His	Leu	Val	Ser	Ile	Arg	Thr		
1070					1075					1080					1085		
gcc	ccc	gac	ctc	ctg	cct	cac	aag	ccg	ctg	cct	gcc	tct	gcc	tac	ata		3673
Ala	Pro	Asp	Leu	Leu	Pro	His	Lys	Pro	Leu	Pro	Ala	Ser	Ala	Tyr	Ile		
			1090						1095						1100		
gag	gac	ggc	cgc	ttc	gat	ctc	tcc	atg	ccc	cat	gtg	caa	gac	ccc	tcg		3721
Glu	Asp	Gly	Arg	Phe	Asp	Leu	Ser	Met	Pro	His	Val	Gln	Asp	Pro	Ser		
			1105						1110						1115		
ctt	gtc	agg	tgg	ttc	tac	att	gtt	gtg	gta	ccc	att	gac	cgt	gtg	ggc		3769
Leu	Val	Arg	Trp	Phe	Tyr	Ile	Val	Val	Val	Pro	Ile	Asp	Arg	Val	Gly		
			1120						1125					1130			
ggg	agc	atg	ctg	acg	cca	agg	tgg	agc	aca	ccc	gag	gaa	ctg	gag	ctg		3817
Gly	Ser	Met	Leu	Thr	Pro	Arg	Trp	Ser	Thr	Pro	Glu	Glu	Leu	Glu	Leu		
			1135						1140						1145		
gac	gag	ctt	cta	gaa	gcc	atc	gag	caa	ggc	gga	gag	gag	cag	cgg	cgg		3865
Asp	Glu	Leu	Leu	Glu	Ala	Ile	Glu	Gln	Gly	Gly	Glu	Glu	Gln	Arg	Arg		
1150					1155					1160					1165		
cgg	cgg	cgg	cag	gca	gaa	cgt	ctg	aag	cca	tat	gtg	gct	gct	caa	ctg		3913
Arg	Arg	Arg	Gln	Ala	Glu	Arg	Leu	Lys	Pro	Tyr	Val	Ala	Ala	Gln	Leu		
			1170						1175						1180		
gat	gtg	ctc	ccg	gag	acc	ttt	acc	ttg	ggg	gac	aag	aag	aac	tac	cgg		3961
Asp	Val	Leu	Pro	Glu	Thr	Phe	Thr	Leu	Gly	Asp	Lys	Lys	Asn	Tyr	Arg		
			1185						1190					1195			
ggc	ttc	tac	aac	cgg	ccc	ctg	tct	ccg	gac	ttg	agc	tac	cag	tgc	ttt		4009
Gly	Phe	Tyr	Asn	Arg	Pro	Leu	Ser	Pro	Asp	Leu	Ser	Tyr	Gln	Cys	Phe		
			1200						1205					1210			
gtg	ctt	gcc	tcc	ttg	aag	gaa	ccc	atg	gac	cag	aag	cgc	tat	gcc	tcc		4057
Val	Leu	Ala	Ser	Leu	Lys	Glu	Pro	Met	Asp	Gln	Lys	Arg	Tyr	Ala	Ser		
			1215						1220					1225			
agc	ccc	tac	tcg	gat	gag	atc	gtg	gtc	cag	gtg	aca	cca	gcc	cag	cag		4105
Ser	Pro	Tyr	Ser	Asp	Glu	Ile	Val	Val	Gln	Val	Thr	Pro	Ala	Gln	Gln		
1230					1235					1240					1245		
cag	gag	gag	ccg	gag	atg	ctg	tgg	gtg	acg	ggt	ccc	gtg	ctg	gca	gtc		4153
Gln	Glu	Glu	Pro	Glu	Met	Leu	Trp	Val	Thr	Gly	Pro	Val	Leu	Ala	Val		

ISPT-1006-Seq.txt

1250	1255	1260	
atc ctc atc atc ctc att gtc atc gcc atc ctc ttg ttc aaa agg aaa Ile Leu Ile Ile Leu Ile Val Ile Ala Ile Leu Leu Phe Lys Arg Lys 1265 1270 1275			4201
agg acc cac tct ccg tcc tct aag gat gag cag tcg atc gga ctg aag Arg Thr His Ser Pro Ser Ser Lys Asp Glu Gln Ser Ile Gly Leu Lys 1280 1285 1290			4249
gac tcc ttg ctg gcc cac tcc tct gac cct gtg gag atg cgg agg ctc Asp Ser Leu Leu Ala His Ser Ser Asp Pro Val Glu Met Arg Arg Leu 1295 1300 1305			4297
aac tac cag acc cca ggt atg cga gac cac cca ccc atc ccc atc acc Asn Tyr Gln Thr Pro Gly Met Arg Asp His Pro Pro Ile Pro Ile Thr 1310 1315 1320 1325			4345
gac ctg gcg gac aac atc gag cgc ctc aaa gcc aac gat ggc ctc aag Asp Leu Ala Asp Asn Ile Glu Arg Leu Lys Ala Asn Asp Gly Leu Lys 1330 1335 1340			4393
ttc tcc cag gag tat gag tcc atc gac cct gga cag cag ttc acg tgg Phe Ser Gln Glu Tyr Glu Ser Ile Asp Pro Gly Gln Gln Phe Thr Trp 1345 1350 1355			4441
gag aat tca aac ctg gag gtg aac aag ccc aag aac cgc tat gcg aat Glu Asn Ser Asn Leu Glu Val Asn Lys Pro Lys Asn Arg Tyr Ala Asn 1360 1365 1370			4489
gtc atc gcc tac gac cac tct cga gtc atc ctt acc tct atc gat ggc Val Ile Ala Tyr Asp His Ser Arg Val Ile Leu Thr Ser Ile Asp Gly 1375 1380 1385			4537
gtc ccc ggg agt gac tac atc aat gcc aac tac atc gat ggc tac cgc Val Pro Gly Ser Asp Tyr Ile Asn Ala Asn Tyr Ile Asp Gly Tyr Arg 1390 1395 1400 1405			4585
aag cag aat gcc tac atc gcc acg cag ggc ccc ctg ccc gag acc atg Lys Gln Asn Ala Tyr Ile Ala Thr Gln Gly Pro Leu Pro Glu Thr Met 1410 1415 1420			4633
ggc gat ttc tgg aga atg gtg tgg gaa cag cgc acg gcc act gtg gtc Gly Asp Phe Trp Arg Met Val Trp Glu Gln Arg Thr Ala Thr Val Val 1425 1430 1435			4681
atg atg aca cgg ctg gag gag aag tcc cgg gta aaa tgt gat cag tac Met Met Thr Arg Leu Glu Glu Lys Ser Arg Val Lys Cys Asp Gln Tyr 1440 1445 1450			4729
tgg cca gcc cgt ggc acc gag acc tgt ggc ctt att cag gtg acc ctg Trp Pro Ala Arg Gly Thr Glu Thr Cys Gly Leu Ile Gln Val Thr Leu 1455 1460 1465			4777
ttg gac aca gtg gag ctg gcc aca tac act gtg cgc acc ttc gca ctc Leu Asp Thr Val Glu Leu Ala Thr Tyr Thr Val Arg Thr Phe Ala Leu 1470 1475 1480 1485			4825
cac aag agt ggc tcc agt gag aag cgt gag ctg cgt cag ttt cag ttc His Lys Ser Gly Ser Ser Glu Lys Arg Glu Leu Arg Gln Phe Gln Phe 1490 1495 1500			4873
atg gcc tgg cca gac cat gga gtt cct gag tac cca act ccc atc ctg Met Ala Trp Pro Asp His Gly Val Pro Glu Tyr Pro Thr Pro Ile Leu 1505 1510 1515			4921

ISPT-1006-Seq.txt

gcc ttc cta cga cgg gtc aag gcc tgc aac ccc cta gac gca ggg ccc Ala Phe Leu Arg Arg Val Lys Ala Cys Asn Pro Leu Asp Ala Gly Pro 1520 1525 1530	4969
atg gtg gtg cac tgc agc gcg ggc gtg ggc cgc acc ggc tgc ttc atc Met Val Val His Cys Ser Ala Gly Val Gly Arg Thr Gly Cys Phe Ile 1535 1540 1545	5017
gtg att gat gcc atg ttg gag cgg atg aag cac gag aag acg gtg gac Val Ile Asp Ala Met Leu Glu Arg Met Lys His Glu Lys Thr Val Asp 1550 1555 1560 1565	5065
atc tat ggc cac gtg acc tgc atg cga tca cag agg aac tac atg gtg Ile Tyr Gly His Val Thr Cys Met Arg Ser Gln Arg Asn Tyr Met Val 1570 1575 1580	5113
cag acg gag gac cag tac gtg ttc atc cat gag gcg ctg ctg gag gct Gln Thr Glu Asp Gln Tyr Val Phe Ile His Glu Ala Leu Leu Glu Ala 1585 1590 1595	5161
gcc acg tgc ggc cac aca gag gtg cct gcc cgc aac ctg tat gcc cac Ala Thr Cys Gly His Thr Glu Val Pro Ala Arg Asn Leu Tyr Ala His 1600 1605 1610	5209
atc cag aag ctg ggc caa gtg cct cca ggg gag agt gtg acc gcc atg Ile Gln Lys Leu Gly Gln Val Pro Pro Gly Glu Ser Val Thr Ala Met 1615 1620 1625	5257
gag ctc gag ttc aag ttg ctg gcc agc tcc aag gcc cac acg tcc cgc Glu Leu Glu Phe Lys Leu Leu Ala Ser Ser Lys Ala His Thr Ser Arg 1630 1635 1640 1645	5305
ttc atc agc gcc aac ctg ccc tgc aac aag ttc aag aac cgg ctg gtg Phe Ile Ser Ala Asn Leu Pro Cys Asn Lys Phe Lys Asn Arg Leu Val 1650 1655 1660	5353
aac atc atg ccc tac gaa ttg acc cgt gtg tgt ctg cag ccc atc cgt Asn Ile Met Pro Tyr Glu Leu Thr Arg Val Cys Leu Gln Pro Ile Arg 1665 1670 1675	5401
ggg gtg gag ggc tct gac tac atc aat gcc agc ttc ctg gat ggt tat Gly Val Glu Gly Ser Asp Tyr Ile Asn Ala Ser Phe Leu Asp Gly Tyr 1680 1685 1690	5449
aga cag cag aag gcc tac ata gct aca cag ggg cct ctg gca gag agc Arg Gln Gln Lys Ala Tyr Ile Ala Thr Gln Gly Pro Leu Ala Glu Ser 1695 1700 1705	5497
acc gag gac ttc tgg cgc atg cta tgg gag cac aat tcc acc atc atc Thr Glu Asp Phe Trp Arg Met Leu Trp Glu His Asn Ser Thr Ile Ile 1710 1715 1720 1725	5545
gtc atg ctg acc aag ctt cgg gag atg ggc agg gag aaa tgc cac cag Val Met Leu Thr Lys Leu Arg Glu Met Gly Arg Glu Lys Cys His Gln 1730 1735 1740	5593
tac tgg cca gca gag cgc tct gct cgc tac cag tac ttt gtt gtt gac Tyr Trp Pro Ala Glu Arg Ser Ala Arg Tyr Gln Tyr Phe Val Val Asp 1745 1750 1755	5641
ccg atg gct gag tac aac atg ccc cag tat atc ctg cgt gag ttc aag Pro Met Ala Glu Tyr Asn Met Pro Gln Tyr Ile Leu Arg Glu Phe Lys 1760 1765 1770	5689

ISPT-1006-Seq.txt

gtc acg gat gcc cgg gat ggg cag tca agg aca atc cgg cag ttc cag	5737
Val Thr Asp Ala Arg Asp Gly Gln Ser Arg Thr Ile Arg Gln Phe Gln	
1775 1780 1785	
ttc aca gac tgg cca gag cag ggc gtg ccc aag aca ggc gag gga ttc	5785
Phe Thr Asp Trp Pro Glu Gln Gly Val Pro Lys Thr Gly Glu Gly Phe	
1790 1795 1800 1805	
att gac ttc atc ggg cag gtg cat aag acc aag gag cag ttt gga cag	5833
Ile Asp Phe Ile Gly Gln Val His Lys Thr Lys Glu Gln Phe Gly Gln	
1810 1815 1820	
gat ggg cct atc acg gtg cac tgc agt gct ggc gtg ggc cgc acc ggg	5881
Asp Gly Pro Ile Thr Val His Cys Ser Ala Gly Val Gly Arg Thr Gly	
1825 1830 1835	
gtg ttc atc act ctg agc atc gtc ctg gag cgc atg cgc tat gag ggc	5929
Val Phe Ile Thr Leu Ser Ile Val Leu Glu Arg Met Arg Tyr Glu Gly	
1840 1845 1850	
gtg gtc gac atg ttt cag acc gtg aag acc ctg cgt aca cag cgt cct	5977
Val Val Asp Met Phe Gln Thr Val Lys Thr Leu Arg Thr Gln Arg Pro	
1855 1860 1865	
gcc atg gtg cag aca gag gac cag tat cag ctg tgc tac cgt gcg gcc	6025
Ala Met Val Gln Thr Glu Asp Gln Tyr Gln Leu Cys Tyr Arg Ala Ala	
1870 1875 1880 1885	
ctg gag tac ctc ggc agc ttt gac cac tat gca acg taa ctaccgctcc	6074
Leu Glu Tyr Leu Gly Ser Phe Asp His Tyr Ala Thr	
1890 1895	
cctctcctcc gccacccccg ccgtggggct ccggagggga cccagctcct ctgagccata	6134
ccgaccatcg tccagccctc ctacgcagat gctgtcactg gcagagcaca gcccacgggg	6194
atcacagcgt ttcaggaacg ttgccacacc aatcagagag cctagaacat ccctgggcaa	6254
gtggatggcc cagcaggcag gcactgtggc ccttctgtcc accagacca cctggagccc	6314
gcttcaagct ctctgttgcg ctcccgcat tctcatgctt cttctcatgg ggtggggttg	6374
gggcaaagcc tcctttttta tacattaagt ggggtagact gagggatttt agcctcttcc	6434
ctctgatttt tcctttcgcg aatccgtatc tgcagaatgg gccactgtag gggttggggt	6494
ttattttgtt ttgttttttt tttttttttg tatgacttct gctgaaggac agaacattgc	6554
cttcctcgtg cagagctggg gctgccagcc tgagcggagg ctcgccctg ggcggggagg	6614
cagtgtgat ccggctgctc ctccagccct tcagacgaga tcctgtttca gctaaatgca	6674
gggaaactca atgttttttt aagttttgtt ttccctttta agcctttttt taggccacat	6734
tgacagtggg gggcggggag aagataggga acactcatcc ctggtcgtct atcccagtgt	6794
gtgtttaaca ttcacagccc agaaccacag atgtgtctgg gagagcctgg caaggcatcc	6854
ctcatcacca tcgtgtttgc aaagggttaa acaaaaacaa aaaaccacaa aaataaaaaa	6914
caaaaaaac aaaaaaccca aaaaaaaaaa aaaaaagagt cagcccttgg cttctgcttc	6974
aaacctcaa gaggggaagc aactccgtgt gcctgggggt cccgaggag ctgctggctg	7034
acctgggccc acagagcctg gctttgggtc ccagcattgc agtatgggtg ggtgtttgta	7094

ISPT-1006-Seq.txt

ggctgtgggg tctggctgtg tggccaaggt gaatagcaca ggtaggggtg tgtgccacac 7154
 cccatgcacc tcagggccaa gcgggggctt ggctggcctt tcagggtccag gccagtgggc 7214
 ctggtagcac atgtctgtcc tcagagcagg ggccagatga ttttcctccc tggtttgag 7274
 ctgttttcaa agccccgat aatcgctctt ttccactcca agatgccctc ataaaccaat 7334
 gtggcaagac tactggactt ctatcaatgg tactctaatac agtccttatt atcccagctt 7394
 gctgaggggc agggagagcg cctcttcctc tgggcagcgc tatctagata ggtaagtggg 7454
 ggcggggaag ggtgcatagc tgtttttagct gagggacgtg gtgccgacgt ccccaaacct 7514
 agctaggcta agtcaagatc aacattccag ggttggtaat gttggatgat gaaacattca 7574
 tttttacctt gtggatgcta gtgctgtaga gttcactgtt gtacacagtc tgttttctat 7634
 ttgttaagaa aaactacagc atcattgcat aattcttgat ggtaataaat ttgaataatc 7694
 agatttct 7702

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5
 catcgccatc ctcttgttca 20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 6
 ccgatcgact gctcatcctt 20

<210> 7
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7
 aaggaaaagg acccactctc cgtcctc 27

<210> 8
 <211> 19

<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8
gaaggtgaag gtcggagtc

19

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 9
gaagatggtg atgggatttc

20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 10
caagcttccc gttctcagcc

20

<210> 11
<211> 6143
<212> DNA
<213> Mus musculus

<220>

<221> CDS
<222> (1)...(4435)

<221> misc_feature
<222> 788, 811, 844, 941-1022, 1531, 1534, 1555-1630, 6094
<223> n = A,T,C or G

<400> 11
g act ggg ctg tgc gga ggg gtg gcc tcc ttc gtg tgc caa gcc aca ggg 49
Thr Gly Leu Ser Gly Gly Val Ala Ser Phe Val Cys Gln Ala Thr Gly
1 5 10 15

gaa ccc aag cct cga atc acg tgg atg aag aag ggg aag aaa gtc agc. 97
Glu Pro Lys Pro Arg Ile Thr Trp Met Lys Lys Gly Lys Lys Val Ser
20 25 30

tcc cag cgc ttt gag gta att gag ttt gac gat gga gcg ggg tca gtg 145
Ser Gln Arg Phe Glu Val Ile Glu Phe Asp Asp Gly Ala Gly Ser Val
35 40 45

ctg cgg atc cag cca tta cga gtg cag cga gac gaa gcc atc tat gag 193

ISPT-1006-Seq.txt

Leu	Arg	Ile	Gln	Pro	Leu	Arg	Val	Gln	Arg	Asp	Glu	Ala	Ile	Tyr	Glu		
50					55						60						
tgc	aca	gcc	acg	aac	agt	ctc	ggg	gag	atc	aac	aca	agt	gcc	aag	ctg	241	
Cys	Thr	Ala	Thr	Asn	Ser	Leu	Gly	Glu	Ile	Asn	Thr	Ser	Ala	Lys	Leu	80	
65					70					75							
tca	gtg	ctt	gaa	gag	gac	cag	ctg	ccg	tct	ggg	ttc	ccg	act	atc	gac	289	
Ser	Val	Leu	Glu	Glu	Asp	Gln	Leu	Pro	Ser	Gly	Phe	Pro	Thr	Ile	Asp	95	
				85					90								
atg	gga	cct	cag	ctg	aag	gtg	gtg	gag	aag	ggg	cgc	act	gcc	acc	atg	337	
Met	Gly	Pro	Gln	Leu	Lys	Val	Val	Glu	Lys	Gly	Arg	Thr	Ala	Thr	Met	110	
			100					105					110				
ctg	tgt	gca	gcc	ggg	ggg	aac	cca	gac	cct	gag	atc	tct	tgg	ttc	aaa	385	
Leu	Cys	Ala	Ala	Gly	Gly	Asn	Pro	Asp	Pro	Glu	Ile	Ser	Trp	Phe	Lys	125	
		115					120					125					
gac	ttc	ctt	cct	gtg	gac	cct	gct	gca	agc	aac	ggg	cgt	atc	aaa	cag	433	
Asp	Phe	Leu	Pro	Val	Asp	Pro	Ala	Ala	Ser	Asn	Gly	Arg	Ile	Lys	Gln	140	
	130					135					140						
ctg	cga	tca	ggg	gca	ttg	cag	ata	gag	agc	agc	gag	gag	tct	gac	caa	481	
Leu	Arg	Ser	Gly	Ala	Leu	Gln	Ile	Glu	Ser	Ser	Glu	Glu	Ser	Asp	Gln	160	
	145				150						155						
ggc	aag	tac	gag	tgt	gtg	gcc	acc	aac	tct	gca	ggc	aca	cgc	tac	tcg	529	
Gly	Lys	Tyr	Glu	Cys	Val	Ala	Thr	Asn	Ser	Ala	Gly	Thr	Arg	Tyr	Ser	175	
			165					170									
gcc	ccc	gcc	aac	ctg	tat	gtg	cga	gtg	cgt	cgc	gtg	gct	cct	cgt	ttc	577	
Ala	Pro	Ala	Asn	Leu	Tyr	Val	Arg	Val	Arg	Arg	Val	Ala	Pro	Arg	Phe	190	
			180					185					190				
tcc	atc	cct	ccc	agc	agc	caa	gag	gtg	atg	ccc	ggc	ggc	agc	gtg	aat	625	
Ser	Ile	Pro	Pro	Ser	Ser	Gln	Glu	Val	Met	Pro	Gly	Gly	Ser	Val	Asn	205	
		195				200						205					
ctc	aca	tgt	gtg	cca	gtg	gcc	gcg	ccc	atg	ccg	tat	gtg	aaa	tgg	atg	673	
Leu	Thr	Cys	Val	Pro	Val	Ala	Ala	Pro	Met	Pro	Tyr	Val	Lys	Trp	Met	220	
	210					215					220						
atg	gac	gcc	gag	gaa	ctg	acc	aaa	gag	gat	gag	atg	cca	gtc	cgc	cga	721	
Met	Asp	Ala	Glu	Glu	Leu	Thr	Lys	Glu	Asp	Glu	Met	Pro	Val	Arg	Arg	240	
	225				230					235							
aat	ggg	ctg	gag	ctc	agc	aat	gtc	atg	cga	tct	ggc	aac	tat	acc	tgt	769	
Asn	Gly	Leu	Glu	Leu	Ser	Asn	Val	Met	Arg	Ser	Ala	Asn	Tyr	Thr	Cys	255	
			245						250								
gtg	gcc	atc	tct	tca	tta	ngc	atg	ata	gaa	gcc	acg	gcc	can	gtc	aca	817	
Val	Ala	Ile	Ser	Ser	Leu	Xaa	Met	Ile	Glu	Ala	Thr	Ala	Xaa	Val	Thr	270	
			260					265					270				
gta	aaa	gct	ctg	gca	aag	cct	tca	atn	gat	cct	gtg	gtg	aca	gag	aca	865	
Val	Lys	Ala	Leu	Ala	Lys	Pro	Ser	Xaa	Asp	Pro	Val	Val	Thr	Glu	Thr	285	
		275				280						285					
acc	ggc	cac	agt	ggg	act	ctg	aca	tgg	gac	tct	gga	aat	acc	gag	cct	913	
Thr	Gly	His	Ser	Gly	Thr	Leu	Thr	Trp	Asp	Ser	Gly	Asn	Thr	Glu	Pro	300	
	290					295					300						
gtg	ctc	tac	cgc	atc	aag	aac	cgc	gca	nnn	nnn	nnn	nnn	nnn	nnn	nnn	961	
Val	Leu	Tyr	Arg	Ile	Lys	Asn	Arg	Ala	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa		

305	310	315	320	
nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn				1009
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa				
	325	330	335	
nnn nnn nnn nnn ntc acg ccc acc gta gag gcc cgt aca gca cag tcc				1057
Xaa Xaa Xaa Xaa Xaa Thr Pro Thr Val Glu Ala Arg Thr Ala Gln Ser				
	340	345	350	
acc cca tca gcc cct ccc cag aag gtg aca tgt gtg agc acg ggc tcc				1105
Thr Pro Ser Ala Pro Pro Gln Lys Val Thr Cys Val Ser Thr Gly Ser				
	355	360	365	
acc acg gtc cgg gta agt tgg gtt cca ccg ccg gcc gac agc cgc aac				1153
Thr Thr Val Arg Val Ser Trp Val Pro Pro Ala Asp Ser Arg Asn				
	370	375	380	
ggc att atc acc cag tac tcc gtg gcc tat gag gca gtg gac ggc gaa				1201
Gly Ile Ile Thr Gln Tyr Ser Val Ala Tyr Glu Ala Val Asp Gly Glu				
	385	390	395	400
gac cgt aag cga cat gtg gtg gat ggc atc agc cgt gag cat tcc agc				1249
Asp Arg Lys Arg His Val Val Asp Gly Ile Ser Arg Glu His Ser Ser				
	405	410	415	
tgg gac ctg ctg ggc ctg gag aag tgg acg gag tac cgg gtg tgg gtg				1297
Trp Asp Leu Leu Gly Leu Glu Lys Trp Thr Glu Tyr Arg Val Trp Val				
	420	425	430	
cgg gca cac aca gat gtg ggc cct ggc cct gag agc agc ccg gtg ctg				1345
Arg Ala His Thr Asp Val Gly Pro Gly Pro Glu Ser Ser Pro Val Leu				
	435	440	445	
gtg cgc acc gat gag gac gtg cct agc ggg cca cca cgg aag gta gag				1393
Val Arg Thr Asp Glu Asp Val Pro Ser Gly Pro Pro Arg Lys Val Glu				
	450	455	460	
gtt gag cct ctg aac tcc act gct gtg cat gtc tcc tgg aag ctg ccc				1441
Val Glu Pro Leu Asn Ser Thr Ala Val His Val Ser Trp Lys Leu Pro				
	465	470	475	480
gtc ccc aac aag cag cac gga cag att cgt ggc tac cag gtc acc tat				1489
Val Pro Asn Lys Gln His Gly Gln Ile Arg Gly Tyr Gln Val Thr Tyr				
	485	490	495	
gtg cgg ttg gag aat ggt gag ccc cga agc caa ccc atc atn ccn gat				1537
Val Arg Leu Glu Asn Gly Glu Pro Arg Ser Gln Pro Ile Xaa Pro Asp				
	500	505	510	
gtc atg ctg gct gag gcg nnn nnn nnn nnn nnn nnn nnn nnn nnn				1585
Val Met Leu Ala Glu Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa				
	515	520	525	
nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn aca				1633
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr				
	530	535	540	
ctc ttg ggc ctt aaa ccg gac acc act ttg aac att aag gtc cgt gca				1681
Leu Leu Gly Leu Lys Pro Asp Thr Thr Leu Asn Ile Lys Val Arg Ala				
	545	550	555	560
cat acc agc aaa ggc gcc ggc cct ctc agc ccc agc atc cag tcc cgg				1729
His Thr Ser Lys Gly Ala Gly Pro Leu Ser Pro Ser Ile Gln Ser Arg				
	565	570	575	

ISPT-1006-Seq.txt

acc atg ccc gtg gag caa gtg ttt gcc aag aat ttc cgt gtg gcc gct	1777
Thr Met Pro Val Glu Gln Val Phe Ala Lys Asn Phe Arg Val Ala Ala	
580 585 590	
gcg atg aag aca tct gtg ctg ctc agt tgg gag gtc ccc gac tct tat	1825
Ala Met Lys Thr Ser Val Leu Ser Trp Glu Val Pro Asp Ser Tyr	
595 600 605	
aag tca gct gtg ccc ttc aag atc ctg tac aat ggg cag agc gtg gag	1873
Lys Ser Ala Val Pro Phe Lys Ile Leu Tyr Asn Gly Gln Ser Val Glu	
610 615 620	
gtg gat ggg cac tcg atg cgg aag ctg att gca gac ctg caa ccc aac	1921
Val Asp Gly His Ser Met Arg Lys Leu Ile Ala Asp Leu Gln Pro Asn	
625 630 635 640	
acg gag tac tcc ttc gtc ctg atg aat cgt ggc agt agc gcc ggg ggc	1969
Thr Glu Tyr Ser Phe Val Leu Met Asn Arg Gly Ser Ser Ala Gly Gly	
645 650 655	
cta cag cac ctg gtg tcc atc cgc act gcc ccg gac ctc cta ccc cag	2017
Leu Gln His Leu Val Ser Ile Arg Thr Ala Pro Asp Leu Leu Pro Gln	
660 665 670	
aag cca ctg cct gcc tcc gcc ttt ata gag gat ggc cgc ttc tcc ctc	2065
Lys Pro Leu Pro Ala Ser Ala Phe Ile Glu Asp Gly Arg Phe Ser Leu	
675 680 685	
tcc atg cct caa gtg cag gac ccc tcg cta gtc agg tgg ttc tac att	2113
Ser Met Pro Gln Val Gln Asp Pro Ser Leu Val Arg Trp Phe Tyr Ile	
690 695 700	
gtg gtg gtg ccc att gac cgt gtg ggc ggg aac ttg ctg gca cca aga	2161
Val Val Val Pro Ile Asp Arg Val Gly Gly Asn Leu Leu Ala Pro Arg	
705 710 715 720	
tgg aac aca cca gag gag ttg gag ctg gac gag ctt ctg gag gcc atc	2209
Trp Asn Thr Pro Glu Glu Leu Glu Leu Asp Glu Leu Glu Ala Ile	
725 730 735	
gag cag ggc gag gag aaa cag cgg agg cgc cgg cgc caa gca gag cgg	2257
Glu Gln Gly Glu Glu Lys Gln Arg Arg Arg Arg Gln Ala Glu Arg	
740 745 750	
ctg aag cct tat gtg gcg gcc caa gtg gat gcg ctc cct gac acc ttc	2305
Leu Lys Pro Tyr Val Ala Ala Gln Val Asp Ala Leu Pro Asp Thr Phe	
755 760 765	
acc ctg ggg gac aag aag agc tac cgc ggc ttc tac aac cgg ccc ctg	2353
Thr Leu Gly Asp Lys Lys Ser Tyr Arg Gly Phe Tyr Asn Arg Pro Leu	
770 775 780	
tct ccg gat ctg agt tac cag tgc ttc gtt ctc gcc tcc ctc aag gaa	2401
Ser Pro Asp Leu Ser Tyr Gln Cys Phe Val Leu Ala Ser Leu Lys Glu	
785 790 795 800	
ccc atg gac cag aag cgc tac gcc tcc agc ccc tac tcg gac gag att	2449
Pro Met Asp Gln Lys Arg Tyr Ala Ser Ser Pro Tyr Ser Asp Glu Ile	
805 810 815	
gta gtc cag gtg acg cca gca cag cag cag gag gag ccc gag atg ctg	2497
Val Val Gln Val Thr Pro Ala Gln Gln Gln Glu Glu Pro Glu Met Leu	
820 825 830	

ISPT-1006-Seq.txt

tgg gtg aca ggc cct gtc ctg gcg gtc att ctc atc ata ctc att gtc	2545
Trp Val Thr Gly Pro Val Leu Ala Val Ile Leu Ile Ile Leu Ile Val	
835 840 845	
atc gcc atc ctc ctg ttc aag agg aag aga aca cac tcc cca tca tca	2593
Ile Ala Ile Leu Leu Phe Lys Arg Lys Arg Thr His Ser Pro Ser Ser	
850 855 860	
aag gat gag cag tca atc ggg ctg aag gac tcc ctg ttg gcc cac tct	2641
Lys Asp Glu Gln Ser Ile Gly Leu Lys Asp Ser Leu Leu Ala His Ser	
865 870 875 880	
tct gac cct gtg gag atg cga agg ctt aac tac cag acc cca ggt atg	2689
Ser Asp Pro Val Glu Met Arg Arg Leu Asn Tyr Gln Thr Pro Gly Met	
885 890 895	
cga gac cac ccg ccc atc ccc atc act gac ctg gca gac aat att gag	2737
Arg Asp His Pro Pro Ile Pro Ile Thr Asp Leu Ala Asp Asn Ile Glu	
900 905 910	
cgc ctc aaa gcc aac gat ggg ctc aag ttc tcc cag gag tat gag tcc	2785
Arg Leu Lys Ala Asn Asp Gly Leu Lys Phe Ser Gln Glu Tyr Glu Ser	
915 920 925	
att gac cct gga cag cag ttc aca tgg gag aat tcc aac tcg gag gtg	2833
Ile Asp Pro Gly Gln Gln Phe Thr Trp Glu Asn Ser Asn Ser Glu Val	
930 935 940	
aac aag ccc aag aac cgc tat gca aat gtc att gcc tat gac cat tct	2881
Asn Lys Pro Lys Asn Arg Tyr Ala Asn Val Ile Ala Tyr Asp His Ser	
945 950 955 960	
cga gtc ctc ctc acc tcc att gat ggt gtt cct ggg agt gac tac atc	2929
Arg Val Leu Leu Thr Ser Ile Asp Gly Val Pro Gly Ser Asp Tyr Ile	
965 970 975	
aat gcc aac tac att gat ggc tac cga aag cag aat gcc tac atc gcc	2977
Asn Ala Asn Tyr Ile Asp Gly Tyr Arg Lys Gln Asn Ala Tyr Ile Ala	
980 985 990	
aca caa ggt ccg ctg ccc gag acc atg ggc gat ttc tgg agg atg gtg	3025
Thr Gln Gly Pro Leu Pro Glu Thr Met Gly Asp Phe Trp Arg Met Val	
995 1000 1005	
tgg gaa cag cgc aca gcc aca gtg gtc atg atg acc agg cta gag gag	3073
Trp Glu Gln Arg Thr Ala Thr Val Val Met Met Thr Arg Leu Glu Glu	
1010 1015 1020	
aaa tcc cgg gtg aag tgt gat cag tat tgg cca gtc cgt ggc act gag	3121
Lys Ser Arg Val Lys Cys Asp Gln Tyr Trp Pro Val Arg Gly Thr Glu	
1025 1030 1035 1040	
acc tat ggc ctc att cag gtg acc ctg gtg gac act gtg gag ttg gcc	3169
Thr Tyr Gly Leu Ile Gln Val Thr Leu Val Asp Thr Val Glu Leu Ala	
1045 1050 1055	
aca tac acc atg cgc acc ttt gcc ctc cat aag agt ggc tcc agt gag	3217
Thr Tyr Thr Met Arg Thr Phe Ala Leu His Lys Ser Gly Ser Ser Glu	
1060 1065 1070	
aag cgt gag ctg cgt cag ttc cag ttc atg gcc tgg cca gac cac ggc	3265
Lys Arg Glu Leu Arg Gln Phe Gln Phe Met Ala Trp Pro Asp His Gly	
1075 1080 1085	
gtt cct gag tac ccc act ccc atc ttg gcc ttc ctg aga cgg gtc aag	3313

ISPT-1006-Seq.txt

Val	Pro	Glu	Tyr	Pro	Thr	Pro	Ile	Leu	Ala	Phe	Leu	Arg	Arg	Val	Lys	
1090						1095					1100					
gcc	tgt	aac	cca	cta	gat	gcg	ggg	ccc	atg	gtg	gtg	cat	tgc	agt	gcg	3361
Ala	Cys	Asn	Pro	Leu	Asp	Ala	Gly	Pro	Met	Val	Val	His	Cys	Ser	Ala	
1105					1110				1115						1120	
ggg	gtg	ggg	cgc	aca	ggc	tgc	ttc	atc	gtc	atc	gac	gca	atg	ctg	gag	3409
Gly	Val	Gly	Arg	Thr	Gly	Cys	Phe	Ile	Val	Ile	Asp	Ala	Met	Leu	Glu	
				1125				1130						1135		
cgt	atg	aag	cac	gag	aag	acg	gtt	gac	atc	tat	ggc	cac	gtg	acg	tgc	3457
Arg	Met	Lys	His	Glu	Lys	Thr	Val	Asp	Ile	Tyr	Gly	His	Val	Thr	Cys	
			1140					1145					1150			
atg	cgc	tca	caa	agg	aac	tac	atg	gtg	cag	acc	gag	gac	cag	tat	gtg	3505
Met	Arg	Ser	Gln	Arg	Asn	Tyr	Met	Val	Gln	Thr	Glu	Asp	Gln	Tyr	Val	
		1155					1160				1165					
ttc	atc	cac	gag	gcc	ctg	cta	gag	gct	gcc	atg	tgc	gga	cac	acc	gag	3553
Phe	Ile	His	Glu	Ala	Leu	Leu	Glu	Ala	Ala	Met	Cys	Gly	His	Thr	Glu	
	1170					1175					1180					
gtg	ctc	gct	cgg	aac	ctc	tat	gcc	cac	atc	cag	aag	cta	ggc	caa	gtg	3601
Val	Leu	Ala	Arg	Asn	Leu	Tyr	Ala	His	Ile	Gln	Lys	Leu	Gly	Gln	Val	
1185					1190					1195					1200	
cct	ccc	ggg	gag	agc	gtc	acg	gcc	atg	gaa	ctt	gag	ttc	aag	ttg	ctg	3649
Pro	Pro	Gly	Glu	Ser	Val	Thr	Ala	Met	Glu	Leu	Glu	Phe	Lys	Leu	Leu	
				1205				1210						1215		
gcc	aac	tcc	aag	gcc	cac	acg	tcg	cgc	ttt	gtc	agt	gcc	aac	ctg	ccc	3697
Ala	Asn	Ser	Lys	Ala	His	Thr	Ser	Arg	Phe	Val	Ser	Ala	Asn	Leu	Pro	
			1220					1225					1230			
tgc	aac	aag	ttc	aag	aac	cgc	cta	gtg	aac	atc	atg	ccc	tat	gag	ctg	3745
Cys	Asn	Lys	Phe	Lys	Asn	Arg	Leu	Val	Asn	Ile	Met	Pro	Tyr	Glu	Leu	
		1235				1240					1245					
acc	cga	gtg	tgc	ttg	caa	ccc	atc	cgt	ggg	gtg	gag	ggc	tca	gac	tac	3793
Thr	Arg	Val	Cys	Leu	Gln	Pro	Ile	Arg	Gly	Val	Glu	Gly	Ser	Asp	Tyr	
		1250				1255					1260					
atc	aat	gcc	agc	ttt	cta	gat	ggc	tac	aga	cag	cag	aag	gcc	tac	ata	3841
Ile	Asn	Ala	Ser	Phe	Leu	Asp	Gly	Tyr	Arg	Gln	Gln	Lys	Ala	Tyr	Ile	
				1265		1270				1275					1280	
gct	aca	cag	ggg	cct	ctg	gca	gag	agc	acc	gag	gac	ttc	tgg	cgc	atg	3889
Ala	Thr	Gln	Gly	Pro	Leu	Ala	Glu	Ser	Thr	Glu	Asp	Phe	Trp	Arg	Met	
				1285				1290						1295		
tta	tgg	gag	cac	aat	tcc	acc	atc	atc	gtc	atg	ctg	acc	aag	ctt	cgg	3937
Leu	Trp	Glu	His	Asn	Ser	Thr	Ile	Ile	Val	Met	Leu	Thr	Lys	Leu	Arg	
				1300				1305					1310			
gag	atg	ggc	agg	gag	aaa	tgt	cac	cag	tac	tgg	cca	gca	gag	cgc	tcc	3985
Glu	Met	Gly	Arg	Glu	Lys	Cys	His	Gln	Tyr	Trp	Pro	Ala	Glu	Arg	Ser	
		1315					1320				1325					
gct	cgc	tat	cag	tac	ttc	gtt	gtt	gac	ccg	atg	gct	gag	tac	aac	atg	4033
Ala	Arg	Tyr	Gln	Tyr	Phe	Val	Val	Asp	Pro	Met	Ala	Glu	Tyr	Asn	Met	
		1330				1335					1340					
ccc	cag	tat	att	ctg	cgt	gaa	ttc	aaa	gtc	aca	gac	gcc	cgg	gat	ggg	4081
Pro	Gln	Tyr	Ile	Leu	Arg	Glu	Phe	Lys	Val	Thr	Asp	Ala	Arg	Asp	Gly	

ISPT-1006-Seq.txt

1345	1350	1355	1360	
cag tca agg aca atc cga cag ttc	cag ttt aca gac tgg cca gag caa			4129
Gln Ser Arg Thr Ile Arg Gln Phe	Gln Phe Thr Asp Trp Pro Glu Gln			
1365	1370	1375		
gga gta ccc aaa aca ggt gaa ggc	ttc atc gac ttc atc ggg cag gtg			4177
Gly Val Pro Lys Thr Gly Glu Gly	Phe Ile Asp Phe Ile Gly Gln Val			
1380	1385	1390		
cac aag aca aag gag cag ttt ggc	cag gat ggg ccc atc acg gtg cac			4225
His Lys Thr Lys Glu Gln Phe Gly	Gln Asp Gly Pro Ile Thr Val His			
1395	1400	1405		
tgc agt gct ggt gtg ggc cgc acc	ggt gtg ttc atc acc ctg agc att			4273
Cys Ser Ala Gly Val Gly Arg Thr	Gly Val Phe Ile Thr Leu Ser Ile			
1410	1415	1420		
gtc ctg gag cgc atg cgc tat gag	ggt gtg gtt gac atg ttc cag acc			4321
Val Leu Glu Arg Met Arg Tyr Glu	Gly Val Val Asp Met Phe Gln Thr			
1425	1430	1435	1440	
gtg aag acc ctc cgc aca cag cgc	cct gca atg gtg cag aca gag gac			4369
Val Lys Thr Leu Arg Thr Gln Arg	Pro Ala Met Val Gln Thr Glu Asp			
1445	1450	1455		
caa tac cag ctg tgc tac cgt gcg	gcc ctg gaa tac ctc ggc agc ttt			4417
Gln Tyr Gln Leu Cys Tyr Arg Ala	Ala Leu Glu Tyr Leu Gly Ser Phe			
1460	1465	1470		
gat cac tat gca acg taa ctactgctcc	cctctcctcc gacgctcccc			4465
Asp His Tyr Ala Thr *				
1475				
cgcggtctcg gagggaccca gtcctctga	gccataccaa ccatcgcca gccctcctgc	4525		
acggatgctg ttgccggcag agcacagccc	actgggatca cagcatttcg gggaacattg	4585		
ccacaccagt cagagagccc agaacacctg	ggcaagtagg cggactggca gcctggctct	4645		
gggcccctcgt ccaccggggc aagtggagcc	ccgcttcaag ctctctgttc agctccgcgt	4705		
tctcatgctt ctcatggggt gggaaaagg	ggcaagccc ccacttttta tacactaggc	4765		
ggggtagact gcggggtcct agcctcttcc	tccgactttg cttttgcagg tctttcactg	4825		
cagatggggc tgctgtggga gttgggactt	gtttgttttc ctttttgagt tcacgttgga	4885		
tcctttcttg tacaacttct gcggaaggac	acagtagtaa ctcgccttcc ttgtgcagag	4945		
ctagggccct acctgagcaa gtcggctgtg	gcccgaggag cagcgtgact cctgctgtcc	5005		
tccagccttt cagatgagat cctattccag	ccaaatgcag ggaaacactt tattttgttt	5065		
gttttaggtt ttgtttttcc ttgagagcct	tttttttagg cccacagaca gtggtgggtg	5125		
gggaggcgat aggaacacaca tccccagtg	tgcatttaac attcatagcc tacaaccaca	5185		
gacgtgtctg ggggagcctg gcaaggcgtt	cctcgtcacc atcgtgtttg caaaggttca	5245		
aaaaacaaaa atcaaaaaaa aaaaaacat	aaaaatat ttttttaaga aaagaaataa	5305		
agattcatcc cctggcctct acttcagatt	cgaagtggga ggcaactcaa tgtgccctgg	5365		
ggctcgccat gggcccacag agtctcgcta	tcatccccag cgtcgcagtg tggcaggtgt	5425		
ttgtaggctg tgggttcttg ccacctcggg	aaatgaatgg cacaggtgag ggcctgtgcc	5485		
acgcccaca cacctcaggg ccaagcggg	gcgtggctgg cccttcaggt caggccagtg	5545		
ggcctggtag cacatgtctg tcctcagccg	gacagatgct ttctctcctg gtttcagct	5605		
gtcttcaaat ccccccata cccgctcttc	ccactccttc aagttgccct cacaaccaa	5665		
tgtggaaga ctactggact tgtatccatg	gtactatact cagtcctctt atctcagctt	5725		
gctgaggggc agggagaggg tctcttcctc	tgggcagcac tatctagata ggtaagtggg	5785		
ggcggggaag ggtgcatagc tgttttagcc	gagggactcg ataccgacgt ccccagata	5845		
agctaggcta agtcaagatc aacagtccgg	ggttgggggtg tggatgaaac attcattttt	5905		
accttggtga tgtagtgct gtagagttca	ctgtggtaca cagtcogttt tctattttgt	5965		
aagaaaaact acagcgatca tgtgcatact	tctgtgatgg tgataaattt gaataatcca	6025		
gattcttaca cactagcctc tgtctcagct	ctgtatctag agtgggatct taagtctatg	6085		
ggggggggnc ccgggggtcc tcccaagggg	gtgagccccc ctgggggggtg cccgacgg	6143		

<210> 12

<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 12
ctcctgcacg gatgctgtt

19

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 13
gttccccgaa atgctgtgat

20

<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 14
cggcagagca cagcccactg g

21

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 15
ggcaaattca acggcacagt

20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 16
gggtctcgct cctggaagat

20

<210> 17

<211> 27
 <212> DNA
 <213> Artificial Sequence

<220>

<223> PCR Probe

<400> 17
 aaggccgaga atgggaagct tgtcatc

27

<210> 18
 <211> 7724
 <212> DNA
 <213> H. sapiens

<220>

<400> 18
 cgggagcggc gggagcgggtg gcggcggcag aggcggcggc tccagcttcg gctccggctc 60
 gggctcgggc tccggctccg gctccggctc cggctccagc tcgggtggcg gtggcgggag 120
 cgggaccagg tggaggcggc ggcggcagag gagtgggagc agcggcccta gcggcttgcg 180
 gggggacatg cggaccgacg gcccttgat aggcggaagg agtggaggcc ctggtgcccc 240
 gcccttggtg ctgagtatcc agcaagagt accgggggtga agaagcaaag actcggttga 300
 ttgtcctggg ctgtggctgg ctgtggagct agagccctgg atggccctg agccagcccc 360
 agggaggacg atggtgcccc ttgtgcctgc actggtgatg cttggtttgg tggcaggcgc 420
 ccatggtgac agcaaacctg tcttcattaa agtccctgag gaccagactg ggctgtcagg 480
 aggggtagcc tccttcgtgt gccaaagctac aggagaacct aagccgcgca tcacatggat 540
 gaagaagggg aagaaagtca gctcccagcg cttcgaggtc attgagtttg atgatggggc 600
 agggtcagtg cttcggatcc agccattgag ggtgcagcga gatgaagcca tctatgagtg 660
 tacagctact aacagcctgg gtgagatcaa cactagtgcc aagctctcag tgctcgaaga 720
 ggaacagctg cccctgggt tcccttccat cgacatgggg cctcagctga aggtggtgga 780
 gaaggcacgc acagccacca tgctatgtgc cgcaggcggg aatccagacc ctgagatttc 840
 ttggttcaag gacttccttc ctgtagacct tgccacgagc aacggccgca tcaagcagct 900
 gcgttcaggt gccttcgaga tagagagcag tgaggaatcc gaccaaggca agtacgagtg 960
 tgtggcgacc aactcggcag gcacacgtta ctcagcccct gcgaacctgt atgtgcgagt 1020
 gcgccgcgtg gtcctcgtt tctccatccc tcccagcagc caggaggtga tgccaggcgg 1080
 cagcgtgaac ctgacatgcg tggcagtggtg tgcaacctat ccctacgtga agtggatgat 1140
 gggggccgag gagctacca aggaggatga gatgccagtt ggccgcaacg tcctggagct 1200
 cagcaatgtc gtacgtcttg ccaactacac ctgtgtggcc atctcctcgc tgggcatgat 1260
 cgaggccaca gccaggtca cagtgaagc tcttccaaag cctccgattg atcttgtggt 1320
 gacagagaca actgccacca gtgtcacct cactgggac tctgggaact cggagcctgt 1380

aacctactat ggcatccagt accgcgcagc gggcacggag ggcccccttc aggaggtgga 1440
tggtgtggcc accaccgct acagcattgg cggcctcagc cctttctcgg aatatgcctt 1500
ccgcgtgctg gcggtgaaca gcatcgggcg agggccgccc agcgaggcag tgcgggcacg 1560
cacgggagaa caggcgccct ccagcccacc gcgcgcgctg caggcacgca tgctgagcgc 1620
cagcaccatg ctggtgcagt gggagcctcc cgaggagccc aacggcctgg tgcggggata 1680
ccgcgtctac tatactccgg actcccgcg ccccccgaac gcctggcaca agcacaacac 1740
cgacgcgggg ctctcacga ccgtgggcag cctgctgcct ggcatcacct acagcctgcg 1800
cgtgcttgcc ttaccgcgcg tgggcgatgg ccctcccagc cccaccatcc aggtcaagac 1860
gcagcagga gtgcctgccc agcccgcga cttccaggcc gaggtggagt cggacaccag 1920
gatccagctc tcgtggctgc tgccccctca ggagcggatc atcatgtatg aactggtgta 1980
ctgggcggca gaggacgaag accaacagca caaggtcacc ttcgaccaa cctctccta 2040
cacactagag gacctgaagc ctgacacact ctaccgcttc cagctggctg cacgctcgga 2100
tatgggggtg ggcgtcttca cccccaccat tgaggccgc acagcccagt ccaccccctc 2160
cgcccctccc cagaaggtga tgtgtgtgag catgggctcc accacggtcc gggtaagtgt 2220
ggctccgcgc cctgccgaca gccgcaacgg cgttatcacc cagtactccg tggcccacga 2280
ggcgggtggc ggcgaggacc gcgggcggca tgtggtggat ggcatcagcc gtgagcactc 2340
cagctgggac ctggtgggccc tggagaagtg gacggagtac cgggtgtggg tgcgggcaca 2400
cacagacgtg ggccccggcc ccgagagcag cccggtgctg gtgcgcaccg atgaggacgt 2460
gccagcggg cctccgcgga aggtggaggt ggagccactg aactccactg ctgtgcatgt 2520
ctactggaag ctgcctgtcc ccagcaagca gcatggccag atccgcggct accaggtcac 2580
ctacgtgcgg ctggagaatg gcgagccccg tggactcccc atcatccaag acgtcatgct 2640
agccgaggcc cagtggcggc cagaggagtc cgaggactat gaaaccacta tcagcggcct 2700
gaccccgag accacctact ccgttactgt tgctgcctat accaccaagg gggatggtgc 2760
ccgcagcaag cccaaaattg tactacaac aggtgcagtc ccaggccggc ccaccatgat 2820
gatcagcacc acggccatga aactgcgct gctccagtgg caccaccca aggaactgcc 2880
tggcgagctg ctgggctacc ggctgcagta ctgccgggccc gacgaggcgc ggcccaacac 2940
catagatttc ggcaaggatg accagcactt cacagtcacc ggcctgcaca aggggaccac 3000
ctacatcttc cggcttgctg ccaagaaccg ggctggcttg ggtgaggagt tcgagaagga 3060
gatcaggacc cccgaggacc tgcccagcgg cttcccccaa aacctgcatg tgacaggact 3120
gaccacgtct accacagaac tggcctggga cccgccagtg ctggcggaga ggaacgggcg 3180
catcatcagc tacaccgtgg tgttccgaga catcaacagc caacaggagc tgcagaacat 3240
cacgacagac acccgcttta cccttactgg cctcaagcca gacaccactt acgacatcaa 3300

ISPT-1006-Seq.txt

ggtccgcgca tggaccagca aaggctctgg cccactcagc cccagcatcc agtcccggac 3360
 catgccggtg gagcaagtgt ttgccaagaa cttccgggtg gcggtgcaa tgaagacgtc 3420
 tgtgtctgtc agctgggagg ttcccgactc ctataagtca gctgtgccct ttaagattct 3480
 gtacaatggg cagagtgtgg aggtggacgg gcactcgatg cggaagctga tcgcagacct 3540
 gcagcccaac acagagtact cgtttgtgct gatgaaccgt ggcagcagcg cagggggcct 3600
 gcagcacctg gtgtccatcc gcacagcccc cgacctcctg cctcacaagc cgctgcctgc 3660
 ctctgcctac atagaggacg gccgcttcga tctctccatg ccccatgtgc aagaccctc 3720
 gcttgtcagg tggttctaca ttgttgtggg acccattgac cgtgtgggcg ggagcatgct 3780
 gacgccaagg tggagcacac ccgaggaact ggagctggac gagcttctag aagccatcga 3840
 gcaaggcgga gaggagcagc ggcggcgggc ggcgcaggca gaacgtctga agccatatgt 3900
 ggctgtctaa ctggatgtgc tcccggagac ctttaccttg ggggacaaga agaactaccg 3960
 gggcttctac aaccggcccc tgtctccgga cttgagctac cagtgccttg tgcttcctc 4020
 cttgaaggaa cccatggacc agaagcgcta tgccctcagc ccctactcgg atgagatcgt 4080
 ggtccaggtg acaccagccc agcagcagga ggagccggag atgctgtggg tgacgggtcc 4140
 cgtgctggca gtcacotca tcatcctcat tgtcatcgcc atcctcttgt tcaaaaggaa 4200
 aaggaccac tctccgtcct ctaaggatga gcagtcgatc ggactgaagg actccttgct 4260
 ggcccactcc tctgacctg tggagatgcg gaggtcaac taccagacc caggtatgcg 4320
 agaccacca cccatcccca tcaccgacct ggcggacaac atcgagcgcc tcaaagcaa 4380
 cgatggctc aagtctccc aggagtatga gtccatcgac cctggacagc agttcacgtg 4440
 ggagaattca aacctggagg tgaacaagcc caagaaccgc tatgcgaatg tcatcgctta 4500
 cgaccactct cgagtcatcc ttaccttat cgatggcgtc cccgggagtg actacatcaa 4560
 tgccaactac atcgatggct accgcaagca gaatgcctac atcgccacgc agggccccct 4620
 gcccgagacc atgggcgatt tctggagaat ggtgtgggaa cagcgcacgg cactgtggt 4680
 catgatgaca cggctggagg agaagtcccg ggtaaaatgt gatcagtact ggccagccc 4740
 tggcaccgag acctgtggcc ttattcaggt gaccctgttg gacacagtgg agctggccac 4800
 atacactgtg cgcaccttcg cactccacaa gagtggctcc agtgagaagc gtgagctgcg 4860
 tcagtttcag ttcatggcct ggccagacca tggagtccct gagtaccaa ctccatcct 4920
 ggccttccta cgacgggtca aggcctgcaa cccctagac gcagggcca tgggtgtgca 4980
 ctgcagcgcg ggcgtgggccc gcaccggctg cttcatcgat attgatgcca tgttgagag 5040
 gatgaagcac gagaagacgg tggacatcta tggccacgtg acctgcatgc gatcacagag 5100
 gaactacatg gtgcagacgg aggaccagta cgtgttcac catgaggcgc tgctggaggc 5160
 tgccacgtgc ggccacacag aggtgcctgc ccgcaacctg tatgcccaca tccagaagct 5220
 gggccaagtg cctccagggg agagtgtgac cgccatggag ctcgagttca agttgctggc 5280

cagctccaag gccacacagt cccgcttcat cagcgccaac ctgccctgca acaagttcaa 5340
gaaccggctg gtgaacatca tgccctacga attgaccgt gtgtgtctgc agcccatccg 5400
tggtgtggag ggctctgact acatcaatgc cagcttcctg gatgggtata gacagcagaa 5460
ggcctacata gctacacagg ggcctctggc agagagcacc gaggacttct ggcgcatgct 5520
atgggagcac aattccacca tcatogtcat gctgaccaag cttcgggaga tgggcaggga 5580
gaaatgccac cagtactggc cagcagagcg ctctgctcgc taccagtact ttgttggtga 5640
cccgatggct gagtacaaca tgcccagta tatcctgcgt gagttcaagg tcacggatgc 5700
ccgggatggg cagtcaagga caatccggca gttccagttc acagactggc cagagcaggg 5760
cgtgccccag acaggcgagg gattcattga cttcatcggg caggtgcata agaccaagga 5820
gcagtttga caggatgggc ctatcacggg gcaactgcagt gctggcgtgg gccgcaccgg 5880
ggtgttcac actctgagca tcgtcctgga gcgcatgcgc tatgagggcg tggtcgacat 5940
gtttcagacc gtgaagaccc tgcgtacaca gcgtcctgcc atggtgcaga cagaggacca 6000
gtatcagctg tgctaccgtg cggccctgga gtacctcggc agctttgacc actatgcaac 6060
gtaactaccg ctccccctct ctcggccacc cccgccgtgg ggctccggag gggaccacgc 6120
tcctctgagc cataccgacc atcgtccagc cctcctacgc agatgctgtc actggcagag 6180
cacagcccac ggggatcaca gcgtttcagg aacgttgcca caccaatcag agagcctaga 6240
acatccctgg gcaagtggat ggcccagcag gcaggcactg tggcccttct gtccaccaga 6300
cccacctgga gcccgcttca agctctctgt tgcgctcccg catttctcat gcttcttctc 6360
atgggggtgg gttggggcaa agcctccttt ttaatacatt aagtggggta gactgagga 6420
ttttagcctc ttccctctga tttttccttt cggaatccg tatctgcaga atggggcact 6480
gtaggggttg gggtttattt tgttttgttt tttttttct tgagttcact ttggatcctt 6540
attttgtagt acttctgctg aaggacagaa cattgccttc ctcgtgcaga gctggggctg 6600
ccagctgag cggaggctcg gccgtgggcc gggaggcagt gctgatccgg ctgctcctcc 6660
agcccttcag acgagatcct gtttcagcta aatgcaggga aactcaatgt ttttttaagt 6720
tttgttttcc ctttaaagcc ttttttagg ccacattgac agtggtgggc ggggagaaga 6780
tagggaacac tcatccctgg tcgtctatcc cagtgtgtgt ttaacattca cagcccagaa 6840
ccacagatgt gtctgggaga gcctggcaag gcattcctca tcaccatcgt gtttgcaaag 6900
gttaaaacaa aaacaaaaaa ccacaaaaat aaaaaacaaa aaaaacaaaa aaccacaaaa 6960
aaaaaaaaaa aagagtcagc ccttggtctt tgcttcaaac cctcaagagg ggaagcaact 7020
ccgtgtgcct ggggttcccg agggagctgc tggtgacct gggcccacag agcctggctt 7080
tggtccccag cattgcagta tgggtgtgtg tttgtaggct gtggggtctg gctgtgtggc 7140
caaggtgaat agcacagggt aggggtgtgt ccacacccca tgcacctcag ggccaagcgg 7200

ISPT-1006-Seq.txt

```

gggcgtggct ggcctttcag gtccaggcca gtgggcctgg tagcacatgt ctgtcctcag 7260
agcagggggc agatgatttt cctccctggg ttgcagctgt tttcaaagcc cccgataatc 7320
gctcttttcc actccaagat gccctcataa accaatgtgg caagactact ggacttctat 7380
caatggtact ctaatcagtc cttattatcc cagcttgctg aggggcaggg agagcgctc 7440
ttcctctggg cagcgctatc tagataggta agtgggggcg gggaagggtg catagctgtt 7500
ttagctgagg gacgtggtgc cgacgtcccc aaacctagct aggctaagtc aagatcaaca 7560
ttccagggtt ggtaatgttg gatgatgaaa cattcatttt taccttgtgg atgctagtgc 7620
tgtagagttc actgttgtag acagtctgtt ttctatttgt taagaaaaac tacagcatca 7680
ttgcataatt cttgatggta ataaatttga ataatcagat ttct 7724

```

<210> 19
<211> 813
<212> DNA
<213> H. sapiens

<220>

```

<400> 19
caccggtctg cccagcagag cgctctgctc gctaccagta cttgttgtga ccccgatggc 60
tgagtacaca tgccccagta tatccgcgtg agttcaaggt cacggatgcc cgggatgggc 120
agtcaaggac aatccggcag ttcacagttc acagactggc cagaagcagg gcgtgccaca 180
agacaggcga gggattcact gacttcatcg ggcagggtgca taagaccaag gagcagtttg 240
gacaggatgg gcctatcacg gtgcactgca gtgctggcgt gggccgcacc ggggtgttca 300
tcactctgag catcgtcctg gagcgcatgc gctatgaggg cgtggctggc gtttcaggtc 360
caggccagtg ggctggtag cacatgtctg toctcagagc aggggccaga tgattttcct 420
ccctggtttg cagctgtttt caaagcccc gataatcgct cttttccact ccaagatgcc 480
ctcataaacc aatgtggcaa gactactgga cttctatcaa tggtagtcta atcagtcctt 540
attatcccag cttgctgagg ggcagggaga ggcctcttc ctctgggcag cgctatctag 600
ataggtaggt gggggcgggg aagggtgcat agctgtttta gctgagggac gtggtgccga 660
cgtccccaaa cctagctagg ctaagtcaag atcaacattc cagggttggg aatgttggt 720
gatgaaacat tcatttttac cttgtggatg ctagtgtgt agagttcact gttgtacaca 780
gtctgttttc tattttaaca aggaaactac agc 813

```

<210> 20
<211> 94001
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> 605-704, 63461-63560, 92457

<223> n = A,T,C or G

<400> 20

aatggggtcc	tagagtggta	ttaggttcat	gctagggctg	ggagccacta	gaaggatctg	60
gatgtagtat	cagagtttgg	tctgtctatg	ttcattattg	gggttcgggt	tcaatattga	120
ggttccggtc	ggtttcgact	tggcgttggg	ttgtggcctg	tcagggcctc	agcggctccg	180
cggctctacg	agcgagagtg	cacgagggga	ggggcgccgc	cggggcgcg	cacggcaggg	240
gcagggcgcg	gggcgcgagc	gcgaggggag	cgcgcggtcg	gagctggcg	gggagcgcg	300
ggagcgggtg	cggcggcaga	ggcggggct	ccagcttcgg	ctccggctcg	ggctcgggct	360
ccggctccgg	ctccggctcc	ggctccagct	cgggtggcgg	tggcgggagc	gggaccaggt	420
ggagtccggc	gcggcagagg	agtgggagca	gcgcccttag	cggcttgccg	gggtacatgc	480
ggaccgacgg	ccccgtgata	ggcgtgagt	gacccccgg	ccccccacca	gccccctccg	540
ctcccgtccc	ttcccgtctc	tccttgccct	ccccgctagt	ccaccggcg	gagctggggg	600
cggtnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	660
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnaaccgg	gtgcaacgcc	720
ctggaggccc	tggagcgacc	tgtcccgtga	ggacgtggcc	actcggacc	tctccgaaag	780
ttcactcagt	ggcgcgcccg	cgccccgtcc	cgccccgtcc	cggctcccca	tcgcccgtgc	840
ggcgtctctg	tctcggctgc	tttctgtttt	cctcggcgctc	tctgcctccc	cgtgtcagtg	900
cctcccaatc	tcacgcccct	gcaatcccag	ggtctctcca	gctgtctcca	ttctttttcc	960
ccaggtcact	ctgttctttt	tccccaggtc	tctcgattct	gtctccctgg	gtcgtcttgt	1020
ttcctgtccc	tgagctctgt	tcctccgctt	gggtctctct	atttctctc	cctgggtctc	1080
tgtctccctc	cttaagtctc	tgcctcttgt	ctctcaccga	tctcttggtg	tctctgcact	1140
ctctgtgcta	ggcgcccccc	catttccctg	gaatgctgcc	cctctgggtc	ttccaccccg	1200
gagggggagg	ggctagactt	tctccccatt	tcaagcccc	ctgccccca	gtgcacggcc	1260
cctgagtttg	agcaggttgg	gggtggggag	cgctacctgc	ctgagctgtg	aaatgggaga	1320
gggaggtctg	cccagcctgg	gggtgtctg	gatctccctg	aggggccaca	gggcagggcc	1380
gggaggctgg	attaggttga	ggaaggctcc	acttttgaag	gaacaggggc	agggatccag	1440
agcgtatctg	tgtcggatct	ggcctgagaa	gcagggaagt	gcactggggt	gagaggcgta	1500
gaaaaggatg	tggggtggtg	gttccaggcg	ggtgctcatg	gggaggaatc	tgctgagaag	1560
ggaagatctg	tgtgggaaatc	tttggggagg	cttcggggat	ctgagggatc	cagaagagag	1620
ttctgacagg	ctatctaagg	aaatttctgt	gcttagctcc	ttattaactc	ttgcttcagg	1680
gagcatgaaa	atccctgttt	ttttactgat	tatatgaatg	agcctagggc	ttcaagaagg	1740
agcaggtgta	actccccaa	tacaaccccc	tacattctca	gccccaggca	caggccacac	1800
tttctcgtac	cctcttgctt	tcatttccac	actcagctca	ccccctccac	ccccacacac	1860
actccctatt	cagctgcttt	cttgccccct	ctcgcatacc	tgggcccgc	tgccggccag	1920
ggctcaagaa	atctgtgcct	gcacactctc	gcagcatacc	tgtgcacatg	cacagtcac	1980
cttgtgtatt	tttgtatatg	cactttcttg	cacattttac	ttgctcagtc	tcttatttga	2040
aatgtcttta	tagtgttttt	tttagtttcc	tttatagttt	ccttttccag	ctgctcttcc	2100
tcttccctct	ttctttccct	taacaagaaa	attgttttaa	cataattcct	tccttccctc	2160
ctccctttct	tccttcttct	tgcaactact	gatacctccc	ctttatccag	ctttgtgtgc	2220
cctgggaggg	ttggcttggg	gtacaaggct	gccaagagag	gaggggggtg	ttgggtgttg	2280
gtgaaggaa	ttggcggggc	agagtttagc	tgcagcaaac	ggaaactagc	tacacatctt	2340
ttactgggaa	gtgtatggat	acgcagcaaa	atactagccc	tggcagtttg	ggcacagtcc	2400
accctttttt	ccatcagcct	gacatagggg	agcttagctt	tgagggctct	ccctgggggc	2460
ggggaggagg	ggaccagac	ctcctgcagt	agaggggttg	tgatacacac	cacggctcct	2520
ccactttcca	gcttcaggcc	tcaaaggagg	ccctttctcc	ctgagctctc	atttctactc	2580
ctgtaaaaatg	gggtagctaa	tccaacccgg	actgggtccc	agggctgttg	taagaatcca	2640
agggaactgt	gtggcagtgc	atcgctagca	gtggcagtca	cttcccttgt	gactgacact	2700
gctgtgtgct	tggttccagc	ttgcagtcag	ggccctaccc	tcgagaagct	cgtggtcctt	2760
gggggagcag	gttgaccat	gggattgcaa	aagcaattca	gttacctgtc	attgattgct	2820
gactgtgtgc	cagaccccg	ggtagcgct	ttcggccccg	gctgcctttc	ttcctttggg	2880
actaacagct	atgtagaaga	ggcagccac	ccctaagggt	caggcatctg	ctcaactaaa	2940
gcagctcgcg	ttctagttg	ggttagaaca	ttgcaagagt	tcataagag	acgggggaga	3000
gttcggagg	cagggtgagg	tgagtcccag	aggagaccaa	gaagaagtga	tgtgaactag	3060
gtttggagg	atgagttaga	gtttgaagaa	gagagaaagg	acttgagata	gataaaaacc	3120
acgatgaata	aagactggga	ggtgttgtca	cttgtgaagt	attcagagat	gtggcagatc	3180
acagaggcca	ttgaatgcc	tgttaagtac	ctgtaatttt	actctgagaa	cccagagaga	3240
aaacacaaaa	ggtttaaagc	ttggatagg	aggggtgag	gtgctgtggt	caggtttatg	3300
tttccagaaa	atgctctgtg	gctatgggaa	aaggatggag	acaggatgcc	cagtggggca	3360
agaggggtga	ggtaagtaag	gtgagagaag	atgctggctt	tgatagggtg	tagcatgggtg	3420
ccatcttgaa	ggtacacttg	tcaggacaga	atgatttatt	ggatgtggga	gtgaaggaga	3480
ggaagaggaa	ggagtccagg	ttcctcgag	tgggtgagcg	ggccttcaact	gaaggccctg	3540
aagcttcaact	gtgttaggga	cttgggtgag	aggggcagag	aataagctct	tagttggaca	3600
tgtggccctt	gaggtacttg	ggacattgga	ggctcagtg	gggaggcaca	tcaaggagg	3660
gctttggtgt	gagggtatgg	gagagaaatg	tcggtcggac	caagagaagc	gagagctgta	3720

ISPT-1006-Seq.txt

tgagagacca	tagagctgtg	cacctcgaga	gaaagtaacc	tccgacagtg	gtgaagagct	3780
cgagttttat	actgctagga	ttggactctg	tttactagca	gcgtgacttt	aagcaagtgg	3840
cttaacctct	ctgaatccgc	ttcctcattt	gtcaaatgat	tataataaaa	accctgtcct	3900
tataaggggt	gttatgagga	ttaaagatag	tatgcataaa	gtgtgtgtag	cacagggcct	3960
ggcatctagt	gagtagctgt	gtctgtgttt	gcagttactg	taatcatcct	caactgggat	4020
ggtgtaaacc	cacctctcca	tcaggggtca	catgagggtg	cctttaatga	gaagatagac	4080
tgctaagggt	aggggtccctg	tctgcctaag	gttgctgcaa	ttctgagctg	agattagcag	4140
gtcaaggagc	tcaacaaagg	gggtgcctgc	ccctattgtt	atcgatggga	ttgttttgtt	4200
tgctcagggt	tttgaccttc	aggtgggtgg	gcttgagaag	actagagggtg	aggcctgcag	4260
aagagactcc	atgtttgggg	taggtggaag	ggaattttga	gaaggggcag	ccttggggta	4320
ttgagttctc	catttcctcc	cacctccctc	gggcccctgg	cttctactga	ggctctttct	4380
gccaccatct	gcctctgttg	tcagatgca	ccatgtctct	gtgtgaccgt	gacttctagg	4440
tctgagaact	ctggttttag	ctccttagca	gtatttttag	tgctgtttct	ggggactgtt	4500
cctggtgcag	ccacaggggc	attctggggg	ttgctccaga	gggcagctgt	gcctgcattc	4560
ccctagggtat	catcgacttg	ctcctgacct	actgccgggc	caggtttcag	gcctggcaga	4620
tgatggggaa	ccctactggg	gccagccctg	cgttggcccc	aagggctttc	tttcttgata	4680
ttggacatga	ctgtggactt	cacctcttct	gaggcccttc	tgggtgccaa	gcagtgtgat	4740
ttctttcttt	ttctcttttg	tttgaaacag	aatctcactc	tgttgcccag	gctggagtgt	4800
agtgtgtcag	tcgtggctca	ctgcagcctc	cacctcctgg	gctcaagtga	tcctcccacc	4860
tcagcctcct	gagtaactga	gactacaggt	gtagtccac	ctggctaatt	tttgtatttt	4920
tttagagaca	gggttttgcc	gtataggttg	ggctgctctt	gaactcctgg	ctcaagtgat	4980
ccacctgcct	tggcctccca	aagtgccggg	attacagggg	tgagccactg	tgactggcca	5040
gcagtgtgat	ttctaacttg	ggtcctgaac	cattcaggcc	ctttctgagt	agctttctag	5100
tcaaccttcc	agatgtcagc	tctggctctg	ttctgggggt	gtatctggtt	gtcctgggtg	5160
ttctgggctc	tgtcccagtg	tgagtgtaga	gtgggttctg	ggagctgcag	ttggtgaatc	5220
tgagtcttta	tttgggttgc	tgataggttg	ttttgaggtc	agtttgatcc	cagactgacg	5280
tggttcaaa	ttactgtttg	gcttttctag	gatactgccc	tcagtctgtt	ctgtgtgcct	5340
cagggctctt	gcaaatgttt	agtcttctaa	aatggcccct	ggccactttg	ggtacacacc	5400
tctttccagg	tgtggcttct	gctccatgta	gggcctgtct	cagtctccaa	gcacgagacc	5460
ctgctgtggc	tgggtgtggc	agcagcgctc	ggccagcttg	gggggccttt	ccattatccc	5520
agttccctgc	cttggactct	gccccctctg	ccagggctct	tgcaaatgg	tgacgcaaaa	5580
aacctcactt	gaatactgtg	agccctctgc	ggcatctcta	gacaaatggg	cctttaagtt	5640
tggggcctgg	aagctgggtt	gtctggccag	acctgctggg	cagcctgtat	gctgggagca	5700
gcagctgctg	gaaactcagc	ttggggagcg	gggaggggag	catgcagaga	gggctgcggg	5760
ttctggtgca	ggtaggtggg	gcagtgagg	ctgggtcgcc	aagctggcga	gggccatctt	5820
gggtcagttg	ggatggcctt	cagtcgggtg	gagtagcccc	atattggcag	aggtgggttag	5880
tgcaacttga	gggtaatcc	caggtgcaga	ggtgtgtcct	tgatttcatg	atgaggggtca	5940
gtcttggggc	ggtgaggaca	ttcccacgca	ccacctccc	actgtgggtt	ctttgtgtcc	6000
ggttataggag	gagccaagg	ggcagagtgg	tgtgggggtg	ggatcactgt	gcatgtgggg	6060
gcttgagggt	agaagcctgc	tgcaagggtg	agcttgctgc	gagtagggcca	aacagctgag	6120
cttccgtgaa	gtggtgatga	ggtggtatgg	gtgtgtctga	ccccacccc	caccagggat	6180
ggtaccacag	ctggtgggga	ctcaataatg	gctctagaag	gaaggggctg	ggctctgtcg	6240
ctgcatgtgt	gccagcggag	gaggcatcca	ggggcacgcc	ttcattttta	aaattataga	6300
gtagagaaa	tcaaaaataa	atattgtctt	tgaagcttct	ttgaagactg	gcatgtatgt	6360
tgggggtgtg	tcttccaggc	tgggctgttt	tctttgaact	cattcatgcg	ttcatccact	6420
cattcagtg	atgctgactg	agcacctact	atgtgccagc	tgtagccag	gcgctgggga	6480
tacggaaatg	agctgggcag	ccacagtcca	tgctcctatc	aagcttatgg	tagtgactca	6540
gtaattgtaa	aaatatataa	atagtcatgt	ttgtgggtcac	ggctccaagc	caagggtccag	6600
gcaggtagtc	tgggacattg	tgggaaggctt	ccctgagaaa	gtgccactgg	acttgagatc	6660
cgagggttaag	ttggccagaa	gagcatgggt	agcctgtgcc	aggcagtggc	attcagcact	6720
ggcaaggctg	ggagacagga	agaaatttgg	cacattttgag	gatcagaaga	ggaagttccc	6780
gttctggcag	gaggagagca	tgggcaggta	gggctgcaga	ggtgggaggg	gccgactctg	6840
cttggctctg	gggtcatgct	gaggagctgg	gccacagagt	ctactgtctga	ggtcagggac	6900
ttggtctgtg	tggctcacag	ctatatggct	ggtgcctgga	aggacgccc	gcacatagta	6960
ggtgcttagg	gagtatcaaa	atgaatgagc	gagggagtg	agggaaaaga	tgggcatttt	7020
taccagatgg	gtaggttctt	acatgaacat	ttccataacc	tgtttttttt	tctgcataaa	7080
cagcaaat	ttaatgtctt	tctgtgtcaa	tacatatgct	gttgtgatga	aattcttgat	7140
gttttctcat	gctttccttt	ctgtccagga	aggagtggag	ggcctgggtc	ccggcccttg	7200
gtgctgagta	tccagcaaga	gtgaccgggg	tgaagaagca	aagactcggg	gagtgtgccc	7260
cacagagtgg	ccaggagcag	gggtgcacag	gggtcctatg	gaccaggctg	agcagcttgg	7320
atttgatgca	gggtcagtg	agagctatag	aggggggtgc	agcagggggc	atgacatgat	7380
ccagtgtgca	ctggtgagag	attgtggagg	cctggaccag	ggaggcagtg	acagaagtgg	7440
agagaaggga	tgtgagtgtc	atttagggag	gtagagtaga	caggacgtgg	tgaaggattg	7500
aatgtggggc	atgaaggagg	ggaggtgtca	aggatggtgc	ctgagtttct	ggctggagtg	7560
gatgatagag	gtggatgggg	aatgacatac	agctcgtcag	ctactgtagg	tgtgaaatag	7620

ISPT-1006-Seq.txt

```

gcttccgggt gatgtcctgg gacttacacc aggatctttc ttctgcttct ccattcgcca 7680
cgtttctgta gaaaagactg ttcccatcga ctgtagggtg tcgtagaaag agcttggtgc 7740
ctgcaggatc tgggcatgtc ctttgatgtc cccttggtct cctctctgtc 7800
tgttagaagc acagaatggg tgggctggag ttgcagggaa tgaggttggt aagttggttt 7860
agagtcagca tcatgggcct tggatgtcag gctaaagact ttagactttt tcctgagggc 7920
aatacagcag cattgaaggt tcttaagcag agaagcaata tccatgtgtt gatctgtcca 7980
ttgcccatcc gttcattctt tcacggaaca ctgtctgaat gcctgctgtg aaataaagtg 8040
gcaaacaaaa gtgcagatgtt gcatttttat gtgctgaaag gtggcactgg tctgtgtgcg 8100
ggatgggttg ggagtgtatt aaggcaggaa gccaccaaa gaggcaggaa gtgatgaggt 8160
cttactaaca cagtggcagt gaggatggag gcaggtcaga ttcaaaacta ttgatgggtt 8220
agatgtgtgg gatgaggaca agggagcatt taaggagggt ttgctgggctt ggtgactgac 8280
aacatgggtg tgctgtcccc accctggagg aggagtggaa ttggggcaga 8340
tgagttctgg ttggccatc ctgagccaag agctcgggtg gtctgttcac cctctgtaag 8400
ctcctcgaag gcagagcctg tgactctctt gttcatcacc ctgccactg aacatctgga 8460
cgggtggctg aactaacaag gctgtggaag agatgggtct ggcctgggta ggggaaggaa 8520
atgtgtatgt cctgggtgtc tcctgggggtc cagaccctac gtttggtgag atgggactg 8580
gggttatgta gagggtgcag caagaggggc tgtgtcacag gctggaagg tcagatggg 8640
aggggtgggtg tagggacact atgtgtccct ttgcctctcc atcctcagat gatggtctga 8700
cctaactcga agtccagtct tgccagaata ggtacctgaa ggtggagccc tctgtcctct 8760
ggggaggcca ctagctgatg gcatgtctgg tggggtgcag atggggtgtg ctataggacc 8820
cgactgtctg gggctgggtg ggggttacag ggggaagatac tctgagatcc 8880
tgaggccagg cgccagcaaa tacaggagtt aagccagggt ggagcttctt tgggtacaag 8940
gccagggtg cccacagggt attgggttct ggggcagggt ccaggtcagg ctctaggctc 9000
aattggcaaa ggatctgtt gtctgtgttg gggtttctca gcctcagcac cattgacatt 9060
ttgatcaga taaccttat tgtgggggca gggcttggtt ttgtagggtg tctagcagca 9120
tccctggttt cttcccccta gctctcccc gctttcccca gtctcgaca 9180
tcaaaaatgt ctccagtcgt tgctgtcttt cactatactg tacaacctg gaaaattggg 9240
aacctctggt ctacagcctc gatagtgtg ggccacttga gcagagttct gaggggtgag 9300
tgagtgctgg ggcaggagaa ggacattttt tccaataga cagaacggca ggtacagagg 9360
cttgagggca caaagtggg aaacagtaat ccaaggggga cccagcccc agaggaagg 9420
gcctggaggc ttaggggtta cagccgcagg aagatacctc tgctgttccc ctttgggtcat 9480
ttgcctccag agttagtctc ctgtgacccc tttgccgcct ccaagtctct gcgacactcc 9540
tcctaactct cccctccact cctcagtgag atggagaaac tgagagctgc aacagggtgg 9600
gactcagttc agctgggtgg agccccgata ccagccgtgg gagggagggc tgttcctggc 9660
tctgtcacg gattctggcc aactggctgg agggaggaa ggggcctcac cctcttccc 9720
acaggccct ccttccctgg gtacgggtgc ctggctgaga ctataattta ttcccgctcat 9780
aatccagtgg ttggtttgtg gagagctgga aacatgttgg ttttccctc ccaagtataa 9840
caagccctgt ttccgctcc agctgccgc tggttagaag atgaacggct ctgtccagga 9900
catgacaaaa gggctcggtt agctgccgc tgggttagaag atgaacggct ctgtccagga 9960
cctgccgaca ggctcttccc ttctgttgc ccaagtgtg gcctttcctc ttggcogtct 10020
gctctgtagg gccctggata cccctccttc tgctcatgtc catttctggg cccaggggtc 10080
ctggcctggg gagtgagat gggggaggct acagaaacag gtggatattg gagactaatt 10140
aatattgtg aataataatg catgccaaag caatctgtgt ttgcgtattt 10200
atgatgagga ctacaggaat atcccagctg ttctccagcc agggagccc ccatcacatg 10260
gtcccttggg cccccacaga ggctggcagg gtggttaggg tgggctgcat ggaggtgaca 10320
tggtcttctg tttttgcaac gtgaatcttc tgtgacgttc atatgcgaat gctgtggctt 10380
ggctagtgc ctgcttcttc cttttccctc aaagcagtga ttcccaggct ctttgggttc 10440
acgaaccaat acaatttcca aaagtactca agagccagac atgggggttg caatttttta 10500
ttttgccaa gtaaaggcatt ataaaaaac aactgctatc tgctgtcccc atcatttcat 10560
acaggaaaga acattttaac accaaggaca atatttgaga ataaaggaca gttcttccca 10620
agaaagggca gttggcagct ttacactgac gtagcaaaag gtagcaaaag attaaaacca 10680
ttctgaatgt gtaaaaattg tgtccaatta tattctataa tatcataccg tatgtaattg 10740
tgttcctgct caagtatgtc agcttggcag aacggatggt ccacagtgc attcagagac 10800
gagcttgagt gccccagtgc tccggccttg tttttatctc ggttgttgaa agcccaggct 10860
caccagcca tgcgtgtgaa gtgggtgttc tgcgtgaaac accgttgcat ggattcaca 10920
gatctcaac ctgcgaaccg cagtcaggct agcagagcc ctgccccttg ttccctctcc 10980
accttctccc cacagggtgac cctgggaccc tgggactctg ggggccaagg tctactcttg 11040
aggccaggcc tggggatcca gggctgctct gctctgatga gggaggccct ggagctggga 11100
gtggcctgaa ccgcctgaca ccagggcagg ctctgtgccc ggagtctcag ggcgggaggc 11160
agctgtctct cggcaggagc ggggcccctg ctcgtacagc tctgtggctg ggtgtggctg 11220
ccagagtgtg tgcctgagaa tgtgtttgtg tgtgtccctt gtgtttcccc atctccctgg 11280
gcatctgtgt ctttgtgtcc atcatggacc actggaagaa gctctctgtt ctactttctg 11340
gatctgaaca aagtgtcctg agcaccocaa cccagatata cagggggttt ctggaggccc 11400
cacgttgggg gtagggttac ctgaggccca agttctccaa caccatggc cagactctca 11460

```

ISPT-1006-Seq.txt

```

tccaggcttg taccacatgg gtgtctatcc tgggagtttt acccccatga tggctctcct 11580
gggagctctg cccccacat gaagtctgta acagcacgtt acacctctgc taatgtatgg 11640
ggagttgcac ccctgtaatg tccttatcag gcagctgcac tccatgatgt ctgtaccctc 11700
tgtgtccgcc cacgtgatgt ctagaccaca ccattacacc tccatgatgt ctgcacctgg 11760
gcgttatact gctatgatta ctgcaccaag gcggctacag gggattaagc ctctgctcat 11820
tgtactgggg agctatatcc catgatgacg gtgctgtgca ttttattttc atagcaggga 11880
gatatgctca tgctgggggc ctatgtccct atgaagcctg cctggcaggg gttgcatgct 11940
tggaatgctt gttcctggaa gttaacctct gtgactatta tattgttata cccgatgatg 12000
ccggtacgag gccactgtgc cctgtccttt ggtgcaacac agctgttgag ttataaactc 12060
atgtgtctca ttcaggggct ccaggatggg ccacagggg accatacccc catgatgacc 12120
tggcctggca taggatacca gatgtgtcca caggcccagg gaggaagagc cactcatagt 12180
ccaccacctg atggccgctg ggaaggtgct ccctcgctgg ctgcatgtgg caccatagcg 12240
caagctcagg cagggccttg gtgatgtgtg acctccatcc cactgtggcc ttgcaggcgt 12300
cattgtggtc tcagccacct cagctctggg atcgtggagc agatccatcc ccagcttggg 12360
gtaaatgggg ctggacacct atcaacgttc ttacttgaag aactgggtga aatgaaggct 12420
ggacaccttc cccgttctt actttgttgt tcagctcctg tctcagattt ttgggtggat 12480
cctgggacag gggacaactc tcacctctt tcctttgtgt ttggcccat cccactttgc 12540
attccacctt gctttgtcca acacctttgc tcaactgctg ccttctgacc tcatgaactt 12600
tgattatctc agttgagaca agggttcaaa tttcagaaac gactggagca cctttgagcc 12660
ctgccatttc ctggtcacct gacctgtcac ctcttaact ctcttactat tgtgggtcag 12720
cggggacctg ggtctgatca caactcccct atcaaaagtc atgcgtatca ctgtggggcc 12780
ccaaggcgtg ttcaccgtca tgcactctgc tctgttgcgt cttcacagca ttcatgaggg 12840
atcgaccacg tctcaccct ctgcccagag catggtgtga tcagagcttg tgggcccttc 12900
catcatccct ctggtgcccc ccagggtgag ggtatgggag agagaccctg gggagctcac 12960
cagtggggcc agggagtgat agcagcgtat ctccatgta tagtgcgcc atgctagagg 13020
cttcaccag gtgcctgcag gcacttcagg ccaggagcct tggaagttaa ggcctagggg 13080
cattcagcca gtcccagacg ctactcagtc tttttgtgca tagcttctctg tctcaaactt 13140
cagccctga ggttcacacc ccactcatccc tacacttgtt tggctccggg cttctggggc 13200
aagggcagaa gagatgtgag gtttgaattc tagggtctaa caccctctc ctggccactg 13260
aggcctccct gtggtttctc tgtgaagtag gaaggtgcca tggaatggg taggacgagg 13320
gtggccaggc agggcagcag cagcttgtca agagcacgtc ctggtgagca ctgaggggtt 13380
gtggctttgg ctggaagcct ctgatacctg gagcctgtct tctgctaaca agcctgtgtt 13440
caggggcctg tgctcagcgt gctcgtggag tctggcctcc cacttctcc ctccctgctg 13500
gggagggag gggcaacaga attctaccag gtagtactcca gactcagttg gctttgccc 13560
tcaactgctc ttgtcactgt cttgtctctc tgcctctgt cccacgtaag cgtctctctg 13620
accctgttcc cctgtcctct tatgggggtg agttagaagc tcaaggtttg gactggaaca 13680
cactgtacat cctctggtct cactcactcc ctgtacctcc tactcaggtt tagagaatgg 13740
cccgaaggcc cctgcgctc tttctccctc cactgtgact gttggctgt ccttgtgggt 13800
gctggggaat aagtgaggag cttgggtggg cactgggtgc agaaggtcta ggtggtcatt 13860
gcacagccca agtggggggc tctgttgaa taggctctgg atggtcagtg aggatgactg 13920
ggggtcagaa agcgtcaggg gtgggcatta gggacagcag taaataccag ctaactggct 13980
ctgcccttct ctccattaca ggttgattgt cctgggctgt ggctggctgt ggagctagag 14040
ccctggatgg ccctgagcc agcacgtagg gggacagcag tgccccttgt gcctgcactg 14100
gtgatgcttg gtttgggtggc aggcgcccct ggtgacagta agtctgacc ctcaagggtac 14160
agatctccca ggttgaaagg tggcatcctt cccagcagga ctctgggatg gggacagacc 14220
ggctactagg agagacaggg tggccagaaa ccctttagac cttctgtcct agagagcccc 14280
cactgcttgg agagcctcct tctaaggaa ttagggagct ctttaggcac ctttaggcac 14340
cagagcgggg cagtgaatc gtgacctgt cttatggggc tggggtgaga cctgtcctgg 14400
attcatgttg tcattgtgtg atgtgcgct ctacagccag ggtcggcat gggatgggg 14460
tgctgaaggc acagtgtgag ctacagccag ggtcggcat gggatgggg ggtggcacgc 14520
agggcatgcy tatgtgatgt tgcccaggac gcggtgtgt ccataggccc aaggagggtc 14580
aaaagcggga gccaccata gctcttcccc tacgtggac cctcaggatc caagtatgca 14640
gatctgagcc cctccttctc ctttcatggg gaccttctag gcaaaggagc atccccccac 14700
cccagctcct cagacctgga aatgggggga agattgtgtt tggccggcag gaagctgagc 14760
aacgcccctc tgttgtgtgt tgtgttgag ggaggtggaa ttgtcccat ccagatccaa 14820
ctccgaactt tggtccttt cctgtgccc ttccccctgc ctggcactat gagactggcc 14880
tcagcccgcc ccactgccc ggttaccact ccttggttac tgggtggagg cggggcacag 14940
ggcagattta gccaatctgc aggtgaggg ggagggcgga ggtcggagcc aaggtccctg 15000
ggggaagggg ccgttcccag cctgtccaga gcccagggg gatccagggc caaccctggg 15060
gtcagccac ccgttcacc gcataggc tccccacct gcctccgtat ctctgggtac 15120
agatctctcc ccttgcacca ccagggtctt ttctccta ggtcattaa ttattcagga 15180
actgattctg gagtgggtg ggactggtgt ggtcccggc tttgtcctca agtgctgggt 15240
cctgggtgga gctagaagg aaaggagaag gggcaggcat tcccaagggg tggggcaaag 15300
ggtcatggga gcaccaggt ccaaagagag ggctggcgag gtgagagcaa ggaaaaaaga 15360
caggtgggga atcacatggg gaagtggggc aggggatctc caggcctggc tggaaacctg 15420

```

ISPT-1006-Seq.txt

```

aggggagcaggt tggagtagaa agccttatca ggtgtgaccc acatggttgg caggaaggtg 15480
aaggcttgtc cagtgtagt cagtagctct tggacattga agtactgtcc ttgccctccc 15540
cgccgaccca accccaggca ctttcagggc cttcagacag gagctctagg gcaggggaag 15600
gatggccag tgggcttca acagataaca catcctggga gaagagctgc cctcctcctc 15660
ctgcctcaga cccaacgcgc cccaacctgt acccctcact ctcatccccc agcctgctgt 15720
cttcccgtgt tctctccgt gaaaggcatt accaccacc cggtcaccca agtcagaacc 15780
tgggctcct ccagcctcct ccctcgtga tatccacat ctaatccatc accaagctcc 15840
gttgcttcta ccttctgaat atctttgaa tgcattccact tctctctcta ccgccttcat 15900
ccaagccacc ctgggctctt gggcttttgc acgcaacagc ctctgacgg tttccctgcc 15960
tccagctctt tcttctctaa tccattctgc attccaaagg tagagtcgtg tcacaaggtg 16020
aaaacatct cctgtcactc ttcagtttag aatccttcat tcctcccac cccaggccc 16080
ccagggtcgt aaccttctta taggcctgc attatcaagc ttctatcaac ctcatccctc 16140
gctgtccctc caccaccccc actcaccac cagctgact tctttcagtg gttcaccaat 16200
tcccagtagt aattggtagg ggcaagggg aacagttttt aaagcagaga acctccatgc 16260
tggttcttta ggaaccaaag cccaaacacc aggtcttgac ggtagaaagc agctgaagaa 16320
gctgaaatcc tgccttcttc aggtaggggg ttcaggggac tcaggccttc tcccaggcag 16380
agagccatgg ggcaggagcc tgggctggg gtcagagtga ccgagccgca ggagccaggg 16440
tctgtcttcc aggcctgtct tacactgcac acagttttg atctctccct gcactgaggc 16500
agggctcagg ctgagcttgg gcaactacta gccaggggca agtggccata cacagacagg 16560
gccactgcag aagatagggt aggcaccca gagaattgac agctggggca gtgaagcgcg 16620
gagtgagcaa atgtgtttca ataggcctc taacgagaca aatgaatggg gccctggcc 16680
tctgagggga gtggagggaa gcgggtggag aagcagctgc caagagttag ccagaggcc 16740
ccagtgctag tgccgcacgc gcagctccag tggagatttg ggcacacatt ggggtaggat 16800
ctgctgcagc gcagcttccc cagccaggct ttgtgcttc tcaggagggg aggttgtggg 16860
gctgagagtg tctgtgcca gggcagaggt ttttctgat ctcaagtgcg tgtcgcgtgc 16920
ctgtcttcag gcaagacctg cagtggtggg gcacaggctt gtgagcagtg accacagggt 16980
gtgctgggta ggtggcactg acacaggcca tggcagaagc atcttgggag aggagtggg 17040
aggttctctg gaagagggga gccctgaag gtgagtgagc atttgctaag gggggggtat 17100
tgcataatcc ggtggggttg cggggaagaa gcacgaatgt ggctgggctt ctctgtggaa 17160
ttcatgggag agccacagtg agaaccgcac agcatgggac agaggtggg tccgaagacc 17220
aggtgggagt gagacctgg ttatggcca tttaccaga atcctaggag ctgagagcag 17280
gatgcgtgct ggctggaggg gtgggtggcg ggtgggttga cagaggtggg cagaggtga 17340
ggagctggga gtgtgtctgt tgtgtcattt ccctcctccc cagagcctgt ggagcacaca 17400
gggtctgttg tctgtcgtca tctctctccc ctgttctat ggggtggcct tctagactct 17460
gctccctgtg ggaacttccc cagattccgt tgccttctct ctctgggcct gttttcctat 17520
tgcacaatgg ggataatcac tcctacctgg aaaggttaac tgaggtcaca tggatgaggt 17580
gcctggaacc tagtatgtat tccccttacc tgaggccatg acctggggct cttgctctgt 17640
ccttggaacc caggcttctg tctgagtgg ctccaaggga gtaccaggaa cagtcacagg 17700
agctcactga gtcccagctt aagctgctca gaccagggga tatctgtctc tccagaagct 17760
cctgcccctg ccttcgcggg cctcatggc cctgctccg tgtgtacatg tgtatgtgta 17820
ttccatggga aaggcacaaa atagcagtc gtctctccat agaagagcct tgatggtggc 17880
ccagtttgac tctcctggg gctggacccc tacagcctc ctgggaggtg gttgcagccc 17940
ccttctccca gccagttcca cttactcct tcttaggcca ctctctccca cctgcatgg 18000
gcttggtggc tcgagaatgt tgccgtccat accccgggag ctgtgctgaa agggctgtgc 18060
ggccccgcac cactgtgtgt gtcaggagg gggcacgctc tcgtgggggtg tcaggccagg 18120
tggcagtggt taactggcag aaaggccctc ctggtgtgct ctggtggcac cctgttgacc 18180
cagtcctcaga agttgtgttc cgaccctcac tgaacaccag ctgtgggtca ggcacggggc 18240
agagtagttc aagtagcttg gtttctgcc tgcctgggga cctgacactg tgggatctgg 18300
tcagtgtctg gatgggaagc tctgggcacc tcaggccatg ggacacagag caggctccta 18360
cagcagcttg gctgggtggg acatgagaga ggggctggg tgggcacact caaaggcagg 18420
gaggagtctg agggcctggc ctgtcagggg gccctaggtg gtgggtccaa gctgtgtgct 18480
ctgcacagtg ctaggcctgt actatagtag gtgctcaaaa aatacttgtt gaaagagtaa 18540
agaagccggg tgtggtggct cataccgta atcccaacac tttgggaggg caaggcaggt 18600
ggatcgccag agctcaggag tttgagacca gcctggcaat gtggtgaaac cctgtcttta 18660
ccaaaaatac aaaaaattag ccaggcatgg tgggtgtcac ctgtggtccc agctactcgg 18720
gaggctgagg tggaggatt gcttgacct aggaagtgga ggcggaggtt acagttagct 18780
gagattgtgc cacttgtact ccaacctggg tgacaaagt agacccccct ctcaaaaaa 18840
aaaaagacta aagaaaagt agcctgagag cttaggagga gcacatttca gaggggaacg 18900
gagagaggaa catcaggccc gttggtagat gaggagaggt gcggttagat ctgtgctccc 18960
caaagatcct ctgtgaaca taaggggcaa cgcttgtct cctgtgctgt gtcctgcggg 19020
tggaggtgga ttggaggaaa gcggaggcg aggcctggtt gaggggcggg gcctgcctgt 19080
ctggtccccc gggctgcctt gggccagctt ggcctagtct gttgggtggg cgggcagggt 19140
gcaggctcct ctccagcctc caaggagggg gagtgttct gcctcctcga tagccccagg 19200
ccttgggcac agcccagcct cccacggctc ttgggcccct ctccttccag gccgccggtg 19260
accacacact ggctctcctc cccggcgtct cctctccgct tctttgtttg gagcggaggc 19320

```

ISPT-1006-Seq.txt

```

cccccccccac cccgccccca ggcgcactcg cccggccatt cgggttcagc cggttccagc 19380
ccccagtttcc tgcgctgca ggtcccgca ggagctggag ggcactttc tccctgggtt 19440
tctcttccct ggtgcagcag gggccgcggt cctcatcctc ctggttcctc agttcgggtcc 19500
ttcttttcatt ctccaccctt ggggtgccag aactgggtca gacactggga caggaatcca 19560
gacaggcatg ctatctgccc tgcccagggt tatgttctag gaggggaagc agccattaat 19620
caaacaccaa aaatgtggaa aagtaataat ctcacacgtg tgcataataa actgtgagt 19680
aaagttataa gctcggcagg taggtaataa gctaggagca gtgctgtggg aggcaaggga 19740
gttaccgggg agtttcaaac taggaactga gctcataggt tgggggcagg gggactggag 19800
aaggcagtgat tacttaaatg gagagcagaa ggatgaatgg aagttagagt gtatggcggg 19860
ggttggcaga agcagcagct tatgcaaagg ccctgtggct gcagggaaca tgacgttgct 19920
cttttagagg gccaaagctg gggctctggg gagagcagct ggtcagacc ccgcggtt 19980
gtctgccata acagggtgtt ggagagtgt tgggagggt tttggagggt tttgatagg 20040
cggggtgtcg ggggaggctg tcagctcact ctggacactg agtagagaac agacgggagg 20100
cgtggggcag gcctggaggc aggggcttcc gcgtgttagg ccagtggagt gccagtcaag 20160
ggaagggtgtt atctggacta ggggtgtgca gcgcaggtgg agaaccctga gctgctttgt 20220
ggagggcttc aagtgtgggg gaagagtga cggatgggg gtgggggaca ggagacacc 20280
ccagtggagc ctgagcagga gagtctgtgc tgagagggtc tgtctggaag gcgcaacaga 20340
ggccaacttt gcagacagct gcagtcggga gagcctggag cctccttcaa agggcattca 20400
ggggaagggg aaggcacgct ggggggttct ggaccttctg tgggtgtctc ttgtcttct 20460
ggtcccttca gctccctga ctggctgcc cgagcctgcc ctaggcactc taagaacata 20520
gtcagtccca aggtctccct ccagggaagg ccgtagggtg gcttaggagt gagaaggctg 20580
gatcaaagcc tggctccatg cctgcatccc tctgacttgc cagtcatttc accctccgag 20640
cctctatttc cccacctctt aaatggggat aataatacta cctaccttat gggattgcgg 20700
taagattcat aatgttgta cagtgacag ctccctcat ggaaggccca ccacgtaaa 20760
cagtttacat ccatctcatt ccatctatga cagaatcctg tgtoactgtt ttggagatgg 20820
gaaaaaagag gctcagagat ggtgagtgc ttgcataata attacataaa acccccagag 20880
ccctggggcc ctggagttct caaaagtcc ttctctgttg gtacctgcag ctgccactcc 20940
ctaccccgct cccatagacc ctctcctcct tggagactct gccccatctg ccgtcccttc 21000
tctgtctgat caacacctt tccctctctg ctggctccca tcagtattta aacattgcct 21060
ttcatatctg tcttcaagaa aaaaagaaaa aaaaaattca caaacctccc tccccgcctc 21120
atcctttcca gctgctggct gtatagtcac ctgtacttcc ctctctccct catcgccctc 21180
cagtcattct ttggccttct ttggtctggc tttggcccc acccaccact ccactgactc 21240
tgttctgtgc aaggtccctg acaatctgt gtgaactgtt ttgtaccagg tgtttgacag 21300
tcaaacatgc ctgaattcag gtcccagatg tgccctcac tggcatgtga tcttgacaa 21360
gtgacttgac cctctgagc ctgtaactg aggataatag caatgaagga ctaaagataa 21420
agaacctggt gcagagtggt tgcttgcaa aggatgtgca tcatcgaca cgttctctgtg 21480
ccagggacca ggctgggcct gggctcctgg ggaccaaaca ggtggtctga aaggtcattt 21540
ctcacagcac tagccctttt ttgagctgtt cattgtctg attaatagga aatggatcag 21600
ctgtcaagat taacgagcta ttgctacaag attgtagcaa atgggttggg cttctctggg 21660
ttcatgacct taggtgtgtg aattcttagg gatagggtgt gtggactggc cctggtatgt 21720
gtactgaggt gatgaggtg tggcagtgcc atgtctgagc ccctacctt cttctcctcc 21780
ctctgcctcc ctgtggacac cttaggaga ctgtcagaag gcaataacta agtcgggggg 21840
gagggtatgg agaggcagat ttacaggaaa gcattcacct gggaagatat ccagagagac 21900
ttaggaactg gactgtctag gcctttggga ctgctgctgg tatgtggggg ctgggagaga 21960
gggaggagtc tcggttctct gcccggagccc cgggtgggat ggtggtgcca tcaactagat 22020
ggagagcagg gggagggaca actctcaggg agagctggag ctcttcccag cagctctcca 22080
gcacgccttt ttcttgagc ttggaattga tgtggggcgg gcaacagaag ggtgcagtgg 22140
tagtgtgaac tccagacttg gaacacctgg gttcagatct tagctctacc acttaccagc 22200
tgtgtcatat gggacaaatc ccttaacctc tctgggcctc tagaaacaga tacagtata 22260
gcactcacct catatgctta acagagttaa aaaaagttaa actctctgaa cagtgcctgg 22320
cacatactaa gcgctacata aaggtgaggt gtccttgttt tctttgtagg tctttctctc 22380
tgcccccatg actgccacct tcctcactgg ccattcctat agtgactgtg ctgtggtgac 22440
ttggtgtctc catctcttcc aggcacacct gtcttcatta aagtcctga ggaccagact 22500
gggctgtcag gagggttagc ctctctctgt tgccaagcta caggagaacc caagccgcgc 22560
atcacatgga tgaagaaggg gaagaaagtc agctcccagc gcttcgaggt gcgtctgtgg 22620
tgggaagggg tcggcagggc tcagggtctg cccacactct ctcctttcag tgtccctcct 22680
catggacctt ttggaggtgg gaggacaact gaccctgagc aggtcctgtg gtcctgagta 22740
ggctgtgacc ccatgtctgt cctctgacag gtcattgagt ttgatgatgg ggcagggtca 22800
gtgcttcgga tccagccatt gcgggtgcag cgagatgaag ccatctatga gtgtacagct 22860
actaacagcc tgggtgagat caacactagt gccaagctct cagtgtctga aggtacgtgc 22920
tagggagacg tggcacggtg ggctgccggg ctgaggcgtg ggaagagcca gccagccctg 22980
atcctgtcct gggcccatgt gcatttggca gaaaggagga ctggccacct cggggtcagt 23040
gaaagtcatg ggtggacagg gatagtcatt ggatctggcc tggattgtgc ggcttatgct 23100
gaggccagcc atgtggggca tgatgccttt gtattctcct gctgagccgg gtcgttggtt 23160
gggtggggtc tggggtctga cttgaggtgt ggagctgcag ctgtgtatcc cttgggttac 23220

```

ISPT-1006-Seq.txt

```

gtgggttatgg ctgtggctgt ttggcagtga accggatttc catgtggagc ctggccgtag 23280
gtgtcaggca ggtgtgttcc ttgttgcccc tgtgagctga gggctggggc tctgtccgtg 23340
gatttttagtg tcttctctca cttggtggct tctccattca ttcacaaaca ctccctggac 23400
caccttgaag tcctctgagc accgaggagg aggaagctgt gtctaagcca agtcttgagg 23460
acaggtggga gttgggggtg gcagttggca gctaggcagg tgcccaggcc cagaagcaag 23520
agaggatgga gctttcagag agctctgagt agttcaattt gggttttctg gagggcagag 23580
ggggagctag agagcacagg aagaaggaga aagcaattca gcatgagtct ggagagggtt 23640
ggagggcaga ttacacagga tctggctgag aaatgaacac tctcctaggg acataggaag 23700
ccacaaacaa ggcgggggtg acatgatcag accccagcca caactgattc atcagtctga 23760
atgtgtttat gttttcaaaa tatagcatcg attgttgctt gctttttttt cttttctttc 23820
tttttttttt tttttttttt tgagatgcag tctcactctt gttgccaggg ctggagtgc 23880
atggtgtgat ctcagctcac tgcaacctct gcctcccggg ttcaagcgat tctcctgcc 23940
ggcctcccaa gtagctggga ttacaggcat gcgccaccat gcctggctaa ttttgtatta 24000
ttagtagaga tggagtttca ccatgttggt caggctggtc tcaaactcct gacctcagg 24060
gactccgctg cctcagcctc caaaactgct gggattacag gtgtgagcca ccgacccgg 24120
gccgattggt gctttctttt taagaatgtg atgtcgatac ctgttccttt ttgaaaaatt 24180
ggaaagtata gaatagcaca gaggaaaaaa ttaaaatgtc tcagtttacc tctagtaata 24240
acatttggtt acttactcgt ggccattttt ctgtgcatac atatataatgt gtgtgtgtga 24300
acagaaatgg gaccacatac tgtccgatga tttgtagact gctttaaaaa caaacaaaaa 24360
aaaatatggc taacatcttc ctgtccacta tgtatcatta ttcttttttt 24420
tttttttttt ttttgagacg gagtctagct ctgtcaccca gcctggagtc ccgtggtgcc 24480
atcttgctc actgcagcct ctgcctcctg ggttcaagcg attctcctgg ctccagcctc 24540
cgagtactcg ggactacagg tgcgcaccac cactcgtgac taatttttgt attttttag 24600
aagacggggg ttccacatat tgaacaggct ggtctggaac tctgacctc gtgatccgcc 24660
caccttggtc tcccaaatg ctgggattac aggcgtgagc caccacgtcc agcctgtatc 24720
attatcctta atggctatgg gtaagctgtc acatgcaagt accctaattt atttagccat 24780
tcccttattg ttggacacat atgttctcag ttttttcgtt tctataaata agtgccata 24840
cacgtcgttg cagatggatg tgttcacctt cctgattatt cccttattct aggttcatgg 24900
aagtggaaat gctgagtcaa aggcacatg catttttaag ctttttgata tttccagaag 24960
attgtgtcaa ttcatactcc tgccaagcag ggcagaagag ggcctcttcc ctgcacatct 25020
tccccactgt tgggaaatat cttcaaaaaa atattttttg ccaagttaat aggcaaaaaa 25080
tggcatctca atttaatttg catttctttg attacaagaa cagctgcaca tgttttcaca 25140
ttggccattt ttacgctgtg gctttatctg ttcacacaca catctccatt cagttactct 25200
ttttgttggt ttgtgtgttg tttgtttttg tgggggtttt tagttttgtt tgagacagag 25260
tctcactctg ttgccaggct ggagtgcagt ggtgagatct cggctcactg caacctccac 25320
ctcccagatt caagtgattg tccctgcctc gcctcccaag tagctgggac tactggcagg 25380
tgccaccacg cccagctaat gtttgtattt ttagtagaga cggggtttca ccatgttggc 25440
cagggtggtc tcgaactcct gacctcgccc cctttggcct cccaaaagtgc tgggattaca 25500
ggcctgaggc actgcgtcca gctgcggtta ctgttttgca tctgtgtctt gtatgagtc 25560
gtgggctcta caagcttaga ggagccatag aggacagtgg ttaagactct ggaccactca 25620
cttctcgtgt gtctttgggt tagtaactat gcctctgacc ctcatattgt ccatctgtaa 25680
atgatatata tgcctaccac ccaagctggg ttggaagatt gaatgctgtg tatgaagcgc 25740
ttcccaggag tggctgggtg gttgctgtgg gcttggaagc tgtacatctt gaggcctcac 25800
cacgtgagct gaaggtgggt ggcctccgtg ctgogtgcca tcatccgggt gatgcagctc 25860
cactgcctgc tcccacgggg ggacatacct gtgcaatagg aactcagaga acaggccctg 25920
ggccagcatc actgattgct gagtgttctc aggtctctcc ctgccacttc tgacctgttt 25980
ccccactcgt gacctggggg caagtatttc aatgctgccc agtctccta ttggcagctg 26040
tcctagcagg gagccatctg ccctgccctg gcatttgga ggtggctgaa ggaccagagg 26100
ccccagagg cttcttttca ggctctcaga ttggggaaca gggcctcctt gttagtattg 26160
aaagaggagt ctttcaaaag cgctaagcc ccaggctcct ggtcaggagc cctcttacct 26220
ctgccactgc cctgggcagc cttacctttc aagggttga ggagatgga ggtggtcttt 26280
caggcctggg gtgaggagga cggacttcag atgacagga ggggctgggt gtggtggctc 26340
acgcctgtaa tcccagcact ttgggaggca gaggcctgca catcactga ggtcaggagt 26400
tcgagaccag cctggccaac atggcaaaac cccatctcta ccaaaaaata caaaattaac 26460
tgggctgggt ggcgcacgac ttagtccca gctacttggg aggtgaggc aggagaattg 26520
cttgaaccca ggaggaggc gttgcagtga gctgagattg cgccactgca ctccagcctg 26580
ggcgacagga gactccatct caaaaaaaaaa aaaaaaaag aggacctgca ggaggtgcct 26640
cdgttttggt tctctaccag gggccagcag tatatgtttg cgcttctggg gtgtgagaag 26700
tgtctgatga ggctggggg agtgtggcgc aagtaccag accctgtcca tgctccgggg 26760
aagggtgtgg agctgtgggc ctctcctgct tctgaaacat agcaccagga 26820
agacaaaatg ctgacttatc ctgctgggtc gtataacctt ggccagcatt gggcttgaca 26880
gaaaggcgtg ccgcaggagg gccagaggga agcagcccag aggggtgaaca cccgccccct 26940
gccccgcctc accccacccc tcccctocct ctaggagga tcaagaaagc tgggtgcctg 27000
caggaaactg gtgaaaggat ggttggaact ggactggagc tctggggtgg ggcggcagg 27060
agccagggcc attcttgga ggccaccaca ggttacgag agggctgggg aggggatgga 27120

```

ISPT-1006-Seq.txt

```

gctagtgtggg gtcgggggaag taagagtcct tctctgagttg cacacagctc tccctgtgag 27180
ctggtctcct tggagaatgg ctgagggctg tctgggggtga actggctcag gtgaagatca 27240
gtgtgcccccc aaaaaggagt ccaggcctgc agtctgttct gtgccctctg cctttgcctc 27300
atgtcacacc aggcccaact gctgtggctc cagggccact cccaccacag cccgtgggag 27360
tgccccccca aatccccccac agcctgtgcc tttgcacctc gcatctgagc aggtattgta 27420
ttcccagtggt ggcctccccct tgacaccccc gccaggactg catacagaggt ggggggtgcc 27480
agacacaagct ggcgggggtg agcctgtcct ggctgtgatg agcgtggggc cgcgcgcca 27540
gcgttctctgt ctgagtggtg attgaagcca ttagcgcgcc agcctctccc tcgcccggta 27600
atggcaggaa aagctcttct cgctccgcac tcttgaggcg gcgctgaat cactccccct 27660
ccaacccgcc cgctgccgcc actgagacag ggaatctgac attttccctc accagggagg 27720
gggagccctg ggggagggga gggaggcagg cctggattcc tggcctttcc ctccaggagg 27780
ttgaggggca gtgaaggctc tggagctcag tctgtaagtc atggattcac ctggggccgc 27840
agatttcagg cctggaagga ctggccggga aagcccagga ggccgccaga cattcagtgg 27900
tgtggggagg gcaactgatga ctttgggtag gttctgggag ggacaaggag gcggggagaa 27960
gaaagaagct gtggagcaga gatgagctgt tttggacttc tcctgggggg cttagctcca 28020
agggttctga gtacaggtag cattacttgc cttgggttca ttgatagggc agataacgtg 28080
cactgttctgt gtggtgtggg tgccctgtgt gccatgttta aggcagtgtt tgtgtgaagt 28140
gtgtggtgca gtgtgtgtag caggggtgct gccttgcaag ctgtgcgcac agaacgggg 28200
gtgcagcggg cagcgcacac gttaccatca ggcagtgggg aaggggcagt gtgtgcagga 28260
ggcactgcat gctgtatggg gctgttatgc agcgcgaggt gtttgtgtgc acgtgtgtgc 28320
gtcaggcagt gcgtgggtgt gtggttaagca ggtagttagt accttatggg ctatgtatac 28380
agcaaggcat atgcatcagg cagtgtgtgg gcagtaggca gtgtgtgtgt gtgttatcag 28440
gcagtatatg tgtgcgggtgt gccgtgcggc aggtacactg tgtttatatac gggtagtgtg 28500
tgtgtgttta tgtgcagcaa ggtgtgtcag taggtgtgca gtagactgtg tgcagcaggc 28560
gtgtgtgtgt gtgtgtgtag gctgtgtcag cagcagtggt gtgtatgtat caggcgggg 28620
gtgtgtgtgt tttatgtgca gcatgcggcg agtactttgt gtggtgtaca gcaggtgggt 28680
tgccgcaggc tgtgtgtatg tatcaggctc tgtgtgtgtg tgtgtgtgtt tgtacagcag 28740
gtgtgtgtgca gcaggcagtg tgtttatcag gcagtgtgtg gtgtgtgtgt gcatctttat 28800
gtgcagcgag tagtttgttg ggtgtgcagc aggtgtgtgt tagcaggcta tgtatgtatc 28860
aggtgtgtgt tgtgtgtgag cgcgtgtgta cagcaggtgg tgtgtagcaa gctgtgtgta 28920
tgtgtcaggc agtgtgttta tgtgtgtgtg tccagcaggt ggtgtgtagc aggtgtgtgta 28980
tgtatcaggc agtgtgtgtg tgcgcagcgg gtagtttgca ggggtgtaca gcaagcagtg 29040
tgcatgggat gtacagcaga tgggtgtgag caggcagtggt gtgtgtgtgt gtgtgtacaa 29100
tagtgggcat gcagtgggca gtgcatttgt gtgcattgag caggctgtgg tgtgtacagc 29160
aggtgtgtgt cagcagactg tgtgtttgta tgcattcaggc cgtgtgtgtg tgcagcaggc 29220
agtgtgtgtg tgtgtacatg cgacacgca acaggcacta tatttgtgca gcaggccatg 29280
tgtgtgtgtg atacagcagg tgggtgtgag caggctgtgt gcttgtacat gcagcacata 29340
gtgtatgtgt gttgatgtca gacaatgcat gtgcatttgt gtggagtgtg cagcaggtga 29400
tgtgcagcag cctgtgtgtg taggtgtgcc tcgggagtggt gtgggggtgg gaggggagag 29460
cagggtgtgt gtgccttaca acctgtgtgg gcagcagcag gagtgggcag caagcagccc 29520
gagctgaagt gtgtgggggt cagtctggca ctggcaggag gtcggagatg ctgtgtctgg 29580
gctcattgtc tctgggacct cgcaggatcc ctggttgagg ctggtgttcc gccaggaaagt 29640
tcgacagagt tggatgtggc cagaatggtc tggctgagct gttctcagca cctgttgtgg 29700
tcgacctcag cagctcctct gtagccaggc caggaggtgg ggtgcaccag ataggatcc 29760
tgcccagacc tgctgcagg aggtcctggg accctttcct ctccctcccc taccaccaca 29820
agcccacagt cccttctgtc tgttccacc tgccctcagc gtccttccag caccatacca 29880
cctatgccat gcgggccagg gaatccaggt gtctcgatgg agtgccctgg gttgccagcc 29940
ttggagcagg ctctggggaa gggctgtccg gcacatgaag tagtgaccag ggtgggggct 30000
aatcagtgtc gtactgggct tggacctctg ggttctgcag gagctctgac cctggctggc 30060
tttggggctc gtgggatgac gaaggacctc ttgatatacc ccctgaccac tccacaacac 30120
agtccttttg gaaatagccc tagagacaga gggccaatga tagacatatg accctgtcct 30180
gaggtatcct gggctggggg ggaactggag cagagctgggt gagggagctt acatttgcaa 30240
gatgggtaca tgtgtgtttt ctcaaggagt catctctccc tgctccacct ccttccctgc 30300
tccaaacctg tatattcctt ccacccatgg tggaaatgact tggcccaggc ctgactttga 30360
tggctgggga gttgggtaaa gggctattgc aggcacaaga tggcttccca agtggcaaga 30420
tgtgtatcct tctattgtc tacatgtgtg tctggggtaa cagtctgctt tggcagaagc 30480
tggggctgtc aactacctga tttgcagcac agaggatgta gaagtggccc cagaacctgg 30540
aaccacaagg agcttctacc tctcccttag caactgaggc atgacctgta taccctgggt 30600
ccagctgtct tagtctctct tgacctgtcc ttacaccccc atgactgcag tagatttcag 30660
atccacgcag acatgaggtt ctacaatcat ttctggagg ttctaggcct cagggatggg 30720
gatgggagag gtattaaagta agttctcctg tttttattag ctgtgatctg ccttgaggcg 30780
cccaagtgga ttcccttccg aatgggtgct cctgtttagt aggtgggtact cctgcctctt 30840
ctgttagcca tggacactgg gcacttcccc tgtgccagc ctgccccctt gccctatac 30900
tcacaggtac ttgtaaggcc cactgtacgt gttccctagc ctcatgacca cgggtggagc 30960
aatggctctg ggaacaggct caccaggatg gcggtttaaa tgcctgtgcat 31020

```

ISPT-1006-Seq.txt

```

gcacattctc catccttggg aaggtgctcc ctctactggt tttgcttgct ggggagagag 31080
gacttgtttt tttttttgag atggtgtctg actctgtggc ccagactgga gtgcggtggc 31140
acaatctcag ctactcgcaa cttccgcctc ccgggttcag atgattctcc tgcctcagcc 31200
ttccgagcag ctgggactac aggcacgcgc caccacacct gactaatttt ttgtattttt 31260
agtagagatg ggggtttcac gtgttagcca ggatggtctt gacctcctga cctcatgatc 31320
caccgcctc agcctcccaa agtgcctgga ttataggcgt gagccaccgc gcctggccct 31380
gagaggactt ttttgaacg gagtctcact ctgccacca ggctggagtg cagtggcgtg 31440
atctcggctc actgcaacct ctgcctcctg ggttgaagca attctcatgt ctgagcctcc 31500
cgaatagctt gggattacag gcatggacca ccacgcccgg ctaatttttt gtatttttag 31560
tagagatggg gtttcacgaa acatgttggc caggctggtc ttgaactcct gacctcaagt 31620
gatttgcccg ttttgccctc ccagagtgtc gggattacag gcatgagcca ctgctcctgg 31680
ccaaatttta atcagagcaa tgacgtgatc aaacttaagc ttcagaaagg tccgtgtggg 31740
tgcatagtgg gggctggaag gaaaccaatg acaggttgtt gcagtccagg tgagtgatgg 31800
cattggcgca aatctgggta tgggtagggg aagatagggg agcagatcac tagaaggtta 31860
gaaagagccc gggcacggtg gatcatgcct ataatcccag cgcttttgga ggccaagggtg 31920
ggcagatcac ttgaggtcgg gagttcgaga ccagcctggc caacatagt aaaccccgtc 31980
tctactaaaa ctgtaaaaat tagctgggtg tgggtggcagg agcctgtaat cccagctact 32040
ctggaggctg aggcataaga attgcttgaa cccgggaggc agaggttgca gtgatatgag 32100
atggcgccac tgcacttcag cctaggcgac caagcgagac tccatctcaa aaaaaaaaaa 32160
aaaaataaga ttgaaagag tagaggcctg ctggctacc ttaggattg gggagggtgc 32220
aggctccagg ttcctggctc tgggctggg taggtggggg tgccatttct aagattcatg 32280
tactagagga ggaccaggtt tgaggaggcg agttggtgag tccagttaga aatctgttga 32340
gccaggtgtg cgcaggcatc cagggagggt tcaaagaggc ctctacaca tttgcctggc 32400
actccggggg acatctgaag ttggaatctt acaggctgag aaatagcaa tctcaggagg 32460
ccagagccag gacagaagga gccccaggaa ccgactctcc atgttgggag gaggttctcg 32520
agagactgga gggaaactgg gagtgtgtga ggtcaagaaa tgccaagaga aaaaagtgtg 32580
cgaaggagga ggagtgtca gcaggcgggg gtgctgccga gaggcccgcc atgtgtcctt 32640
aacagttagt tccgtggagc cattgttggc tttggtgttg ggagacagca gggctgagaa 32700
gtgagagga ggctatcagt gtctgtagtg actggaaggg cccgaacctc gggagtgaat 32760
ggatgcaag agtctccctg gagtaggact gaggttgggg agccactgaa ggagagtcca 32820
gtgtggggcc gagtctgga ctccagtgtg ggtcgggtgt atgctgagg catggcccct 32880
gggttcttgt ggtggggagg cctcaactgg gttgagtagg gcgatgtggg gtgccaggga 32940
aaccggagga aggaggggag gactgggagg gggacgcccgt gcctgccaac aggccccaaa 33000
cagctcagat tgaaaaacaa aacaggcttt taagatgcca agtttgatga aatctgagt 33060
ctggaagagg tgggagtttg ctcttgaaa aacagctgaa aatcgagact caaagctgcg 33120
aaggagatg ggcccaaggc tcccaggcc ccccttactg cctggaagcc tgggggtggg 33180
gctgggctct ctgggagagt gtgggagcgt gcagatctgg cagccttcga cttttggaag 33240
gcgtctggct ctggcctgct tgagatgga gctgctggag gtggccttgg cttctgtgga 33300
cggctgaag ggcaggggga gccagcagcc ctgccaccta cgaggttcct tcatgtgtct 33360
cgtccctgca tgtgtctcca ggcgcacgtg ttttggcata ggtgtgtctg gctgtgcatg 33420
tctccacatg tgtgtttcgt tgtctctgtg tgcaccgcct ctggatctgc ttgcatgcgc 33480
ctgtttccac aggtgctagt cactgcaggt gccctccac atgcacatgt aggtttctat 33540
ttttacacct tctgtttct ccatgtatat ttctgtgggt tcttggtgtg aactcaag cttaggggag 33600
atggtgtctg tgtgttgaga ggcagggtga ggccaggccc aactactcaag cttaggggag 33660
gcggtcagcg tcacagacgg tgccacccca gggggcctgt gtctgtgtgt gtctgtgtgt gcggtgctg 33720
gcctgcgttt gcacggagac gccacgaagc tgggtaaaca tgggtgaaaa ggtcactact 33780
acagcgggtg ctgcctgccc caggaccctg ccatctgtca gcttccctgg gcttccctgg 33840
tgacagcccc tccctctggc ccagagactc accctcaggc gtccaaggct gagctggaca 33900
aagagacctg tgtgtacttt gtagggggcc ccacccccat cttaggctcc 33960
tctgtcagga ccccaacaca tgcccagct cccaccagac tgccttgggt actgtcatcc 34020
caccaccttc ccccaacaa gcctttacaa aggcagtttt cccctcctcc cctgaaagct 34080
ttctgcctcc catgctcatg tgtttcctgt ccttgaatct ccctcctcca ggaagccacc 34140
aagatagcaa gtgagctgtg gagtcaaacc gatcagctcc aactactgctg tgggaggtta 34200
gccaagcgct catccacttc tgaaccttgg attcccacca tgcacccccg accctcccct 34260
cgctagggct tgtcatcgtc ttctgcccc ggggcaacca aacctctcca cggaagggga 34320
caggctcctt tgctgcagtg ggtgcaagg ggtgcaggag gcattcacac 34380
acagctgcac actccccacc ttgcacacat atctgcgtga gccggggaga ccctagggaa 34440
tgtgtgtgca tgttgtctat gcatgcgggt agaatccgca aacggtgtgg agactcgggc 34500
tcttgggtac ctctgaaggc ccctgaagtc ccatgggct tctccttccg tccagggcac 34560
cctcttatca ggccattgcc ctgagacgcg tagtgacag gcccccgcg ctgaggctga 34620
ggcctcagat ggcccctccc cgcactgtgc agggcacccg gttgggggtg gaggggaggg 34680
ccgctcggt gaagcgggaa agcctagtgg gaggattccc tggagctgag gagccggggc 34740
ctgggaaggg gcgcagagcg tccaccagg cggggcgggg aaggcggtg ccaggcgga 34800
cagcggacgc gcgcgctgc acggactcgg gcacacgcag cccttccgcg gcagcggccc 34860
ccgctccacc gtcgccatgg ctaccggctg gcctggagcg gggaggggcc cttcctcccc 34920

```

ISPT-1006-Seq.txt

```

ttcggcgcca acaggaggcg atttgagggg actcagcgtg actggtgcat cccgggggtg 34980
gaaaatgggt ggggtgcttgc gactgtccac gtgtggggga ccctggggtt cgctttgcgg 35040
tagatgcaaa cgccgcgccg cgtgtgcggg gctctgcagt ggagcctgag ccgtgccggc 35100
cgaggcgtgg tgtgggggag gctgccggcc ctctcgccgc cggggtgttc acgcctagag 35160
cgctggggct gggggcctac caccgggtct cctcccagcc ccacctccga tttagctgtg 35220
tgaccttggg caggtgtcca gatgtctaga tctctctcag ccctgggttg cccatgtacc 35280
tcataagggt ttggtaaaga tttaaagtcat tttgtaaagc attttaacat agtacctgga 35340
acctagtata tgcttcataa atcttactgt cctccatacc tgggtctcag ttttccag 35400
tggtgatggg tttggagtga tcatgtgaca tcatctgagg agttgccag gtcctcagcc 35460
tgagtgttga ggctgcggta gaccagctt ccgcggggtg ccgtggggga aggtggtgaa 35520
tgtgccagtc tggctgatag atcagtttac accaggatgc ccagtgtcca gccaggccag 35580
gcgcatgggt ggctgcagga aagggtgtgt gtacttggct gagggtgatg ttcagaggcg 35640
cctggatggg agagaaggaa gaggcagcag caagtcgctc ctgaggggct ggagccctcc 35700
tgtaagacct acttcccttc ccgggtggca gaggggcaga cttccgagtg ctgcctagaa 35760
gcctagtggg cacaggggac tggtttttgg gtcccgtgt tttatggaca gctctccaca 35820
cattctgggt ttaggtctct gcggcagtg ctgagggatg atctgagcca aggacagagc 35880
cactgagggc ctctgtaag gaattcagag cttaatttgc cttaatttgg cgtaaatccc 35940
aaagaccttc ctctgtgtaag taattcagag tagattccga gacacagggc tgcacacatt 36000
tgtacttccc ttcccttccc tatctgcggg tggagatgaa ggccacttga ctctggggcc 36060
ctgactctgg caggccatgg ccacgtcttc cccatgagct gggcaggtag gaatgaggtc 36120
ttgaaagagt tagactgggt ctctggaggg gcccttagca gccccgagtg gcccagtg 36180
tcccaggtg tttggggagg gacccctgca cctctgggtc cctcaggcc ttctatgga 36240
agcaagcagc agctgggcca aaggaggctg atcccctgcc tgggtgcatc cagtcctctt 36300
catttccgtc ctccctccct tctcttgcca ctgttgaaca ttttactttt aaaaatctga 36360
aagggcactg tgggatcata tttacagcca aggagacact gggtttatat ccagaacttc 36420
tagggctgca ggtgggggaa cgtacagcca ggtcccagga aaggctgggg cggaaggcc 36480
gtgctgggaa tcctattgct ctctagcctg agacctctgc tcctcatggg ccacagtccc 36540
tttgggatgt ccctggcagc tagagccttg gggagcatcc cctgggactg gcagcagata 36600
gataggatc ttgtctctgc ctgttggggc tcgtccaact cctcttctta cccgcccccc 36660
agtctctctc cctgggtctc caagaggctc caggaggggc tagtttctgc cagcctttac 36720
cttctctcatg tctgaggatg ccatgtgcct ttactctggc atagaagcct gacttccctt 36780
ggcacatgtt ccatacacc catcttctgc tgggcttctg gaaaggaggt agagtgtgct 36840
tggtctcccc caccatgagc ccagctcccc gccttcccca ggagacagac aaagaacaca 36900
cattcccttc gcccacatt ggggtgtgtc ggcattccca ctgggagaga cactctgtct 36960
aggccttgaa aattggtggt ttgggatggg gcttgggtgc tcacagctgt aatcccagca 37020
ctttgggagg ccgaggcggg tagatcacca gaggtcagaa gttcagagcc agcctggcca 37080
acatggtgaa acccgtctc tactaaaaat acaaaaattt gccgggcgtg gtggtgggcg 37140
cttgtaatcc cagctactcg ggaggctgag acaggagaat tgcttgaacc caggaggcg 37200
aggttgcggt gagctgagat gcaccactg cactccagcc tgggcagcag agtgagactc 37260
catctcaaaa aaaaaaaaga aattggtggt caattggtgt ttggtcctag tgggaagggc 37320
ctctcaccag cctagagtgg aaaaggaggt tcccgactct agtctcaata cctgtctgcc 37380
ccagtggctc agcccttact agttacacca gctaataatt actgggagtg aattccgcat 37440
cagatgctcc gcaacacct gcatgcatga tcagatacag acctcacagt agccttacca 37500
tcaaggtggg cacttgaacc ctgtgtacag ataaaggaga caaagaatga gtaacatgcc 37560
aggccctaaa gctagtctgt ggtgaacgtg ggagtcccat ttgatctata ctagtctga 37620
gcctgtctcg gacttgtgct tccaaggggt ggagagtga tagccttgcc ctgcagcccc 37680
tcggggctga tatgggagcc catgtacagt gggagtgggt ttgctgtgta catctgttcc 37740
tcttactcta tctagtgc tctctgtgt gccgccaacc cctagcaagc tgggagaagg 37800
cagccaggag ggagtttttt ctccccctac caactttttg tgtctttaga gcttttttat 37860
ctcctttgcc tccacacact caggcatggt ctgcagccct gaccgtgact cccagggtca 37920
ggactaagtg agggagaaag ctcaagggtc aggtgtcagt aacgaatagg tcaaggctag 37980
gatcgaggtt agaagggtat cattggtagg gctgggggtg ccccggttca gggctagaga 38040
ccaggcggtg acctggggct ctgccatgtg atagagctga aggtggatg aagggaacac 38100
tgtgtgtgctg gacaggggag agggggctgg acagcacaga ggccttcagg ctgagctgtg 38160
gctgttggat gctgcgcgag ctccctgcta gcccctcccc ccacccctcg cagccccagc 38220
attcatgcag tgctttctgc tgtgaccagc agagcattga ttctcgttct tctcagggcc 38280
tgagagata agtctagtcg cttcagctct gaggcgttgc ctctcagacc tggaaactcc 38340
ctgacagggc aggggtgggc cccactgcag cctctgccct gccaaagaga cttaggacct 38400
tggttccctc aatcggggta tgcttcatgc ttagaagtca aggaaagggt agggggagct 38460
tgagggccct ggccaacctg cagttgggga ggttaccctc agagggttca tagggggcag 38520
gcagagccag ccctaataca cacttctgtg tttgtctgca gaggaaacag tgccccctgg 38580
gttcccttcc atcgacatgg ggcctcagct gaaggtgtgt ccctgagatt tcttggttca 38640
catgctatgt gccgcaggcg gaaatccaga ccatgagatt ccttggttca aggacttctt 38700
tctgttagac cctgccacga gcaacggccg catcaagcag ctgcgttcag gtgagcagag 38760
ggcaggggtc aaggggcat gacagctca gaacaagcgt cttgtcagat cccagcacag 38820

```

ISPT-1006-Seq.txt

```

cctactccct tgggcctggg cacctccagg gctgagcggg gggtagcctgg tggggtgggc 38880
tgggtcttac tgcaggtgtg cctggctcag ggaagagagc tctgtggttg ctgtgccgtt 38940
acctctcttc gatgtgcaga ctccagactt tgggccagtt ctgcccctcc cagcacatgt 39000
gatgtgccag tgtggtggac tcttcaaggg tgctctatgg atgttccacc tctccttcc 39060
ctgtagcctg gcctgagaca gggcctggat gatgctctc tttgttccct cagatggcag 39120
ggcttagctg gaaaaagagg ctaaagggtgc ctgattcatc aggcttcaaa aggctggatc 39180
tcaggggcct ggaactaagg ggacttgctg ttgtccctcg accaccagag ccacctgtct 39240
cctctggatg tctccgtcga gccagctcgg agccctggga gcaaggatgc catcgtgcag 39300
gaggggagtg tcacccatt gatcgaatct cctgtgaggc tcctgccagg ataattgatt 39360
cagtttttgt gggaaacagag caggcgggaa aagaggctca gaatcagctt ggctgcattc 39420
tgcatctgct gccagcacgg cctggaccaaa tagtctttgc ttcagaagcc ctctgtctag 39480
ctatgggatg gttggcctcg ggcaggatgg ccagtgcgg ccagagcccc ttctgcctgt 39540
cagttgtgat gtcaatgatg aaaaaggagga catgactctt gcccttttca ggggcctgca 39600
ggcttcagag gtgccctccc actccctggg atgccagccc ctcccattca attcccacca 39660
gcctcacagc cccttgggtgc ccagcaggag gaggagaga caagctgccc agcagggcaa 39720
gattctgggc ccagccacgg ccgctgaga cagcccacga agtggttagct catttaattt 39780
aattgaaagg caacaagatg atgggttcac tagcgcagtt aattaaaaca gccataatca 39840
aggcagcaaa cgcccgagcag tgtttgtggc cgctgccag cgagcacag cgccagcac 39900
ggttcggctc ctctgcattt tctcatagt cctccaggca ggctcccaa gcagccagac 39960
gtcctccct gctggcctgg gccctccac agaaccacat ggacttgtct ggcagcagct 40020
ctgtgaaagg aatgcctcag attggttcac ctagtattta tatagtgctt ggggtgcccg 40080
gtcctgggac atcccttttc ttgctatca ctccactgga tgccactcag gcccatgct 40140
acttgagcta tgggtaggat ctaagattgc tgccttctta tcaaccacac tgccgttttt 40200
agctagactt tgaaggactc tgctgttgca aataggctgt tagctatagc tatatcctgt 40260
atttaattgt atataatgc aaattatc ttaactctat aaaactaact ttttatggtc 40320
taagtaataa atgaaataa gattaataa attaattata aaagatatga ctccctctt 40380
cctagtggcc ctccctgca gcagcatctt ccctccacc aagccctgcc tttgccctat 40440
ggacacagcc ttgccctgga cgagctcacc ccctccataa gctccaactg ccattcctc 40500
acctgcaact ctagctttag tctttccagc ccaaactctt tacctgagct ctatgtcaa 40560
aattcgacct gccctctggt caccctgacc agtgggtgac agtgatgagt gatgacctt 40620
ttttcagaca gctgtaccct ctttccataa gtggcaccct ccaacctgga acatgggtct 40680
caagttgggt tgagagctct caaatgtacc accctcgtgg ctctcaaatt ggccccctt 40740
tcccctcctg ctgcgtcagt cctatcccag gcaccagaca ctgctttccc tgccctcggg 40800
ccctcccgag cctgtaggtc aggtttgctg ctcatacctt cctgtgcctc 40860
agtgggtct ccttgccctac ctggtcaagt gacgctccca agcaaggctt agagggccct 40920
tcttggtctt cccctgcccg tgtctcatcg ggtcctggct acaccactta ccagctctct 40980
ggcattgggt aactttttcg tgtgtcagtt ttctcatggt tgaaaaggag ttacagtaag 41040
cagtgaagtga gtcaatggca gtcaaacctt gagttgatgg cctggcctct ggtaagggt 41100
tcattggagct ctttctactt ctgtaccct tgaccctcct aacctgagc tgtgctgacc 41160
cgtccttggt ccttgcccac ctccggccct ctgctcacct tccggctgct ccacttgaaa 41220
acctccaccc tgctcagcct ctggtgctg cctcaggcct caccttgctt tacattgtca 41280
ccatctgggt ccagttctgc tcagctaggc cttgcaggga gggcctgggt ctgatcacac 41340
ttggtgaggt cagctgtagg acaggtcttc tctgagccct tgtcaagtga atgatttcat 41400
gaacttgacc ttggcactt gtccctgtag gctaatact gctctaagt tcaactctcc 41460
ttctgctttc cagggtccaag gaagacttcc ttatttctct tcctgccacc tggaagttgt 41520
gacctcaggg tctggtggcc aggggtccagc tcctgggatg gagccagatg gcacctaaag 41580
ggcctcaacc atcccacctc tgcagtaata actgggctct ctcccctccc tgccctgacct 41640
ggcctgggac cgttggcctc agttgttgct ggccttatcc cattaccatt tagaagggtg 41700
ctaaggctat tccgtgcaca tttttcaggg acagcccttc atggagtga ctcaggcccc 41760
tgagactca gctgtttacc gggaccttta cggtttacgc atcaccgaca gtttacaaca 41820
gagctttccc cgcttttgtt gcagctgatt ctcttgagc cctgtgaagt aggacaggct 41880
gtgattacca tgcccccttc acagctgagt taaggagtc acttggggtc acacatcgag 41940
actcggccta ggagctcccc tgtgagatca cctcaggacc tagtatcaca atagcaaacc 42000
tggggacctg aggagcagct ggaccttctt ggggcttcag agctgcacat tcccagcttc 42060
tccagacccc agccccccac tgaccagtac ccagaagtcc tccaccatct gcaacctgag 42120
ccacagcaca tctaaccagg gtagtaccct ccaagtagga gctggacagg aggtagctga 42180
cgcatgcgc tccccagatg tgagctctgc tcagcaggcc ttttctctc tgtagtgatg 42240
tgacatgctg ccaaaaccac ctccctggaga attggaactt gagaccggg taggcccagg 42300
aggaacagga acaagcttat agagtggaaa tggagtgtg agcaggggct cagagcccc 42360
gctgggtcct gagaggagct gttggcctgc aggtgtgccc gagcctggac agggcttgag 42420
gagattcccc cactcctgct gtggcctgaa catatgagct gccatcctt gtcgtagagg 42480
acagcctaac tactaagtc catgtgctca tccagagagc agtctcttcc ccacccccag 42540
cacctgagg cgaaacctg gggctttaag aagagatgca gcatctggct gcaggaggag 42600
gcccgtgggt gggacgcaga gggcttgtag cccctcacc tgctggctgg ccccgactct 42660
ggctggaaga gcctgtcccc accccactct gctctgcat ctgcggggc tgccagggaag 42720

```

ISPT-1006-Seq.txt

```

gcacactgcc agtgcacgtc cacaatttcc ctttggccca gagctccctg gcacctcttg 42780
gacacgaata caccctaag gatgctgact tctgggcccc ttcagtcacc cacacccatc 42840
ttgtgaaatg gaaaagtcag attctctgtt tgggtgggaa attactgtta gattctttca 42900
gaatagggtta ggttctggaa gagctgaggg caggagcgag ggatgccagc cctggaccat 42960
atccactgct cccaccccca ccaagtctct gcgtggatga caggagatca gcaatgtcaa 43020
ctttttggtc tcaggacctc tacttgtaaa tatcagagaa cctcaaagag ggtttgcttg 43080
tgtgggttct tttttttttt tttttttttt tttttttttt tttttgagac agagtctcgc 43140
tcttggtacc taggctggag tgcaatggcg cgatctcggc tcatcgcaac ctctgcctcc 43200
caggttcaag caattctcct gcctcactat cctgagtagc tgggattaca agcatgagtc 43260
accacgcctg ggtaattttg tatttttagt agagacaggg ttccaccatg ttggtcagac 43320
tggtcttgaa ctccgaacct cgggtgatcc gccgcctca gcctccaaa gtgctgggat 43380
tacaggggtg agccaccgtg cccagccatt gtgtgggtta tttctattga tgtttaccat 43440
attagatatt aagactgaga ttattttaaa atatttatta atgcatttta aaataataaa 43500
aacctattat atattagcat aaataacatt ttttaaggaaa aatagttatt tttttaaaac 43560
aaaaatattt accaagaggg acaacattgg tttaccctta ttacaaatct ctttaatttg 43620
ggactttatg tatgagttag tggaatttct agctactttt gcattagggc aattgtgata 43680
gcacatgtca tgtagctctc gaaaaactct acgttcatga gagaaagtgt ataaagcaaa 43740
taatttctta gtattatgaa aacagttttg accttgcaga cctccttatg gacctcctga 43800
aagggctctc tggagagaga gaatcattgt gcggattctt cccacataac cctcactccc 43860
aggtcccagc ctttgccttc tcccctgcct ctgcactctg aggactggca gcctcatcct 43920
gtgggcaggg tatgagttag atggaccttg tgaagtcttc ccacttcaact cacaagctgg 43980
tgtgaccttg ggctttgagt aattccctga atgtctcttg gcctctgttt tctcatttga 44040
acttagagat gaagaattcc tctagtgctt gttgtcaagt tccatgaaac ggatttgtgt 44100
tgatttttct gcacacttcc caatccccag acgtgggcag gaagcaggca gcagggcagg 44160
gtgacgtgg tctggacctg ggcccatctg tgggctcctc actcctcttg ggaaggcagt 44220
ggttgcacag ggggcttgag cctcagagaa ggtacctgtt ggggatgaaa cccgctcaaa 44280
tctcctaata ggcctggata tggaggggtg acgcctggcc ctctgggtta ccaaccctca 44340
gggttatgag gtgctagaca ggaaaagggt gggccctgat ctctgcctct cgccagccag 44400
gccaaatttg ggaagttcag tagtcccca gtttttagca ggtttgagt ggctttctag 44460
ggactctgtc tctgggctgt gagtttgctg agtccctctg cccgttccctc tcggctgggc 44520
tgctgttgtt gggaggccca gtgtgctagt agcccatggc aagccctccc tttagcctgt 44580
gtcctgtctg ccttaacacc aggcctttgt ttgtaagtgt ctttgttttg gaatcttacc 44640
caccgggtgg atttgggtgg ccctgtgggg tggggttact acctcttttc ttcaccttcc 44700
cctccatttg gccccagcca gtgggtctg caggagtctc gactcacctc cctgattctc 44760
gtcaccccca gccccactga gccccctcct cctccccaga gcagagccag tgacctggga 44820
cacagcttca ctgacactca gtctggctct gcctgcttgc tcacacactg tccgtgtcgg 44880
cctaactcag gcctcaattt ctccatgtat ttaaggccct ttcttgtgtt ttattttacc 44940
tgatttggct tctgtgtgct ttcttccctt ttactaatat gcttctctct gatcttattt 45000
gcattcaaat taactgcaca ggtggttcac caatcagagg taagaatgct gtccgtgcct 45060
ctcgccacac caagccttgc cactgccgtc acctccactc catcccgtcc agtctgtcac 45120
ctccccatcc ccatcccaac ctcttcagcc tccctcatctc cagctccagc acccccaaca 45180
ccaccggcca ccacacacat ccactctcag tcattccctc ctgtggactc atccattgca 45240
agtctgaatt gtgaagatac tcgcccggcc ccgctagga cagcaagccc tgctgcccag 45300
gccttccagg ccatcccccac agaagggacc ccatcagctc ctactgtgaa acttagcctg 45360
tcccccggtc tccctagaca gaagagcttc ccttgagggt gaggagtgtg accaagcctt 45420
gccttttctc ttgacagtct cttttggggg gacctcaatt attacttgac tttcccttta 45480
gtatcccgcc tctgtaccgt ggtagaatga ggtatcatcc ttcagcctgg caaggattag 45540
gaggaatgtt cacttaagag ttctgtgtag gtgctaggat gacaacaggg aggtaaacag 45600
gctcgtgcgt aactccatca cctgacctgt cagctcggag tccccgctag gctgcctcca 45660
cgcagcaggg ccctgcagcc taagagttaa aagcacagat tctggactca ggaagatcca 45720
ggttcaaatc tgacttacca cctatgtgat cttcagaaac tcagttcatc tctcagaagt 45780
gtatttccctc tttaaattgg gtcacggcca cctgccgcac agggctcatga gaattagagg 45840
agaggaggat gtgtagtgtc tggcgagag cagacacctg taaaatggtg gcttgtctat 45900
tcacatcatt ttctctccag ttctctcagt gtctgggcac atctagacct tcagagctca 45960
ggaccaggat ggtctcaggc aagagcagct gccttccctg gtgctatctt gccatcacc 46020
cggagctgtg ctcttgcttc acctgggagc ccccacatcc cctgcccctc ctactcagcc 46080
tgtgggtgact ctttgttgct cctgctcctg ggtcctgtgt ttggttccag atttgggga 46140
ttctgtatgc aaataggcac ccagtctctg ttaggcccc tgaccactct taggctcttg 46200
ttgcagagga acctcctatt ttctgggtca gaaatttcac ccaggaacca ctttctgccc 46260
caagcctgtg gcaccagcca ccaggtctcc ctcacccccc ccacaccccc ctgcctcact 46320
caggtgacct tagggcagcc tcgacccctc agcggcctga acccgacctg cttgaaggaa 46380
cattttctgt actagtgtcc atccatccca tcagcatgac ctgttgggtg cccatcaggg 46440
ctgctcttaa aggagatggt atttggcatg tgcactgggc cctgggtgctc cctggcatct 46500
ggtggggagg gctgaggcca gcaccaaaga ggcaggtgtg tctgtgtctc tgcattgtgt 46560
gcctcccctc ttcccttacc tccagctgcc agcccctgg gggttcccag tccctcctgc 46620

```

ISPT-1006-Seq.txt

tgccctgggt	tagatgggtg	aagagggaca	tcaggtagtg	aggtggctat	aggtcagacc	46680
caggggtggt	cccctttggg	ccccaaccgt	gagagcatga	cttggaactc	ttcctctggc	46740
tcctgtccag	tccaggcagc	ggggggcccg	cagcttctgt	ccatgtcctg	tgtgggtgtg	46800
attgtccatc	agcctgggcc	ctgggaaggt	gggggctgtc	aggttaggct	ggctgttctg	46860
tgcaggaggt	ggttttgtca	gactgtgtcc	tgtgggggtt	cttaactgtt	ggaccgtcct	46920
gtgtgggtgt	aattgtctgt	tggattgttc	cagggagggg	tgtgctgcct	gtgcccgggg	46980
gtgtgtctgt	cacagacagc	ttgccagtg	tgtcttoaca	agcagttttt	tcaagtgttt	47040
attggtgggg	ccaggggacg	gccaaagtcca	gtggatccac	ccccaccttg	ccgctctgcc	47100
ttggcctccc	ccgccaggac	ctgtcagaac	tggcctcaag	cccaagattc	ctccaccctt	47160
tctgagggtc	cttttgctac	ccaccccgat	cctggctcct	gtctgtccgt	ctgcgccag	47220
agcagccctc	cagggcactg	gcccagtgga	gagctccaac	ctocattagc	ctcttgaatt	47280
atgcaggagc	cgtgggtggg	cgaagcactt	tagcaggacc	gggctgagga	gtggagctgg	47340
aatgggtggg	gctggcgggg	agggggtgga	gtaggagggg	aagatgggtg	tgggagcaga	47400
ggctgctggg	caccaggccc	ccagggcaaa	cccatctcct	cctgggtggc	ggcaaatctt	47460
caagctccag	cctgatgagg	gcatggcggt	cttgtgaatc	ccaggcccg	cagtctgcag	47520
gctgctccca	ccctggctc	tgactggctt	agtggggctg	cggggcccag	aacactaaca	47580
gggatgttga	ttgggaaata	ggctccagta	ctggcaagag	tgtggcagaa	actgaatgga	47640
gctgggggtt	ggggtacagt	ccctggcaga	gcaaaggtgg	gtcttgctgg	actgtgggga	47700
gcatgagatt	gtgctccaaa	gcacaaccgt	tggttctaga	caggaggcca	ctgggctctt	47760
cagggcagag	ttcctggagc	cagcaggggt	ggcaggggtg	ggcctggatg	agcttcgaca	47820
tctggtcaac	atcagccaca	gatgtgtctg	agacctctca	ccgtgttcca	ggccacactc	47880
gacatggggc	gtgcctgacc	tctcgcttct	tgtaccacac	ggtgccttgc	agatagagag	47940
cagtgaggaa	tccgaccaag	gcaagtacga	gtgtgtggcg	accaactcgg	caggcacacg	48000
ttactcagcc	cctgcgaacc	tgtatgtggc	aggtaaaggac	tcaggcagtg	cctggcccct	48060
gtcaccacag	agctgtgctg	cacctgcggg	gtctctctgc	cagagccctt	ggtgcagaca	48120
cgcaaggggc	tggcatgggc	ccagtctctt	ctccttctct	cttctttctg	cagcagcagc	48180
aacagctccc	actgggcaag	ttcctggcgt	ctgccactac	ttcgcccttc	ttccttgcag	48240
gccccggggg	aagcagccac	tcttgggagc	atttgtatct	tttgtaggtc	ttgccgcatg	48300
ggcccgagc	cccatgggaa	tttgagccca	tccaatccga	cttcttggtg	tatgtgcatg	48360
tgtgtgtgca	cacacgggca	cacttatctg	tgtgtaaatg	catgcatacc	tggcctggct	48420
ttccttctag	acatcctcct	gcctgccgca	gcatgggtgg	ctccagaacc	accatggctc	48480
tgggcttttg	ggtagttaag	cctcagggaac	ggaccaggcc	aggtgagcct	atcctctggc	48540
caggtctctc	tggagccttc	ctggaggaac	ccttgtgttc	agctgtgagc	ccctgtgggt	48600
atgttgctct	tggtgagcac	tgtgtgtgtt	ccagatgttc	tttgctggga	gcgagtggac	48660
agtgtgcttt	ctggaagtcc	aagtctccag	cagagaggaa	cctggggact	gttttgggg	48720
ttccaatctc	tgctatgctc	acagcctagg	ggtgactaaa	gctggccacc	ttgcccttct	48780
ctgagaacac	actgggtctg	gtatacatgt	gcccagaagg	ggccctgaga	gcccccttct	48840
ccctcatact	gtcccctcac	ctagccttct	tgtacagatg	gatgtcatta	aaagttaaac	48900
tgttgaccgg	gtgtggtggc	tcacgcctgt	aatcccagca	ctttgggagg	ctgaggcagg	48960
cagatcacga	ggtcaggaga	tcgagaccat	cctggccaac	atggtgaaac	cccgtctcta	49020
ctaaaactac	aaaaattagc	tgggcgtggg	ggcgcggtgc	tgtaatccca	gctactcagg	49080
aggtctaggt	aggaaaaatc	cttgaaccag	aggttgtagt	gagccaaggt	cgcgccactg	49140
cactccagct	tggtgaaaga	gcaagactcc	atctcaaaaa	aaaaaaaaaa	gtacaactgt	49200
ctccacccag	gggattgtaa	aggaaagcgg	acatggctcc	ttgcagtgat	gattccatca	49260
cgccaagtgc	ttagcgcggc	ttcctgaggg	gtgtcgtctg	actctccacc	cagtgcacgt	49320
ggtgggtgat	ggcggtggcc	tgtccgactc	tttggggcca	tgtggtcaga	cttgcttact	49380
cagagcagag	agaattagcc	tgtcaaggct	gtcaaccaaa	atacacttat	caaggagtgt	49440
ctgtctgtca	tgggagaggg	tggttctgga	gaggccacag	gctgccagcc	cattcgggtg	49500
ccagttgagc	tgcagaggaa	ctatttgtgg	tgggcaaatt	gtgcttcaga	gactattaaa	49560
gatgcttcat	gagagttggg	ggcatgggat	gggaggctcc	ctagcttact	gtcaggtgtc	49620
ttactcctca	aggctcaggc	ctcaggtcag	cttgtctgtc	ttcaggaaca	agagcctgaa	49680
aacttcccaa	atggcctaga	ggagtggagt	tgtaaagcgg	acagcccttg	ccccaccctg	49740
ccccaggcag	agtgtctggc	aggcattggg	gctggcgagt	ccactccaac	agaggagcag	49800
ctggaatgac	ccttctcaaa	gatctgcctc	ctcccaccct	gactatcgca	aatgtctgtc	49860
tctctagagc	tctgctcaca	agactgtagg	gtcgagagtg	gcagttccag	gcctcagcaa	49920
gaaagccttt	gcattgtggc	gcaccagggg	gaggagaggc	ccagtagagc	cactgtaaac	49980
ccaagccagc	tgcaagggcg	tggcctatgg	gcacatttcc	cagggcacag	ctacaggagg	50040
cagtgtctgag	gcagaagaag	gccagagggt	ggatggaccc	ccgcattgtc	ctcttgacta	50100
ggcagcattc	tctgaagtca	ctgttacact	ggccccagcc	ctggaggcag	agcagtggtt	50160
ctctttggag	atcgactggc	ctcagctgct	ttagctggga	gtcagctcac	tgcccaggga	50220
gctcttatgt	gcagcccttt	ggagcatccc	tgtctgtggg	gtccctgtgt	tacacatggt	50280
agactcaggc	agggccctga	ctggctcttg	ccatggccca	acccctaact	ctaccagctc	50340
ttcttgaatc	tacccttctg	gtccatcccc	cacatgcctt	ttgtaggaa	ataggggggt	50400
tcttttagtt	ccagccccac	ttgccaggga	ctccaaaaca	gccaaacctg	acttctgttg	50460
tctctctcac	acacacatac	gacgttctct	taggccctga	tgtctcagga	ccgtttctaa	50520

ISPT-1006-Seq.txt

```

gctctgtccc caggacctgc ctcatgtaga ccctaattga atctacacca ccctgctttg 50580
ccaagagcaa cctgccccat agggccctact gtcctactga caggacttag gcacacctga 50640
aaggccctgc tccctgggtg ccttgccctct ggtgccccca ctgctcgtca tctcatggtt 50700
ggcaaaaccc ctgcttcttg ccctcagcag tactaggggc ccttcagccc cagcgctgg 50760
ggacagcctg tactgggctg accaccagct ctgcatcctg agccctgctt gtgggtggat 50820
ggccgtggag gagtccccag tgccagcctg ctttctggcc tgcaccccg tccatctccc 50880
agcagagagg cttcgaggtt tccctccaca gcaggctcct gagcctcaga cggcttgatg 50940
tgggctctag ccctgaactt ctcagccgca gcactgttga cattttgggc tggacgattc 51000
ttagttgtga ggggccatcc tgtgcattgg aggtgttga gcagcatctc tagctacta 51060
gatgccagtg gcacccctca gtcaaaacaa acgttgcaac gtgtcacctg ggggaaatta 51120
ctgatggctt cccactgcca ttgtctccac ccacttgact ctcttcacct gtgtccactg 51180
gcgcgaaggc ttcgtctcct catcagactt gctctcgggt tctacctcac atctcccttc 51240
tgtcccccaa attctcaggg ctcccagtg tgcctctctga ggccacgcga ctgctacatt 51300
taatgggaca gtacacgtga agcaccaggc acattgccag gcacacagga agcacttgct 51360
agtcagtagc ctctgcagct agcactcggc tactagttag tagcctctcg gatagcactg 51420
tggggggatg tgtcatccag ttacatctga cttgtttcac agttgcctgc agctccacc 51480
acagtctagc agggccaggc atgctgggtg ggcagagcc tttctccttc accacctgac 51540
tctccctgag tgactcattc tctccttcca tctacagctc tctgggtgta cagctgctgg 51600
ggccagggtg gagccctgcc ctccctcagag cctggcctac ctgtgccagg actaccagcc 51660
ttcccccttt ctctagggac ctggctgcgg gccacagctg tctaaaacag ggacagtgcc 51720
ttttccccca cagggtccca gacatgctcc ttacaccggt ggtgtgtgtg ggggtggctt 51780
ctagtggctc ctgtacctg gcaggtttgt gggctgggtg ggccctgacc ccagagcccg 51840
gtccacaggg tctgtctgag ctgtgggtg cgtgtgaggc atgggggcct gcctgtgcc 51900
cattttcacc tgccccggcc ccaccctcgg cctccctggc gcctgctggc gggcctcagc 51960
cctgtccacc atgtcctcca tgagtcctga gtcttttctg agtgatgtgg ttcgtgtgca 52020
cctgtgtgca tgtgtgtgtg cgagggggca caggagtctc gtctcgtctc cgtgctgtgt 52080
gggcagatga aggttgccct gtttttactc tctctgtgtt tctccttgtc ttttttttat 52140
tccctcctca tcttcatcgc actctgccat caacccaaac tctcatctct cagatcagcg 52200
agaaggttgg tccctttcac tctttatcca tctacagttc gccatcgat gggacacgcc 52260
tgtcagtagg gccacggg ctcggtcagc tccctcaggc tcaactgcgc gtgcctgcc 52320
ggcagttctt gttgtttggg ccggcgggca ggcaggacca gggatgggtg ggcagacccc 52380
tgacctgcat gttcctgctg cttgggtccc tgggtcacca cgtgtctgca tgtcccccta 52440
gcctggttcc cctgcaaggg tgggtgggtg ggcatgctgc atggcatgaa actgtacccc 52500
acctttgcac ccaggccggg ccagctgtct gtccaggcg gtgctcagga atggttgtgg 52560
ggggtctggt tcagagagag gtgtaagacc tgtagcgctt tgtgtgcacc tgtgggacct 52620
ttcaccgccc tctcgccta gagaccagg ctacgccgaa actactggaa cattaaggcg 52680
agaggctaga gcaggctgtc ctcccagtat cctgcagcac agggcaaaaag tcctgcagt 52740
tgtaccctgt ccttgaggcc ctcaggtccc ccaccagggc ttaatggggc agtcagccct 52800
ggtctgcctc agggagcttg gtgtccatgg cgcagggtga gtagectcat cttggcacc 52860
tgaggaagtc tcccataagg ttgtcttttc cttctccagc cagatccaaa ttaagatcct 52920
cctacctgcc ccaggccctc ctgcccagc ttccagcta gctcccgtgt ctgtttgagg 52980
gtggaattta gccaccagc cagctaactg acattcctta gcttgatgct ttgcattcag 53040
actcaagttg ctcttacctg gagtaactga acgtcagct gcaacttagc aggatccata 53100
tgggagcctg gaagtggccc ctgactcagc cacaggtag gaagggtttc ctggagactg 53160
tccttgagcc cattccagag caggtctgtt tggggcttgg ttttccgcc cacccttga 53220
gccagacccc caccactgat gctgggttg gcagcagggg ctagtgggtca ttcatttatc 53280
acatggtctg tgtggtcaga ggagactcac ctgtccattg ggttttgggg gttcaggata 53340
gcagtgtagg acaggctgag cctcagggag caaaccagg ccactcctgt tccctctgcc 53400
acatcctccg tggcttgagt ttctctgtg agggtaggg agccggtcga gaggagggt 53460
atagcctagg ctacagatat agccctgagc atccatccat atgcacagct gagcactggg 53520
gcatttctgt tacaccattt tgcagaccgg gcagatctgc gagggcgtcc agaaaacagt 53580
catcagcaga gacagcccag cctcctccat ctccctccat gcccttccat ctaccctcct 53640
ggtccctcgt cccctccctt ccccacccc accctatggg cccaccaaaa ataagcacat 53700
ggacaaatat ttagcgggaa ggcagacatg agtttctaaa tattccaggg ggatttgccg 53760
ggctggtaat ttgtttgggt ctgataattg catcttacat ttttccagct ttacttaaaa 53820
ctgtgtgccc ggttttgccg catttaatta ctgctctgag gcagccaaa ggttatttat 53880
taaaagagta ttttatcttg atacagtga tccctcccct catcccctcc ttaatgttgt 53940
gttattttca tcagagaaat ttctctgagt gaatgcagat tgcggggctg cctccccctg 54000
cgattaggct gtcactctac tgaatgtgga tgccctggg cgccgcaccg ccctattata 54060
gggggttgtc agcgcaaaata attagactta aaagttacag gtgaaatata atccagaaat 54120
ggcagggccc tgttttggaa attgtctata aaatgtcagc actaaggatg cacagggaac 54180
ggtaatatata tggcattgtt ggagacctaa gattaggacc tgaagtggca tttttcccag 54240
ctccagtttt tctttccctg ctgttgcttc tgtcaataga ctgtccaggg tgaggcctgt 54300
tccttttttg agggcctgtg cctgcagcag tgggtggagg atggttgggg ctgctgcagt 54360
gagatgccag ccactccagc tgttggcatg ggggtggctg tctaggatgc 54420

```

ISPT-1006-Seq.txt

```

gggtccctgt tggcacttgg aatacaagga ggttgtccct tgcctgtttc cccacccctt 54480
cctctgtaga cataccctga cctccctcac atggaaaatg tctcagtctc agtaacgttt 54540
ctgctgtggt gaagcccagt gtcccttgta gagtgaaggt ggtgtgcccc ggagcctctg 54600
gacctgaggg ccttgtcttg tgttgacagg gaccctaaag gccactgttg acctctcaca 54660
cttatgccta gcccttagag ctctccctgc ccctgcatc taggagggaa aaaataaaca 54720
caactcttct gtgaagcgcc tcaatttcct gacagccgca ggagttagag gctttagaag 54780
acgtggctca gggcggttggc ctgacctcca gggctgatcc atgaagtcog ccttttgccc 54840
tgaagacctt gtccctccagg gacaatttgg cctgatgttc cagtcaagtt tctagggttg 54900
tgcccaaggt ttattggcca aggacctact tccttctgct ggggctcttt gtccctggtat 54960
ccaacgacgt gattaggccc catgattcca ccaccgactg gggccaagcc tgcaatcatg 55020
acctctccct ggacacaggc gtctaaaccc atccttacgc ccgctggagc agcgtccctt 55080
cctgcacgcc tctgtctaatt ctgatgcttc tcccagagc cttctgggtc ttttttcagg 55140
cctgtcagct agggctcgaa aggttgacag tttttcatca cacagacctt ctctactac 55200
gtatataaac ttggtcatgt ggcttggttt taaaacagtt cccttgactg taattggcag 55260
gtgatagcat ctacagcctg gaaacctgca cctagtaggt gcttaagcat agcttccctt 55320
cccataaga ggaggagaca gggcaccacc tggccgagag gacaggagag atttagttca 55380
ttaaggctgc ttctctgtgc tgccccacc ccgcttctgt ggcaggcctg gacctgatct 55440
gcaaacagac ttgcctgcct gtgcctgtcc ctgaggccca tctccagagc agagggagg 55500
catgcaccgc tgggctgggt ggtggtcctg gctgagcctc ctgctctcac cttggacctt 55560
ttgaggtgctg tgctcagaga gtcccttgtt gccatgagac acttgccagc catgccccgg 55620
gatccacctg ttctgcacaa agaaactgtgt ctgtgacatg ctgtcatcat tggtagagac 55680
tccctgcact agaagcatg acagaaaccc acttatacca gcgtaagcaa aacaaggag 55740
tctgtgttta caaatctgaa aagtgtagta gatttgggtc tgggcagggc tagatccagg 55800
tacttaaaaa ggttgccag tcatttgtct gtctgtttct gagctctctc ctctctctgc 55860
gacatctttg ttctcaagca gcttttctct gtgttggtga gaagccatcc ccagctgctc 55920
taagcttagc tacctcagta gcagagaaag gtctgttttc taatagtctc tgcggaagtc 55980
caaaggctgt ttctccatag tcagatctgg gtccacaccc ccagtgtatga agaatgcagg 56040
tagaagtggg ttctctaaag acaatgggaa tgctcattga tttgaggaga aagcagaacc 56100
ctgaatgtct acaagatact ctcatgccct aggtgaacct ggggacacag atccagcccc 56160
ccagcctctg tcaggcctgg tctctggggc tgccagggtt tgggttctgt ctggagcacc 56220
agagtaaggc aggtcttgga aggagttgaa gcaagtgtct aattaggtag ggtctcttgg 56280
gctgggcaga ggagtcactg ggagccatgc aggagcttgt taaacaggga gtggcatcag 56340
atthgtgcca gctgtttgtg gaggcccgct gaggcaggaat tggggcagtg gacaacaagg 56400
caggaggact gacgcagaac acattgcagc aggtatgtga tggcttggaac 56460
tttggtgggt gctgtgctc gtgtgtatgg agagaaatag atggatttgg aagatatgtt 56520
atgccacgct gttgacagga cctggtgact tgctgaatgt ctgatctctg ggtctaagtt 56580
ttgaccctct tatggtgagg tcagacgttg gaccgggagg tctctgaagt tgctctagc 56640
tctagtctct tgatttgggg ctgtgtgagc agcatagtct ggtgcttata gtggagatgc 56700
tccttatgtg tgtgcttggg gtcttggcat gacctggccc ccagcagagg gtcctcagag 56760
accagtgtct tcagcagtg ccttgggtac tgactagcct gctgctgcc gcctttggcc 56820
ctgctgtgta gagtgcctgt gtaggacaca ccctggcctc tgctcaccag ctgcatggcc 56880
catctgcatg ccagacatgc ctgcccacgg ctgggtttca tcacctccct tccctctgca 56940
tgctcctgtg tctgtgtcaa gcttccaaact tcggggggcg gtggttctag gctgtacct 57000
ggactagaaa cctcagaaca gcttctggtc aggggagtc aaggctggag gtcgtggcca 57060
ggcacagcca cagccacccc tccccttgag acccttgttt gttggcgcaag gaagccgtct 57120
gttcgctgccc ctcatcatgt tactgccatc gtcatgccca tcctgcccgc agaccatgtc 57180
cctggcctgc cctgaccctt gcccctcccc agtccctctg agggcagccc ttttgcttgg 57240
gttcccagggt tgtgcccctga gcatggctga gacctggcca ggcggccctg ctgcttgctt 57300
tatttcttcc cctcaggcca tggcctggag gtggaggcag tgactccacg gcaggtggct 57360
gtgtccctct ggactggcct tctgctctgc ccagccatgc tctgaggacc ctccacctta 57420
gggcctgctt tctctccttg gtgtccacgc caggagcagg cagagatagg ccctggagaa 57480
caccctgggt tgtgtgctct accaggcctg gacctgtac tgagtccctg tgtgacctg 57540
ggcagacagg accttctga caggcctcag ttctctaggc tataaaatgg gagcttggtt 57600
gcaagatctc tcattagtag agtcatcgtg ctccagacag tocctgagtg tgggggcccac 57660
ttctaggctg gaagtgggtg ggggtggagt ggatgatgag ctgggggtctg gcggtgccac 57720
ccctcctgtc tctgagcatg ggttgggtc tgaccagagg ggcttctctga atgaggggcc 57780
cctgccttct catgcatcgt tgtgtcctgc ccggcctgt agtgccctc tccctcctcc 57840
tgcaagtgcgc cgcgtggctc ctcgtttctc catccctccc agcagccagg aggtgatgcc 57900
aggcggcagc gtgaacctga catgcgtggc agtgggtgca cccatgccct acgtgaagtg 57960
gatgatgggg gccgaggagc tcaccaagga ggatgagatg ccagttagcc gcaacgtcct 58020
ggagctcagc aatgtcgtac ctactgcca gctcgtctgt gtggccatct cctcgctggg 58080
catgatcgag gccacagccc aggtcacagt gaaaggtgag tgtggcaggt gctgtaacca 58140
gtgccctccc tgtcatctgg gaggtcctgg tgggtggcga atgtgagctg gctgccatgg 58200
gcacaggcat ggctgaggga ttcttgccct ttcctgggtg tccctgccct ggggtcctcc 58260
agcccttaga gggaggaggg gatttctgtt attagccggc ttaatgataa tagttaaggc 58320

```

ISPT-1006-Seq.txt

```

atattgagtt tcttgggtggg agacatcatg ctagcaagca cagttgattt tgtttttttc 58380
tgtttttacc tgaggagatag gtgctcttat tatttccatt tttgaaacga gggaaaccgag 58440
gcacagagag ggtgtatcac ttgccccagg gtcacataaa aataaatgac agagcaggga 58500
cttaaaccce gtgtgggtctg aatccatata tcaccctcac cactacatag taccagacct 58560
tcaggtttaa tagcctccca gcaagaaggg tgtggtaaaa tagtagggga aagtgtgttc 58620
tctctgccct gatacctggg gacaggcaca catgtattac acatatgtca catatatgta 58680
accgattctg gccaggcacg gtggctcatt cctgtaagcc tagcgctttg ggaggccaag 58740
ttggaaggat tgcttgagct caggagtttg agaccagccc agttaacgta gtgagacccc 58800
catctctacg aaaaaaaaaa aaaaaaaaaa actgggcatg gtggcacaca cctgtggccc 58860
agctacttgg gagggctgag acaggaggat cacttgagcc caggagggtg aggctacagt 58920
gacgcagtga gccatgatca caccactgca ctccagcctg agtgacagag cgagacccta 58980
tgaaaaaaa catgtgctt ttccttcctg gtctccccgc tgcaattctc aacagcctct 59040
gatccattat ctgtttttgca gcttgagtga tctttaaaaa atgtaattca ggatcaagtg 59100
actocctttt aggaaaggga gaaacacctt ccagtggctt cccgttggtt taggatacac 59160
atcaggatcc tcactgtggt ctcccagggc cactggcttc ccaccctgtc acgcgccagc 59220
tgtccagaca catgtgctt tccgtttgct gtgctccttg cctggcccct totgtcactg 59280
gctccatgta cccttcagg cctcagcttg gtgatgcttt ccttccctca tcaccgcatc 59340
caaggagatt ccctggatct tactccacct cagcaccctg attcctgctg tccttgca 59400
tggcagaatc atgagtacga tgcacttgtt tattgattct ctctgtact gaggtgtaaa 59460
ctccatgaga gcagggtgga gactgtgtgg cactgtagcc ccagcacaat gtctggcatt 59520
gagtggtgct ttgttaatta tttgttgaaat gactgtggac tcaggacctt tccacttcaa 59580
tttgagccaa gctgcagggt ctgtggggcc agcagcccca tcaacttttc tatccgggcc 59640
agtcocctaa gaaatatctc cccttccctt gcctattaca catactttcc accagggtgg 59700
ctcagggtgac ctgcagagcc acatagctgc taccagctct ggggtgtctt catctacatg 59760
ggactgtcag gtgaacccca cctccagctc atgtgtcttg atgagtcttg tgtgtgatg 59820
ggagggtcca gacaggcctg gccactgtcc ctcaactgtg taaatgacct aaggccctgg 59880
gtggggcact catttttcaa ggtaggctgt gggatatcag ccttcagagg tcaccataag 59940
cttttccagc agatattcct gataactccc aagtctaggg ttggttccca aggatcttga cctcgggcag 60000
ctttgagcct tccacttttg ctccagctct tccaaagcct ccgattgatc ttgtggtgac 60060
agagacaact gccaccagt atccagtagc gcgcagcggg cactgagccc gggaaactcg agcctgtaac 60120
ctactatggc atccagtagc gcgcagcggg cactgagccc ccctttcagg aggtggatgg 60180
tgtggccacc acccgctaca gcattggcgg cctcagccc ttctcggaat atgccttccg 60240
cgtgctggcg gtgaacagca tcgggcagg gccgcccagg gaggcagtgc gggcacgcac 60300
gggagaacag gcgcctcca gccaccggc ccgcgtgcag gcacgcagtc tgagcgccag 60360
caccatgctg gtgcagtggg agcctcccga ggagcccaac gcctgggtgc ggggataacc 60420
cgtctactat actccggact ccgcgccccc ccgaacgcc tggcacaaag acaacaccga 60480
cgcggggctc ctacacagct tgggcagcct ctgcctggc atcacctaca gctgcgcgt 60540
gcttgccttc accgcgtgg gcgatggccc tcccagcccc accatccagg tcaagacgca 60600
gcagggaggt aggtgggggc atgccggctg ggcagccaac agcagagaag gggaggctga 60660
gggtgtggcg gtgcctttcc ccctccctcg gctgtgaggg aggataaggg tgtgaggtta 60720
aagggtgccg attccataga tgtgtgtgca gttgggatgt gacctcacgc agatgaggct 60780
ggagctgact toctcggtc cctcctccct gggcacccc cctcaggagg gggaggatc 60840
gacctgctg gtgtgggggt ttgcagtgc tgcccagccc gcggacttcc agggcgagg 60900
ggagtccgac accaggatcc agctctcgtg gctgctgccc cctcaggagg ggatcatcat 60960
gtatgaactg gtgtactggg cggcagagga cgaagaccaa caggtgtgca gggggcagag 61020
aagcactgag ggggtctcct ggtctgtgat ggtctgtgat gggcctaacc caggagggta 61080
ttttctggat tctgtggctt atgtgggcac agcctctaag gtttctgctg gaggcttagt 61140
ggtgcatgcg tgtcatgtgg ccgcacagc ctgtatgaat ctggagtcag tgtcaccctg 61200
tgctaggggc aaagtcccca gggctgcct tgggtttcct aggcctctgt gctcatatga 61260
ctggcagagc cctgaagttt cccagaagc catgcgtccc agatggctcc tgtggtccat 61320
gtggtctgtg aggcgtctgt ggcattgggt aagccctgag ttctttttgt gctccatgtg 61380
gccttatggt gtggagccag tccctggagc gtggtgggtc cagagggtgt acattgcagc 61440
ccatgttggg gaacaacctg tgagtactt tgagctcaga gctgtcagtg agtgctccct 61500
gctcttccca gcacaagggt accttcgacc caacctcctc ctacacacta gaggacctga 61560
agcctgacac actctaccg ttccagctg ctgcacgctc ggatatgggg gtggcgctct 61620
tcacccccac cattgaggcc cgcacagccc agtccagtaa gtgtctccca agtccgctgc 61680
ctgttacacc tgggctggga cacacacaca cacatgcaca cactccttc cccctcgacc 61740
aggcagggtg ggtggtcagg tctgctggcc aaaccgaact ctggcctggg ctctgagctc 61800
gggcctcggg agagggccag gtaagtgcct cccagtctgt ccagtccagg tggctgtctg 61860
cctccctgct cctgcccag cctcctccc cctcctccc ccatgcccc cactagctt 61920
aggtaagttc tgtgtctgtg cctcatctcc gccccactc tgtgtgtgtc acactagctt 62040
agctgatggg ccatcctcgg tgggtctgcc atgtcccaga cctgcttttg cggctgttcc 62100
tcctccctat ggccccgcac ctgctctccc catcaccac attcccttcc tcatactccc 62160
catgaaagtt acctgagagc catgtgatca cctgagctg actgcactg gggacaggtc 62220

```

ISPT-1006-Seq.txt

tgagaatgcg	gccatgtgac	ccagcctgcc	cacgtgtgcc	ttgaattgtg	accacgtggc	62280
cgtgcagggg	actgtctgca	aggctgtctg	tgtgagactc	tgggtgtgtg	tgtgagagac	62340
tccgatgctg	cagctgtggg	agtggcactg	cccatgagtg	tgagtgtgtg	accacacctg	62400
accagctggc	tgtgcagcac	ctgtgtatgt	gcacagtggt	atcttgggca	tgacccttgt	62460
ctttgtgggc	gactctggcc	tgatcctgta	accgtatttg	tgggtctcgg	tagcccccga	62520
gacagtagac	tgtgtgtgtg	tgtgactctg	tgggtgtctg	tgggcgtcct	gtgtgtgtgc	62580
acacagccac	agtcagctgc	tgcgtgagac	tctgtgtgat	aggggtgcat	ggatgtgact	62640
ggctgggtag	cattgtggga	ttgagatggt	gaccacatct	gatgtggcca	tgtgatgacc	62700
agaaacatgg	cggtgtctga	agtgtgcctt	atgaagtggg	accatgtgca	tgtaccagtg	62760
atgtcaagag	gctgtgtgtg	accttgtatt	catggattca	ttccagaagc	acctgtctgt	62820
ctgcagctgg	gggccaggcc	ccatgcacgg	tacagggctg	gcagcatgac	cagacacatg	62880
gtgtctgccc	atggggatcc	tgcattccag	cagggcagac	agacattgca	cctgtaatta	62940
cccaaagtga	cttttttatt	ttattttatt	ttcaagacgc	agttttgctc	gtcaccagg	63000
ctgcagtaca	atggcaccat	ctcggctcac	tccaacctct	gcctgtctgg	gtcaagtgat	63060
tctcctgcct	cagcctcccg	agtatgtggg	attgcaggca	accaccacca	cgcctaaaaa	63120
tgctcattgg	gtaattacag	gtgcaatgtc	tgtctgccct	gctggaatgc	aggatcccca	63180
gtggcagaca	ccatgtgtct	ggatcatgtg	ccagccctgt	accgtgcatg	gggcctggcc	63240
cccagctgca	gcacagcagg	tgcttctgga	atgaatccat	gaatacaagg	tcacacacag	63300
cctcttgaca	tcactggtac	atgcacatgt	accctgtctc	tgttcattta	ccagtgggct	63360
cccacccttc	cttcaggcct	tgggaaagtg	tcacctcccc	aaggcaaccc	tccttgacc	63420
ctgctcaaa	cagtgaactc	cgtctcaaaa	aaaaaaaaaa	nnnnnnnnnn	nnnnnnnnnn	63480
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	63540
nnnnnnnnnn	nnnnnnnnnn	gtgtaatccc	aaatactcgg	gaggctgagg	caggagaatt	63600
ggttgactct	ggaaggcgga	aattgtgggtg	agccgagatt	gcgcatttgc	actccaacct	63660
gggcagcaac	agtgaactc	cgtctcaaaa	aaaaaaaaaa	ggtaggatgg	aagagacagg	63720
gtggagagat	gatgagacct	cctttgatct	gaggggtcaa	agaggggttc	cttggggagg	63780
tgacactttc	ccaaggcctg	aaggaagggt	gggagccaac	tggtaaatga	acaggagcag	63840
ggagcacaca	ggcctccggg	agagtctgca	ggcctgaagg	ccttccagct	gcaaggcaca	63900
tggttatggt	cacaaggtaa	gcagcaggcc	agtgtggctg	cagtagctgc	cggatctatg	63960
gcagtcaggg	ccttggggag	acagggtagg	caggagagct	gactctggct	gctctgtgag	64020
aatggacagg	gcagcctgtg	aggaagcaga	gaccggttag	gaggctttgt	agcgggtccag	64080
ggaaaagatg	gtggcgcaag	tgaggtgatg	gcggtggatc	tgagaactgt	cagggtatgt	64140
gactggtcag	acttggtaat	gggttatgaa	tagggggcca	gggggaggga	agtggagggtg	64200
aatcttgttt	ctggtgtatt	aacctgggag	gagagtgggtg	ctggcgtaga	atgggaaatg	64260
gggcagaggg	aggtgtgaaa	actacagctg	gtctcagaca	cccaagttca	agatgccatg	64320
tgccatctac	atggcagtg	tcggcaggct	gtgggaatcc	agggctgggc	tggagctaaa	64380
ggaccctgag	aagaaagact	gcagatgaga	ggaaatcagg	ggaggggagc	gacttgagg	64440
ttggaaggag	agaaagtctc	aagaactaga	cgagatgctg	ctgagcggtc	aggagtacct	64500
gttgaccca	gcaacatgga	cagatggccc	gtgagatgaa	gcttgggtga	tggtaggacc	64560
aaagctggtg	gatgtttcat	gaggcctgtg	tgggtgtctga	gaatgtggag	gcagcaagcc	64620
tagacgttgc	cagaaagtgt	agctctgaac	aaaggggacca	ctatggctag	agagggccgt	64680
ggagctgagg	gtgggatttt	gttttgtttt	gttttgtttt	gttttgtttt	ttttgagaca	64740
aagtgttct	ctgtctccca	cgttggagtg	cagtggcatg	atcttggctc	actgcaacct	64800
ccgtccacct	cctgggttca	ggtgattctc	ctgcctcagc	ctcccgagta	gctgggttta	64860
taggcgtgcc	cgccaccaca	cccagcta	tttttttttg	taattttagt	agagacagt	64920
tttcaccctg	ttagccagg	tggctctggat	ctcctgacct	cgtgatccgc	ccgcctcgac	64980
ctcccaaggt	gctgggatta	caggcgtgag	ccaccgcgcc	cggcctggga	tttttctttt	65040
aagatgggaa	aatttcaagc	atatttaaat	gctattggaa	acagtcaata	ggaaaaaaag	65100
aaaccgtgga	aaagagggtg	actggtggag	ccttgggagg	tggagagaag	gggaacagta	65160
tgggtggtga	gagagcttag	ccttggacag	ggtggctcaa	ctctccattc	tcattgggtg	65220
aaaggagaga	attgctgcag	atgcaagtac	ggtggggggg	ttgtagcaag	agatggagg	65280
agctgctgtg	aaagcctggt	cttctctgca	gtgtgggaga	catgggtcatg	cgccaagagg	65340
aggcaggcaa	agggagctgg	aggtctgggg	agcatggagg	agggggactg	tttcatgtga	65400
ggtggcagag	cgagccaggc	agggggcaga	aacaggcagc	atggagagtc	ctggaggatg	65460
aggcctctag	ggacgtgtgc	ataggacgcc	agcctgcctc	agtgccgtg	tagagaagga	65520
gggggagagc	tggattcatc	tagggcttgg	cagcggccag	gaaggagcat	ggaaaagatca	65580
ggaggcagag	gaccttgcga	tattgtgtg	agtgtggtag	gtggtagact	gtggaagctg	65640
aacatggagg	gtgggaagga	caaggttgat	ggacaggcat	cctgaggagc	tggcgagcag	65700
gctcagtgcc	cggggcctgg	agtactgag	caagaacaag	ggggtggggt	ctgcaagggg	65760
atgtgagagc	ccgtgattct	ggagggagg	ccatccccag	tactggcagc	ctccagggca	65820
tgaccacagc	tgtgcagggg	agagaaaagt	cttggagatg	aggggctctg	gggccaagtgg	65880
gtcaaggggc	tgctgaagtc	cccatggcag	ggggtgggtga	cagaacttga	agaggaaacc	65940
tgtgcattgc	agcagagtcc	tcgggtggcg	tggagtctgg	acacatcatt	ggatacaagg	66000
agacacgtgt	ctgcctccta	attcccaaag	aagctgttga	gtgagggcac	ctctgttgg	66060
gggtactttt	tctccacgcc	aggggctgtt	ggccttcatg	ttcggcctcc	tgttggtgat	66120

ISPT-1006-Seq.txt

tacctgtggc	actggcaaaag	agactgtttc	caggcaggca	caggtgaagg	ctgccttatg	66180
ccaaaggggc	cactggggcc	actcttcctc	ggaagagcag	aacctgggc	acagcagatg	66240
tgaagcagtt	ctccatatgt	ggctgtgtgt	gcgggtggca	gtgggatggc	cagtgcttg	66300
tgtgtatgtg	atatcgtgta	tgttttgtgt	gagacagcat	atgtgtggga	gagacctcgt	66360
gtgagagatg	ctgtgtcaga	actctaagac	attgtgtgtg	agagtgtgtg	tcagatgcc	66420
tgtgtgagac	accaagacac	gggtatgtga	tactctgtgt	atatgtgagt	ctgtgtgaga	66480
gacactgata	ctccaagaca	ttgtgtgtgt	gtgacactgt	gagacaccaa	gacagtatat	66540
gtgcgagaca	gcctatgtat	gtgacagtgt	gtgtgtgaga	caccatgaga	gactgtgtat	66600
ttactgtgag	agactgtgtg	agagacacgt	gtgagacact	gtgtatatga	cactatgtat	66660
acgtgagact	gtgagacact	atgtgtatgt	gacactgtat	atgtgtgaga	ccgtatgaga	66720
cagtgtatat	gacactgtat	atgtgtgaga	ctgtgtgtgt	gaaacactat	atgacactgt	66780
atatgtgtga	cactgtatat	gacactatat	tggtgagact	tgtgtgagac	actatgtata	66840
tgtgacacta	tgtatgtgtg	tgacactgtg	agagacactg	tgagacacca	agacagtata	66900
tgtatgagac	accctgtgtg	tgtgacacag	cgtgtgactg	tgtgagacgt	gtgtgaggca	66960
ctgagactga	cactgtgtgt	gaggctgtgt	gagagtcagt	gtgtgtgata	actgtgtgtg	67020
tatcacctgt	tgtgtgtgtg	agagaggga	ggagagagag	ggaggcaggt	cagaggaggt	67080
caggcgctct	tgccgagagt	ggcagcagcc	tgcttgagg	gacctggga	tggccatttc	67140
agcacctaag	gggtagcctg	cccgggtgag	tctccagtcc	actgtgactc	agtcattgtg	67200
cctgtgatcc	ccaccctcca	tctgcttgct	tcccccccat	ttgtcttccc	cagccccctc	67260
cgccctccc	cagaaggtga	tgtgtgtgag	catgggctcc	accacggtcc	gggtaagttg	67320
ggctccgcgc	ctgcgcgaca	gccgcaacgg	cgcttatcacc	cagtactccg	tggcctacga	67380
ggcggtggac	ggcgaggacc	gcggggcgga	tgtggtggat	ggcatcagcc	gtgagcactc	67440
cagctgggac	ctggtgggac	tggaagaagt	gacggagtac	cgggtgtggg	tgccggcaca	67500
cacagacgtg	ggcccccggc	ccgagagcag	cccgggtgctg	gtgcgcaccg	atgaggacgg	67560
taggcagctg	caccggggcg	ggaggggag	cgctctgcct	cagacaccac	ccaccaagct	67620
ccccaggggc	ttccttttct	gaacacagcc	ccaggtcaac	tcatctttct	ggttcaggtg	67680
taatggccta	aagtgggggg	atgtcactta	cgggataact	gaggcccaa	tcccagcctt	67740
tgggctgtgc	tccaagcag	ctgaaacctt	cacaggctaa	gatgggagaa	gcagccctgt	67800
ctaagatttg	aaaggtcaag	attgggcaga	ttggtgtaaa	agataactca	agtagaatca	67860
gcaagactcc	acgttggctg	tgacattggc	tgattggggc	ctaggaggag	tcaggacagg	67920
ttgtgtgac	taggggtggt	caaagacctg	gtgccccacc	tccacctgtt	cccccatgtc	67980
gacctcctcc	accaagtgtg	aggcctgggc	cagaggggtg	ggcaggggca	gtcctgggct	68040
cttaccctgt	gcgggcagag	ggagccttcc	gtgtgcctca	ccagggacag	atgatctaag	68100
gaaactgtat	cagggccttt	cctgggggag	tgggggtgctg	aggcaggacc	ctcaagtttg	68160
ctgtgcccac	ctgagctagg	gttgatacct	ccaggcctga	cttcttctc	tacctgacct	68220
cccagtgcct	agcgggcctc	cgcggaaggt	ggaggtggag	ccactgaact	ccactgctgt	68280
gcatgtctac	tggaagctgc	ctgtccccag	caagcagcat	ggccagatcc	gcggctacca	68340
ggtcacctac	gtgcgctgtg	agaatggcga	gccccgtgga	ctccccatca	tccaagacgt	68400
catgctagcc	gagggcccag	tgacagcattg	ggtggtgggtg	gggtggcagg	gtgagcacag	68460
accagcatgc	acaagctccc	ttttggggcc	cagatatgtc	cctcttcccc	tgccctgccc	68520
cagcagtgct	gtgactgcct	ttccttggtt	gtgagaccctg	agatgccttg	cagcatcagg	68580
ggtttagctg	gggttttttg	ggtgtgggtt	ttttgtttgt	ttgtttgttt	tgagatagag	68640
cttccactct	ctgcgcctagg	ctggagtgcc	tctgggttc	aagcaattct	ccttccctcag	68700
cctcccgagt	agctgggatt	acaggcgtct	gccactgcgc	ctagccaatt	ttcgtatttt	68760
tagtagagac	aggttttcac	catattggcc	aggctggtct	cgaactcctg	acctcagggtg	68820
atccgcctgc	ctcagctctcc	cagagtgtctg	agaatacagg	tgttagccac	tgtgccccac	68880
caggtcgggg	ttttgagatg	tgcccttccc	ctagacagtg	ctgggctggc	atccactctt	68940
cccacagaaa	gggtagagag	agtgtctccag	ggctgtctta	ccccactggc	ggccatgggt	69000
ccgtggttgc	tgcaagctc	tgtgagtgc	caagtagagt	gttgccctgc	tcctggccct	69060
gcagggaacg	attcagcccc	tgtgtttcac	cctcaagagc	taggcctgct	ggccagcctc	69120
acacctccct	ctgtgcacat	ctgtcttccct	gggaggatgg	tcctgcccct	gagcttgggg	69180
tgaggtccct	gggttattct	gaacactgggt	ctgtattcag	atgaagaact	tggaatgctg	69240
gggggttatg	agagtgggtat	ggaattattc	agcaagtagg	tggctgctgc	gcttggatga	69300
gaagccatgt	ctgtggaccc	ctaggaaagg	gccacagtgt	ctgtcatgag	ccccctccca	69360
aaagaccctg	ctggagagtc	acaacacctg	gtgtggtgct	ctcaaggctc	ccctatccag	69420
gagcagggcc	tccccattga	gcctctcacc	tctgcctggg	tgagagcag	gggtgcgtgt	69480
accactcaat	ctgtacagag	ctgtgcagag	gggtggggtc	acccacacag	acaggagcct	69540
tattctctca	gctgggctca	gccatctgaa	gcaaaattct	ttctgcccag	aggggtgctct	69600
cttccccctc	tcagcctgcc	cagtgtcaag	gcatccgggg	tggaggaggc	aggcatgtgc	69660
acccacctgc	attcctgggg	caggttgagg	gtctcttgtg	gagcctcagt	gaacacacct	69720
acccagaaac	atcccaggaa	tgggttcccc	tctctgaggg	tctctgaggg	ggccagtggc	69780
cacagctgtg	gccagtgggg	ttccagagaa	gccacttcaa	gtgccccctt	ctggtcccaa	69840
gaggttcgga	aggagctgg	gccagaggct	cagggacgct	gcccatttag	tctcagacat	69900
cccatcatgg	ggcggtaac	tcgagtctgg	gctcccggag	gacactgaag	atggaggcct	69960
gctccgtagc	cctctcagg	ctgggtcatt	ctgttctctg	ccagtgggag	agcagtgggg	70020

ISPT-1006-Seq.txt

cctggtcccc	agcgtggcca	cagggcccag	ctgtccctgt	gcttctgtca	agggcggcac	70080
attctgtcct	tcacgcaaca	gcacatccc	ctcagctcat	ccccatcat	gcctgaagga	70140
actatgtggt	gcaggttccc	acccccagcc	tggaagtgtg	gagccagacc	tgtctccttt	70200
tacgtcagat	tccatctccc	tgccctccct	tttcccctct	cgtggcctgc	atttctctat	70260
ccttcttgga	gtctctgttt	ttgtcttgct	ctttctcttc	tctctcctcc	ttccttccct	70320
cctccccctg	ccattctctc	gaccccttcc	cttcatctcc	atttggtttc	atcctccgtc	70380
cttcccttct	ttcttgctct	gcctctagcg	caggacaggg	tccatgtgat	gtgagaacct	70440
ccacgccaag	gcttggttgg	gacagcccag	gtctccccgc	aggcaaggag	actggaaggg	70500
acgtgggccc	agccacaccc	tataaagtgg	ccatgcacta	aggacctgtc	cagagtctcc	70560
tctcatattc	gtttccatgc	ttcttgcaag	gactttccaa	cagagtgtcc	caggacagga	70620
ggaaccttagg	gcacccagca	tgaggccag	ccagacaggg	ccagaccggc	actgtggggg	70680
tgcttgggct	ggaggacccc	aggtacttcc	ggcttggaag	catcctggac	catctccctg	70740
tgatgtttca	tggggcctca	gaatggagac	ctcacagtcc	ctccacctgt	ccatctagaa	70800
tatctacatg	caccaaaggc	ccgcaacact	gccagccccg	aaacattcct	tcctacctta	70860
atcctcagac	accccagagga	aggaacgggt	ataggtgatt	tcccgtgcct	gtgggctaca	70920
gccacaggctc	tgagcttggc	actcacagcc	ttcatagtct	tgctgactgg	cttgcccttg	70980
ggccaccctc	ggccatgtgc	cctgttcacc	cccaactctt	actgttggg	gacacttctc	71040
atgctgggg	tgattgtgta	atgtatgatc	acatctggga	tgcttggcg	ggtggaagga	71100
gacactgaat	agtcaattcc	atggcaacaa	gcacaggcca	ggactgtccg	aggcaaacca	71160
gggcatatgg	gcacccatt	cacccctcag	gtcttccctt	tcccttggcc	tgagctgttg	71220
aacccaccct	tcttgtctgg	cagcctctcc	ctcccagcaa	gccccaaatt	gtcagagcat	71280
ctgtagctgc	tttgtgttct	tagggccttc	tgtcagcggg	tcctctccct	gcaggctgcc	71340
tgccctccct	gtctccctac	cctcctcagc	cctggcacac	ccagtgggtg	ctcagtggag	71400
cagggtattca	aatctttgaa	ccgggagtgt	ttctgggggtg	ctacccccat	gggtactttg	71460
aggcccaaaa	gcctctccct	tgctcctcc	ggccaaggctc	ccttccaggc	caggccctct	71520
ccaggctcaga	gtccttcacc	atcctgtctc	cctttctctc	cctctccgcg	ggtcagtggc	71580
ggccagagga	gtccgaggac	tatgtaagta	acagggtgtg	gaacgcggac	aagacatggg	71640
tcaagctggg	ctcgtgggac	gctcctcctc	tccctccttt	cctgctagcc	tgcaactgcca	71700
agatccacag	ggctctagcc	acatcaggag	aaaattggcg	tttagacaca	agcaactgagc	71760
tgagcagcga	ttggcatttc	ctctaattct	tacttcttgc	ctgtcgagca	gcaatttgag	71820
gccagtgttc	atgatcgacc	agggcctggc	ccctgccccg	gccagacagg	gatggagtta	71880
aatccaatcc	tgatcgttag	gccttattga	tccctggagt	gaaaaatcac	ctgcttttag	71940
gcccaggctg	ggagggtctg	ctggagagtc	ggattctggc	attggtgcat	tctggagccc	72000
cagccctggg	agacccctca	gctgtggcag	gaggggtcca	tgagggggtg	gtggcagctg	72060
caggggcccc	actcaaggcc	agagctggag	ggataccagg	ggtgatgaca	gctctgttcc	72120
cactgcacgg	tggtccctgc	cctgcttccc	actcttctct	ctgtgtgggtg	tggtctgacc	72180
tcccatgggt	tttctccgca	tgtccagaga	tgatgccttt	gctgcagatg	ggtatatggg	72240
caaggctctgc	caagcgggga	ggacattggc	ctggctgtctg	tctcaggcat	cactgagaac	72300
agatgtggaa	gccagttccc	cagggtgtgga	ggttttctta	ttctcctagc	ccctccctg	72360
cccttctcaa	gaggtattgc	agggatataga	cattcacaga	gttagtggcc	tatatggggg	72420
cagcggagtc	ctgactgggt	cctataggat	ggcaccttag	cccatcctgc	caocttgctc	72480
tgtctgtgca	tgcatgcact	ggtgtccaca	ggcagcctta	cgctgcttta	tgcaaggagt	72540
gtaggctgtg	tgctgtgtgc	tgccaagagc	cacgcaagggt	gctgggtgcg	tgcgaggctg	72600
tgccctgttg	atatactcag	tctccgttca	cagcacagtg	gagtgaaggga	aacagtctgg	72660
ccctttgttc	ttgtctgaaa	agaataatga	gctgtctgcc	ccaggcgtgc	ggctcctggg	72720
atgggcgggg	tcctcccagg	cctgcacctc	acctgcctgc	ttcctctcca	gcagaggcca	72780
ccattgtata	gccccacctt	ccacaacccc	tgcccttgtg	tgccccgggg	ctcccctcag	72840
gctagggtcc	tgaggctcct	gacaaggctc	ggcctctccc	tgcatctctg	tgatgggaac	72900
gaacccctcc	tcctccctca	ggaaaccact	atcagcggcc	tgaccccgga	gaccacctac	72960
tccgttactg	ttgtctgcta	taccaccaag	ggggatgggtg	cccgcagcaa	gccccaaatt	73020
gtcactacaa	cagggtgcag	tgagtgaagg	gtcaggacgg	acctgagggg	ggggcagcag	73080
gagggcagcg	ccagagccca	gcccgtgggtc	cttcagtccc	aggccggccc	accatgatga	73140
tcagcaccac	ggccatgaac	actgcgtctg	tccagtggca	cccacccaag	gaactgcctg	73200
gcgagctgct	gggtaccggt	ctgcagtact	gcccggccga	cgaggcgcgg	cccaacacca	73260
tagattttcg	caaggatgac	cagcacttca	cagtcaccgg	cctgcacaag	gggaccacct	73320
acatcttccg	gcttctgtgc	aagaaccggg	ctggcttggg	tgaggagttc	gagaaggaga	73380
tcaggacccc	cgaggacctg	cccagcggct	tccccaaaa	cctgcatgtg	acaggactga	73440
ccacgtctac	cacagaactg	gcctgggacc	cgccagtgtc	ggcgagaggg	aacgggca	73500
tcatcagcta	caccgtgggt	ttccgagaca	tcaacagcca	acaggagctg	cagaacatca	73560
cgacagacac	cgcctttacc	cttactggcc	tcaagccaga	caccacttac	gacatcaagg	73620
tccgcgcatg	gaccagcaaa	ggctctggcc	cactcagccc	cagcatccag	tcccggacca	73680
tgccggtgga	gcaagggtgtg	tgctgtggac	atggcatccc	ttcccagagt	tggtctgcatc	73740
tgggggtctc	tgctctcctt	gagccactga	cctctggcga	ctgtgatcca	ccagcctctg	73800
gtgtgtgacc	tccaatctct	catgactgtg	accactaacc	tctagtgaat	gggcaccaca	73860
ttcttgggtgc	ctgacctctg	ctgtccttaa	cctactgacc	tctgctgtat	gaccttctga	73920

ISPT-1006-Seq.txt

tctcttgtga	ccttgaccca	ctgatctctt	ttgactgtgt	cactattctt	gggtgtgcaa	73980
cctcctgata	tttgggtgtg	gacactaata	tcttggggcc	atgacccacc	gacctctagt	74040
gaacatgctc	caccacgctc	tggtgtgtgg	ccacatgctt	ctcatgaccg	aaacccactg	74100
accctctgat	cactctggcc	tggtgtccat	cggctcaagc	ttttacactc	gcgtttcttg	74160
agattctgac	cctggttgct	gtggcatccc	ccgccctgtt	tggtgtcac	tgtggaagag	74220
cttgggctgg	gagttcaact	gtgccgtttg	aagctggctg	ggagtggggc	gcttgggtact	74280
ctgcagccat	ccttcaaccc	cctgttcccc	aaccagtgtc	tcacctggc	cattcacctt	74340
ccacccttcc	agccattca	ccccacctca	tataccagc	agagctgact	ctctctatgc	74400
ctttgcagtg	tttgccaaga	acttccgggt	ggcggctgca	atgaagacgt	ctgtgctgct	74460
cagctgggag	gttcccga	cctataagtc	agctgtgccc	tttaagggtga	gtaagggccca	74520
cggccagctg	agcctggcac	acacacagc	ctgctgggtg	ctgtctttcc	agtoctaacc	74580
catgtgcatc	cggctgtgga	gcaggaatgt	gggtgtgtat	ccgtgactg	tgcccttgca	74640
cccgtggtag	ggaacctcac	ccaaaggcat	tgattgcccc	tcccgtcccc	cacagattct	74700
gtacaatggg	cagagtgtgg	aggtggacgg	gcactcgatg	cggagactga	tcgcagacct	74760
gcagcccaac	acagagtact	cgtttctgct	gtgaaccgt	ggcagcagcg	cagggggcct	74820
gcagcacctg	gtgtccatcc	gcacagcccc	gcacctcctg	cctcacaagc	cgctgcctgc	74880
ctctgcctac	atagaggacg	gccgcttcga	tctctccatg	ccccatgtgc	aagacccctc	74940
gcttgtcagg	tgtgcacacg	aggtatcggg	ggaggcgggg	cagggctgga	ggttaaccagc	75000
agtgcagctg	ctgattcctg	ccctgcccac	ccaggtggtt	ctacattgtt	gtggtaacca	75060
ttgacgtgtg	atgctgacgc	caaggtggag	cacacccgag	gaactggagc	tggtcagctg	75120
tgagcagagt	acctggggag	gggatgggga	cactgacagc	cccattgcag	tggtcagctg	75180
tgcccttcct	gcctgagca	ctgtccagct	gactctcaga	ttcactcccc	aaattgaaat	75240
ctctcttctg	gttggcagcc	cgccctctc	tgagagagag	gactctgagg	aaacctatctg	75300
ggagtattca	cagaactccc	ggagggctta	cgaagaatcc	ctggggtggg	atgtcgtgga	75360
gatgcctctg	caggtctaga	gaatggcaag	ccctgtagac	actgcagagc	ctcgcagatc	75420
tagaagctat	ggagggctta	gtgagcctta	tagccaggag	tccctgaatg	tttgaaatcc	75480
ttcagtcctt	tctcatagcc	agtgtggcaa	cagcctggtt	agggtgggtc	agcttacaca	75540
cagggtctgt	tctcatgggg	tgatggggag	gagtggcttc	acggtgtctg	ttactctgta	75600
ggggcagtg	gttgggcagg	tgtgggctct	tacacggaag	gtgagccttg	atctcggccc	75660
agggagctga	catcccaggc	cacagcccca	gggctggccg	gcatgctcca	aggccctca	75720
tgaccccat	gctctgctct	gccagcttct	agaagccatc	gagcaaggcg	gagaggagca	75780
gcggcggcgg	cggcggcagg	cagaacgtct	gaagccatat	gtggctgctc	aactggatgt	75840
gctcccgagg	acctttacct	tgggggacaa	gaagaactac	cggggcttct	acaaccggcc	75900
cctgtctcog	gacttgagct	accagtgtct	tggtcttgcc	tccttgaagg	aacccatgga	75960
ccaggtctgc	ctgagccggc	ttggctgtca	gcacctgat	tccctgggcc	tggcctgaga	76020
cgatgccagt	ctcaaacacc	acaagacccc	aggtctttat	cagtttgggg	gcttcgagat	76080
cctggggcag	actaaagac	ccaagatctg	tcccggggat	cctaagacgc	ggccctggga	76140
cccagaggcc	agacctaatg	tggtctcagg	gacccagtcc	tgccaggtcc	acctgttagg	76200
gtctgggaga	ccaggcccag	ggtaaccacg	accagagacc	ctttctccag	gattgatagg	76260
cagagggtgg	gggttctca	cgctgagctc	acagcctgct	gttctccacc	gggccacaga	76320
agcgtatgc	ctccagcccc	tactcggatg	agatcgtggt	ccaggtgaca	ccagcccagc	76380
agcaggagga	gccggagatg	ctgtgggtga	cgggtcccg	gctggcagtc	atcctcatca	76440
tcctcattgt	catcgccatc	ctctgttca	aaaggtgagc	actgccctca	gagctccggg	76500
aacggccacc	tgccctcgc	ctttcaggcc	ctctccgggt	gtggtgcctg	tggagagcgt	76560
gcagccttgc	atcctggacc	ctgagcctca	ggctcagcag	gaaggcagga	agggcaggag	76620
cagtgtgtgt	gcctacctgt	gtctgcaggc	ctgcactctg	caggtgaggg	agcctctgca	76680
gcagcctggg	cgtgaggaac	taaagcctca	gaggggtgtc	tcattgtgat	ccctggcacg	76740
tctgtctgtc	tctgtgtttc	tgtggataag	agtgcgtctg	tctcctcttc	agttttaaga	76800
caccgccatc	tcctgagctc	ctacctcgag	tcctttcctt	ctgccaccat	tcctggatga	76860
ttccccagcc	ctactctcct	gcttaggcct	agagaggctc	agctggaggc	ccacaggcca	76920
tgtagctca	ctaacagaca	tgactgatgg	cctgctgtgc	ccgtgccatc	cgcagcggcc	76980
tcagcctcag	tgtgtctttc	ccactcagtt	ctctatcggc	agtggccacc	acctgcccta	77040
ggagtctccc	ttcctatccg	tgcaacctcc	agcctgaaag	ggatttccaa	agatttaact	77100
ttgtcactct	cagtttaaaa	ccttttgatg	gctgccacg	taaagcccac	cctcttttagc	77160
ctgacagcca	aacacctggc	taatctgacc	cctgccacac	tcctgacatt	gcgacactga	77220
actcattcag	tgttcaggcc	cacacagggt	gtgccctctg	cggatctccc	tccccctgcc	77280
cacttggcaa	cagcaatctc	atcgttcagg	actcaagtcc	atgctctggt	gcctgcaaag	77340
ccttgcctgg	cccctacccc	ttccttgca	agctgtcccc	tgtgatgctc	cactgcaaac	77400
gcagctgggc	ctgtgtgcca	agccttcagc	ccccagcact	gggctgagcc	cacaggcatg	77460
tcagttagca	cctggcagat	gaagatatgc	tagtctgtgt	gtctgagcac	atctctgcac	77520
catgcaggag	agcctgtatc	ctgtgtgcct	acctggacc	cactgttcct	tcctaaagag	77580
tcactcctt	cctcccaggg	tggtggacc	tgtggcggg	tccttaagga	gtgtcccaca	77640
gatgcactca	tccttcccac	ttccacctgc	attctgggtc	tgtccagaga	ggtagacccc	77700
ctccctgtga	atgtcatgtg	ggtgccatat	aaggggcctg	cagggtcctc	atgtcattag	77760
agggctgagt	gcttgggtgga	aactgtgacc	gttcctttct	tctgtccttg	cttgtctttc	77820

ISPT-1006-Seq.txt

```

gggacctaagt aaacaagaaa ggtaggagtt gttccttctc tcttcacaca cctccccctc 77880
tactttctaag ccttggggcca gcaggagggg atgacgcctt gaccagaagt cccctggcct 77940
atggcttttaa gcagcaaaact gtccagtcag ctacagcaggc tocctgggtc aggactgagt 78000
cctcattggt gtgaggaggc agtttctgtc tactcttgc cagttcaact ctgcagagga 78060
tgcttcttct ctggggcaca tacataatac agactgcatt gctttccctg agcgtacaga 78120
gtccaccaga accatcaccc ggctcccagt tctctgagaa gttgcctaag tgctgcgaga 78180
gacagtctcg cacagagcaa agagcagtc ctgtgtggaa cagcagagag gcatgtcctt 78240
gtaccacact gagcacactc actcaaattc ttcttcccga agcacatgcg tctgcagacc 78300
acaagtagcc tctggctatt tgttggcagc tgaatcctat ggtctgtctc tgaccctgtc 78360
ctttagatag ggaaaactga ggccagtgag agaggactct gccagctag ggtgacgcct 78420
ttcccgtccc tcccctgtct ccctgggcat ttaccctgat actctgaggg ccaaaaagct 78480
ggggccctgt ctctgtgtgt gtttgtgtat ttatgtgtc atttgcatgt ttgttcccg 78540
tggttctctg tactcagctg ggtggccttg gagatagcag tcaactgtcct gcagtgcact 78600
gccttctatc caaaggagct gctcgcctct gcaacccctt cctccctgct gcaactgccc 78660
tctgtctcag ccacactcct gctctcccta cccctcctt gccctgtgtt ctctcatgtc 78720
aaggctgttc tggccctggc tctcccgccg ctacagatcc tgggaagagg tggggcagta 78780
ggaggacaga gccgtggaca tgggggctcc ttggcagcca gccatgccat gtgtcactgt 78840
ctcagccggg acctcagggt ctcaccagcc tccttctgt ctctctagga aaaggaccca 78900
ctctccgtcc tctaaggatg agcagtcgat cggactgaag gactccttgc tggccactc 78960
ctctgacact gtgagctcaa ggacagacc ccaggtaggg cactcctatg 79020
gcctgtgtgc cccagcccca gcctagcag gcctgtgggt ccgttctgca ggtctcagg 79080
tcgccactga agttcttggg ccgcatgcac ttgttctgtc tccttttctt cctttctgcc 79140
cttctccctg tgctcatcca ctttgggttg aatgactggg gagccccat atcctgcagc 79200
tggacaggtg cccaggcca ggacctctt aggtggcaaa gccacttagc cactgccttg 79260
tcttcagtcg aggcctctga atatgggctg aggacctccc agagccacg tctctgccac 79320
aggggtggcca gtgtctggcc cacgctctga cgcctccaca tgaaagaggg gcatgttagc 79380
agtgggagat gcctcaccag acatctgttg ggagatgaag tgcctgcacc tgagccttcc 79440
tggaggccga cccagggtt accataccac gtacctgccc ctctctctag ccactctcat 79500
ggggctgtgc acccttctct tctacctgaa atgttactcc tcccaacacc cagcagacac 79560
agctcagacc tctctcttg ccacaccccc cacagggtta ggtgtctctt cttggctcca 79620
ggaacctccc tcttcttcc ttttgacgcc tctcacagt agctgggatt acctcagtga 79680
cagtctctga gctctgtgt gccaggaact gtgtcttct atccccatc ccttgtattc 79740
agcgcacgat gggttcttgt tgaatgcctg tgaaatgaac acacagacaa atgaaggaat 79800
gagtgaacta atgcatacac caagggtttg tgaatgtatg agctggttat tctgcagtgc 79860
aaattacccc aaaacttagt ggcttaaaac aacaataatt atgtattatc tgtcacagtt 79920
tttgtgaggc aggaattcag acaggggcac agcaggaaca gcttgtctt attccagaaa 79980
gtctgggccc tcagccggaa gacttgaagg ctgggagcta gactcattta aagcaggggt 80040
tggcagacta tggcccgtag ccaagtacag ccaccacct gttttgtaa ataaattttt 80100
actggctggg cgtgggtggc catgcctgtg atccagcac tttgggaggc tgagccgggt 80160
ggatcacctg aggtcaggag ttcgagacca gctaataaaa tcccatctct actaaaagta 80220
caaaaattag ccaggtgtgt ggcctctgtc atcccagcta ctcaggaggc tgaggcagga 80280
gaatcacttg aaccaggag gtaaagggtt cgtgagccaa gatcgtacca tcgcattcca 80340
gcctgggtga caagagcaaa acccatctc aaaaataaac aaataaataa aattctactg 80400
gaacagacac acccatttat ttatatgcta cctacctatg gttgctttt cactgtaaag 80460
gcaccattaa atagatgcag tagataccag atgtccacaa agcctaaact atttacgctc 80520
tggcctgtta tggataccaa gtttgccaac ccctggactc taaagcctct ttcatccatg 80580
tgactggttg ttgatgagac agctctgagc ctgtcagctg ctgtcagctg ggacacccaa 80640
catgaggctt cttcagggtg cctgggcttc ctcacaacat ggtgactgag tttcatgagc 80700
atgtgtcttg agagtgtgcc aggcagacct agcaggctgt tgcaaccag catgattaga 80760
tctctgaaga atcaagcacc aggatgcgat gctgggacct ggagtgcaga gaagcctctt 80820
cggggatggg atgtgagcc atgtggttat tggctggaa aagaaggatg ggagagagct 80880
cctcagtgga agcatgtgca gaagcttggg cagattgcat gtgcgtcaaa ttatgagcac 80940
ctgagggttt ctgcagcatg agagttaggg gcttggggaa tactgagcca agagaagact 81000
ggagggttag gcagaggtcc agtcaaaaagg accttgaatg tcaggctaag gggcttagac 81060
ttctcttca ggatgccagg gaggtaggta ttaaaggttt tcagcggggg agccagggtg 81120
tcagaacccat gctttagaaa gtctactctg gctccttgag gagactggat tagagaggag 81180
aaattgaggc agggagacca tttaaaaggc cagcaaccaa gtgaaagggt gcagtgggaa 81240
cagaggggac agacttggga aacgtgaagg aggtgaggac agcagagtcc gggcttaagc 81300
ccacttgggg agaggtaagg gtggctctgc agttgtctggc tgaatgagca gggggtaggg 81360
gtgtcctggg gctgggtggc ctgtgggtct gagacttct gagctgacat cagggctgaa 81420
gccctgtggg aggggccaa gacatgttg tagtcaaagc ctgagaatag atgggctctc 81480
ccagggtgag gccagaagg agaccgggac caaaaagccc agggcagggg aggtggtgca 81540
gcattaagga aagatggatg gagagcagct agggagattg agaaggagca gccacagcca 81600
gacgagagca ggagcgcagt gtccctgatg ccagggttg gggagttgtg caagggacga 81660
gaggacttaa tgaggtaggg cagtggggac acccagtggt aggaccgtt gctttggcag 81720

```

ISPT-1006-Seq.txt

atgggggcctt	gaagagaggg	tgggtggccac	gtcctgtggg	cagaagtgtt	gcagttagca	81780
gcgtggcaag	tgggggctga	gaaagtggag	aaaccccttt	caaagatcct	gggaagatac	81840
ctgggaagga	ggcaatgagc	agggcacagt	gggagagtag	aggggtgtgg	atctgagaag	81900
gagggctctt	ttttccaatg	tggaaatcat	ctgaaaaatcg	ccaagggcaa	atttttggtat	81960
caaaaggggc	agggctgggt	tggacttaag	tatttagtca	tagagcccc	caaggctgcc	82020
gagccaccag	gctttagaag	tgctgcctc	tgggggtggg	acaccagtc	tgtattaact	82080
gggagacaga	aggagccttg	acggaacttg	tccgcagccc	cagccctca	ccgccccctc	82140
ctcttctccg	ccagccctc	gcaagcccg	tcggcacctc	cactgtgtgt	gatgggtgctg	82200
taagcagaaa	aagttaacgg	gctctctttt	cttgccccgt	tgtttttttc	gtttgtttgt	82260
ttgttttttt	ctctgcagg	tccagtgtcc	ccagtgtccc	gaatacctca	agttagtttt	82320
caaagtcccc	gtgtttgggg	gatactttgg	cttctgtgtc	tgtttccact	ccttactttt	82380
gtttacccca	tcgcctccat	ccttccttga	attcttctct	ccccctccct	ttcttctccc	82440
ccaatcccac	tgctctcctaa	cctttttcct	tccctaccct	ccccctgtgc	cacctgtgctt	82500
cctccaggcc	tgtttttctc	cccaccggcc	ccgtctctgt	tctgcctctc	tggcctccag	82560
tcccgccctg	acacccttcc	tctgcgtgc	ctctaccctc	catctcctct	cctctgtctc	82620
acacccccc	cctggctctc	gcttctctct	ctattgtgtc	tgtacttcat	gaccactcca	82680
tctacacact	tgggtcccgg	gatgacgatg	gctgtgagtc	tcccatgggtg	actgccaccg	82740
gtgaggggca	ggagggctgt	ctgcaggcag	atgcgatgga	gcccagctcc	tgtcacgtct	82800
gctgccaccg	acctgggctg	cccacccctc	ctgggaggaa	ggaagcctct	cttccatctt	82860
gagagacctg	ccaggtgccc	cctagtgtcc	ccactcagca	ccccgccacc	aaaacaggct	82920
ccacatgctc	atggcacaa	accgcccctc	gtcctctccc	accctccgcc	atccctgtcg	82980
ccgcatgtgc	tgctgtctcc	atgccaccag	ttccaagtgc	tccatggtca	cacatgttca	83040
catgtgcaca	tacatgcgtt	ggggctttct	atgccacact	gctcaagcct	cacactaatg	83100
ctgcctgtgt	atgccctacc	tcccctaggt	ctgcgagacc	accaccccat	ccccatcacc	83160
gacctggcgg	acaacatcga	gcgcctcaaa	gccaacgatg	gcctcaagtt	ctcccaggag	83220
tatgaggtga	gatgttcccg	ccccctacca	cgtgcctggc	ccaggcctac	ccaaaccagc	83280
toctgtcctg	tcctagggtcc	cagctgtggg	gggtgaggaa	gcaggggtcc	agctttttca	83340
ggagcacaga	gaggagggtt	ggcagtggta	agggtcagct	gggaaccggg	tgccctcagat	83400
gctgggtctg	cccatagcct	ggcccagcac	cttcttgggg	tcacccttag	gagatgggtt	83460
caaaaggctg	tgagtgcac	cagggtctgg	acactcagac	acgtgctcaa	gtgctcacag	83520
gcagacacaa	ggccacaggc	atacagacat	agatcagtga	taacagccac	agtagctggc	83580
atctatcaag	agcatcctgc	aggccagcac	gggtctgggc	acttggcatg	cattatctct	83640
tttggttccc	ccacagtctc	cagaaatggg	gactgttatt	atcccattct	ccaggtgagg	83700
aagcgggggc	tcagagaggg	gaagtgactt	gcccaggtca	aacagctgat	gagtagtgga	83760
gccaggattc	aaacccaggc	ctgcctgctg	ccctgtgtct	tgacatgca	tgtgtcacg	83820
tgtgtactcc	gatgccacag	ctcacgggga	gtcggggcct	cgagactggc	tgctcaggct	83880
gtacaagtcc	cgcttgagc	cctccacacg	ttcatcttgt	tctggactta	actcctagga	83940
gcctgtctgg	ggctgagcct	tcaggagtct	aggggtttcc	caccacaga	tgggtgtcgg	84000
gtgactctga	gcatccccag	gctgcccac	taggaagggg	atttgtaga	gaaggagggtg	84060
atttaaagac	aagactcctg	gccagggcga	gtcgctcacg	cctgtaatcc	cagcactttg	84120
ggaggccgag	gcgggtggat	cacctgaggt	cgagagtgtg	agaccagcct	ggccaccgtg	84180
gcgaacctgc	atctctacta	taaatacaaa	aattagccag	ctgtgtgtgg	acatgcctgt	84240
agtcccagct	acttgtgagg	gctgaggcag	gagaatcggt	tgaacccggg	aggcggagggt	84300
tgcggtgagc	caaggtcatg	ccattgcgct	ccagcctggg	tgacagagtg	agactccctc	84360
tcaaaaaata	taaaataaaa	aaatactctt	aaaaaagagt	atttttactt	aaaaaagaga	84420
gagagagacc	tcctcctctt	ccacctcctc	caagcagcag	cctgtgtctg	tcgttctgcc	84480
ttgtccacag	ctgtttcctc	agcacctggc	actggcctca	gtagatgggt	ggtggacagg	84540
caattgaggg	gttggctgag	cctaacctgt	gagtttgccg	cccttctgat	gtccaccctc	84600
agctgtgttt	gggggatgca	tcctagggtc	caaagattgc	ctttcccaag	ggctgtgggc	84660
caggttttctg	aagagaaaag	tgggcttggc	aggcaaattg	atgagtatgt	ctgcggcaca	84720
gcaaccgtgc	tgccctctgc	tatagggcc	ccctggggcc	ctgctccaca	caaggctggg	84780
ctttgggtca	cggagcccgt	aagggtgggt	ccctgcctcc	catggcctcc	acccacactc	84840
atctgtacca	tgctctacac	ctgcccctcc	ttccagcgca	gccctgtctc	cccatctggg	84900
ctcgtggggc	ctctgttcac	agtagtcccc	ttccatcttc	tacctgtctc	cctcctctga	84960
tcagagcttt	ccttacaaga	ccctcctcct	ccagggaagc	ttctcaggct	ccccaaaggct	85020
gcogtgggct	ctccctcagc	caggacccca	tagctctggt	gtcctttttt	tttttttttt	85080
tttttttttt	tttctttttt	ggaagtctcg	ctcogtcatc	caggctggag	tgcatgggeg	85140
tgatctcggc	tcagtgcagg	ctctgcctcc	tgggttcacg	ccattctcct	gcctcagcct	85200
cccaggtagc	tgggactaca	ggtgcccgcc	accacaccgg	gctaattttt	tttattttta	85260
gtagagatgg	ggtttcacccg	tgtagccag	gatgggtctg	atctcctgac	ctcgtgatcc	85320
gcccaccttg	gcctcccaag	tgctgggatt	acaggcgtga	gccactgcac	caggcctgct	85380
ctgtttgtctt	taacgttcag	tcagtcattg	atcacacatt	ttocatgtgc	cagtcocccgt	85440
gctggggatg	tggagacaca	tgccctcagg	gaacccagtc	gtggggagca	tgtgcagaca	85500
gataatcagc	attgaatatg	tgactctgac	agcatgcctt	ggtgttgaat	aggaccgaca	85560
ggcgtgcaaa	aggtgggctg	acagcaccag	agcagcctga	gggggtgggt	gtgctgcggg	85620

ISPT-1006-Seq.txt

```

gtctcacgga agcagtgcag cggctcctgtg gagagtaatg aggctgggga caacatatgg 85680
aggacattgc gtgctatgct gagaacttca gatcgtatcc atctggaaaa tgtgaagata 85740
ataatggaac ctatctcgta tgagaatttg aggaggaat acatgcaaaag tgctcacagc 85800
ggtgccaggc acactgtggg tcctcactaa cgcttcgcta ttatcattat tgctctccga 85860
ggtgaagaag agccacagaa ggcttttaag caggaatttg atattcacat ctgcattttg 85920
gaaggattat tctggctgtg gggctgagtg ggtcagagtg ggacaagagg aaagaggcag 85980
gaagaggctg agcctcaatt ggggtggcct ggcccagggc agtggcagca ggttgagag 86040
agctgagggg gtggggaagc accagaacct ggtgactggc agggcggggt tggtgaggc 86100
cggaggaatt ttgagcttga cttctagggt ctggcctggc actgaggggt gaggtgcct 86160
ttcgctaagg tgtagtccca gcagcagcgc caggtttgga ggggaagctg atgaactcag 86220
ctttgaaagg actgcggttg aagacacctc cgggtgaggt gtcagagagg ctgctgggta 86280
ctcggggaag agcctctgtg tgtctgtgag gttatgggca gctccagcat gtggtgtaag 86340
aatcagggtg gcaaatgagg tcacccagga aaggtttag agagagaaga gggcctagaa 86400
ggaaccttg aggagctctg cgtcctgccc acgggaaggg caggggagag agaggaaaca 86460
gagaaggagc agctgaaagg aagagagccg agcagggagg gatcctggac tacctgagag 86520
gggccaccat cccttccatc cttctgggt catttcatta ggtgaatgca gggcttcggg 86580
agggactctg ggtgttcaga gccctcagca gtttcgggac tgctgagag ggggccacca 86640
cctgtcctag ctcatctcat tagtgagtg cagggcttcg agagacctt cacctgcccc 86700
atcccagctc agaccactct accaggcaag gggatttggg accatggtca gaggagtccc 86760
cagatccatc ctttctgtg agtgatgtg gcaacctgtg agctccatgg ctggcaccac 86820
gagatagagg gcctggctgt ggctgtgga gtgaaagcag gatgtgagca tcaccgggaa 86880
ggctgggtcc cctgcaggag aagcagggtc accttggctc ttacccacc ccaccgctt 86940
tctccattct ttgcagtcca tcgacctgg acagcagttc acgtgggaga attcaaacct 87000
ggaggtgaac aagcccaaga accgctatgc gaagtgcac gcctacgacc actctcagat 87060
catccttacc tctatcgatg gtgagccaag ggggtgcccc tcccatcccc ttgctctccc 87120
ccttgctagc tagggcaaca tgtcattcta cagaggatgt ccacgagtct caggggtgca 87180
ctgaggcatg gtggctggg ctggggaccc tgtagtaatg ccctcccacc tccttcttta 87240
tccataggcg tccccgggag tgactacatc aatgccaaat acatcgatgg ctaccgcaag 87300
cagaatgcct acatgcgcac gcaggcccc ctgcccaga ccatgggcga tttctggaga 87360
atggtgtggg aacagcgcac ggccactgtg gtcagtatga cacggctgga ggagaagtcc 87420
cgggtgaggc tgcaggccc tgcaggagg cgggtgggaa atgccagcc acaaggatg 87480
acagggcacc ttctctgtg ccgcttctt ctgtggagga agtcgctcaa gtgatcccca 87540
gatgctattg ttactggggg tattatgctc cccaaatact ggggtgttct gggatacagc 87600
atgttcccca atgtctagt gtttcttaa gatgttaata tgtttcacca aatgctgtca 87660
ttttcggaga atgttaatgt gttccccagt tgctggcgtg ttcccggggt attcgtgtgt 87720
tccccagatg ctggagtgtt cctggggcat taacacatct cctaagttaa ttagtggaag 87780
gagctgctgt tatctgtttt tggactgcaa agcattgact ggaacgtaaa atttacagag 87840
cttgaaaatg gcacataaac gttatgggta aatttggcag aaaatgtgcc tggtcgcatc 87900
tggcgttgaa taaataatgt tcaattatga cccttattcc actagctagg gcaggcggt 87960
gacatagctt gaggacctga tgtgcttgt ggaggacagg gggcaatgga tctgagagct 88020
cagggtctgg gggctttgta gccagaaagg ctacagccag ggagttagc agcctccacc 88080
ctgctctctg ccgtctgagc ctgtgggctt ccttcagcct gccctgctca tcctcctgca 88140
ggtaaaatgt gatcagtagt ggccagcccg tggcaccgag acctgtggcc ttattcaggt 88200
gacctgttg gacacagtgg agctggccac atacactgtg cgcaccttcg cactccaca 88260
ggtatagcct ttcccagtg catatctctt acccagacac tgtaaggaca gtggcctggg 88320
tgtgtgtgtg tgggtcgggg ggaagctgga gcctgggtgt tggagggctc gaggtcagg 88380
tgtgtgagtg atgtgatgat ccatgttatg ggaacagtgc taggagcttc aggtactct 88440
gtgtggcttc tgagtcccat ggggaagtgg cgggtatggc ctacgcatca ggtcattcag 88500
tcctgagctc atggcaggta ggctcctagt cgccagtagt tccccacttt gtccccaga 88560
gtggctccag tgagaagcgc gagctgcgtc agtttcagtt catggcctgg ccagaccatg 88620
cccttccctg gtacccaact ccttccctag ccttccctag acgggtcaag gcctgcaacc 88680
cagtagacgc agggcccattg gtggtgcact gcaggtaga gggtagatg ccaccagag 88740
gggtgggtgg ggtgggagggt gggggcgct gtgcctcaag ctgagccgt gtctgcagc 88800
gcggcgctgg gccgcaccg ctgtctcatc gtgattgatg ccatgttgga gcgatgaa 88860
cacgagaaga cgggtgacat ctatggccac gtgacctgca tgcgatcaca gaggaactac 88920
atggtgcaga cggaggaaca gtacgtgttc atccatgagg cgctgctgga ggctgccacg 88980
tgccggccaca cagaggtgcc tgcccgcaac ctgtatgccc acatccagaa gctgggcca 89040
gtgctccag gggagagtgt gaccgccatg gagctcagat tcaaggtggg gctcgggtg 89100
gcctgcttgg ctccagggcc tagactgggt catgcagatg acccccacc ccacaggaag 89160
cctggcctga ccaatccctg cctctcaata gtgtctggcc agctccaagg ccacacgtc 89220
ccgcttcac agcgccaacc tgccctgcaa caagttcaag aaccggctgg tgaacatcat 89280
gccctacgaa ttgaccctg tgtgtctgca gccatccgt ggtgtggagg gctctgacta 89340
catcaatgcc agcttccctg atggttatag gtcagcatgc atgtcactgc cccaccatgc 89400
cctacagggg cctaggcctg tgctggctg gtgggggtg gcagcagag agggccagcc 89460
tagaagacca gagagggtg gtagagcag tgaggacttc ctggaggag ggtgatctga 89520

```

ISPT-1006-Seq.txt

```

gcaggggcccc aaggggctag gcagcctaag ggggagactct aggggagca gcacctccag 89580
catgtccagt cttatgtcca cccagacag cagaaggcct acatagctac acaggggcct 89640
ctggcagaga gcaccgagga cttctggcgc atgctatggg agcacaattc caccatcatc 89700
gtcatgctga ccaagcttcg ggagatgggc aggggtgagcc caccctttcc cccagggccc 89760
ctgtcatacc tgggagaaca ccagccaccc ttgggggagc tgccgcctat gttactgtct 89820
cctttgacac cccagctgct tgtcagcatg gcctcaggcg cccgttatta ctacctgagg 89880
catctgtccc agaatcctgt gaagcctggc acccctcccc tattccttct cacctgatta 89940
tgggggcccg accctctgtc cacaggagaa atgccaccag tactggccag cagagcgctc 90000
tgctcgctac cagtactttg ttgttgaccc gatggctgag tacaacatgc cccagtatat 90060
cctgcgtgag ttcaaggcca cggatgcccg ggtgagttag tgcattgagt gtgtccataa 90120
cgctgcctgt ccacacgctg ggtggatggc tgccctgcat gtaccttagc tcaagcttca 90180
gaaatctgag gcggtgggtg ggtattaggg tgtgagcaca tctccccctg tggcctcggg 90240
tgcaagtaca cagatgcatg cctgtatcat ggtactaccc ttgtctagtc cagaggggtg 90300
gctgcctaag gcacgaattc taatcatgta cccacccac ctttcccagg atgggcagtc 90360
aaggacaatc cggcagttcc agttcacaga ctggccagag cagggcgctg ccaagacagg 90420
cgagggattc attgacttca tcgggcaggt gcataagacc aaggagcagt ttggacagga 90480
tgggcctatc acggtgcact gcaggtggga ctggccccct ggagggtggt ggtgggtggg 90540
cctgaaggcc tggcagaccc actgcatgag gcaagcagga ctccctgacc aactgtgttt 90600
ctgagcagtg ctggcggtgg ccgcaccggg gtgttcatca ctctgagcat cgtcctggag 90660
cgaggtcgct acgagggcgt ggtcgacatg ttccagaccg tgaagaccct gcgtacacag 90720
cgtcctgcca tgggtgcagac agaggttaacg cagaccaggc tgcaaggcca gggccttggc 90780
agcagcgctg ctgggaaccc taggctttag caacagtttg atgccacag gcatgtgcat 90840
tcatlcatgc tgccaacctt tcacgtggcc tgcgataggc atggtggtgt gtgcttatgg 90900
tctacctac ttgggaggtt gatgtgggag aatcacttga ggtcagaagt tcgaggctgc 90960
agtactctat gattatacca gcctactcca ccttgggtgg cagagcaaga ccctgttgct 91020
gaaaacaaaa caaaacaaaa caaaaatgct gcaacattgc ctgtgctgcc tgggggctca 91080
ggggattgat gagttaagatg tgttctttca ttcggcagct ctctgctgag cccagtggtt 91140
gtgcctggct ctgggcaagg ttgcacagag caatccttat ggggtgcccc gtccaggagca 91200
gagaacatg attgggtagg cagatggaag gcaggtagat gtgggggcct gagagaatga 91260
caggagagag atgagccttc agaggctcct tcaggctccc ccgcacactg cctgatgtag 91320
ctgccagggt ccagcacctg ctcttggcca gcagaggcta actccatggc tgcagtgtga 91380
gtgtcagctg tgtagtgggg gtgtccactg gcgcgacca cactgaccag cccctatcc 91440
tggcaggacc agtatcagct gtgtaccgt gcggccctgg agtacctcgg cagctttgac 91500
cactatgcaa cgttaactacc gttccctct cctccgcccac ccccgctg gggctccgga 91560
ggggaccag ctctctgag ccataccgac catcgtccag ccctcctacg cagatgctgt 91620
cactggcaga gcacagccca cggggtcac agcgtttcag gaacgttgcc acaccaatca 91680
gagagcctag aacatccctg ggcaagtggg tggcccagca ggcaggcact gtggcccttc 91740
tgtccaccag accacgcttg agcccgcttc aagctctctg ttgcgctccc gcatttctca 91800
tgcttcttct accgggtggg ggttggggca aagcctcctt tttaatacat taagtgggtt 91860
agactgaggg attttagcct ctccctctg atttttcctt tcgcgaatcc gtatctgcag 91920
aatgggccac tgtagggttt ggggtttatt ttgttttgtt ttttttttcc ttgagttcac 91980
tttggatcct tattttgtat gacttctgct gaaggacaga acattgcctt cctcgtgcag 92040
agctggggct gccagcctga gcggaggctc ggcctggtgg cgggaggcag tgctgatccg 92100
gctgctcctc cagcccttca gacgagatcc tgtttcagct aaatgcaggg aaactcaatg 92160
tttttttaag ttttgttttc cctttaaagc ctttttttag gccacattga cagtgggtgg 92220
cggggagaag ataggaaca ctcatccctg gtcgtctatc ccagtgtgtg ttaaacattc 92280
acagcccaga accacagatg tgtctgggag accctggcaa ggcattcctc atcaccatcg 92340
tgtttgcaaa ggttaaaaaa aaacaaaaaa accacaaaaa taaaaaaaca aaaaaacaaa 92400
aaacccaaga aaaaaaaaaa gactcagccc ttggcttctg cttcaaacc ccaaganggg 92460
aagcaactcc gtgtgcctgg ggttcccag ggagctgctg gctgacctgg gccacagag 92520
cctggctttt gtccccagca ttgcagtatg gtgtggtgtt tgtaggctgt ggggtctggc 92580
tgtgtggcca aggtgaatag cacaggttag ggtgtgtgcc acaccccatg cacctcaggg 92640
ccaagcgggg gcgtggctgg cctttcaggt ccaggccagt gggcctggta gcacatgtct 92700
gtcctcagag caggggccag atgattttcc tccctggttt gcagctgttt tcaaagcccc 92760
cgataatcgc tcttttccac tccaagatgc cctcataaac caatgtggca agactactgg 92820
acttctatca atggtaactc aatcagtcct tattatcca gcttctgag ggcaggag 92880
agcgctctt cctctgggca gcgtatctat gataggttag tggggcgagg gaagggtgca 92940
tagctgtttt agctgaggga cgtggtgccg acgtcccca acctagctag gctaagtcaa 93000
gatcaacatt ccagggttgg taatgttggg tgatgaaaca ttcattttta ccttgtggat 93060
gctagtctg tagagttcac tgtgttacac agtctgttt ctattgttta agaaaaacta 93120
cagcatcatt gcataattct tgatggtaat aaatttgaat aatcagattt cttacaaacc 93180
aggactctgt ctcagctgtt tctggaacca aagagtctgg gccaaatcag tagctaggat 93240
gggttctgga gattccctgc tcctgaggag acggggaggg taccctaagt atttgtgcca 93300
gtgtaggctc ctggcatggc taccacattt cagaaaggag tggttataaa ccctgaaaac 93360
caggccacca agagccagcc aggcagagc caccagtga tgtgaagagc accctaggcc 93420

```

ISPT-1006-Seq.txt

```

ggggagcata ccctttgcct ctctttccct ttaagattct gtgggttgca ctatcggggc 93480
attgggactg cccctctccc actaccttgg aggagagggg tggccctgtg gcagtagaga 93540
ctgaatgtat ggaaatttgt tagtgagatc tcctgtaatt attgcaatgt ggataatgga 93600
cacaaaaaac agtgtgtcca tctggcccct ggacacacag ctgcatcacc cactgagctg 93660
tgcagctgct ccactggtga gcagacaagt cctaccaggt tgtcaaattg tggaacttct 93720
agggatacag atgaaggaga cccagaacaa gctgcgaaga gaaatgcgta agtcagcaac 93780
aaccacacca aggcagcatc tgacccaggg aaggcttcct ggaggaggtg gcattcagag 93840
tgtttcgtag aatgagtagc agttagtttt tttttgttta tttttgagat ggagtccac 93900
tctgtcgcaa ggctggagtg cagtggcgtg atctcggctc actgcaacct ctgcccccg 93960
ggttcaagca attcttctgc ctttaccctc ctgagtagct g 94001

```

<210> 21
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21
 gactttcttc cccttcttca 20

<210> 22
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22
 ttctccacca ctttcagctg 20

<210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23
 tggagaaacg aggagccacg 20

<210> 24
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24
 cccggaccgt ggtggagccc 20

<210> 25
 <211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25
cacggagtac tgggtgataa 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26
ctgatgccat ccaccacatg 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27
tgtgtgtgcc cgcacccaca 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28
accagcaccg ggctgctctc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29
tgcacagcag tggagttcag 20

<210> 30
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30
gcatgggtccg ggactggatg

20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31
aagggcacag ctgacttata

20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32
agcttccgca tcgagtgcc

20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33
gtgcggatgg acaccaggtg

20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34
acaatgtaga accacctgac

20

<210> 35
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35
gcgcttctgg tccatgggtt 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36
gaggatggcg atgacaatga 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37
ggtggtctcg catacctggg 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38
ccatcgttgg ctttgaggcg 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39
tcgcccattgg tctcgggcag 20

<210> 40
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40
accgtcttct cgtgcttcat

20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41
gtcagcatga cgatgatggt

20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42
tgtccttgac tgcccatccc

20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43
agcactgcag tgcaccgtga

20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44
atagcgcata cgctccagga

20

<210> 45
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45
gccgcacggt agcacagctg 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46
gctcagagga gctgggtccc 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47
aacagagagc ttgaagcggg 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48
acctttgcaa acacgatggt 20

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49
gcccccgctt ggccctgagg 20

<210> 50
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50
ctaccaggcc cactggcctg 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51
tagtcttgcc acattggttt 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52
ccacttacct atctagatag 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53
atcttgactt agcctagcta 20

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54
gtaaaaatga atgtttcatc 20

<210> 55
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55
ctacagcact agcatccaca 20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56
gtttttctta acaaataaaa 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57
gggcaccatc gtcctccctg 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58
tggcttcacg tcgctgcacc 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59
cggtgcggcc aactggcatc 20

<210> 60
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60
tttgaagag ctttcactgt

20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61
ggttgggtcg aaggtgacct

20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62
cccatatccg agcgtgcagc

20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63
tataggcagc aacagtaacg

20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64
gcgggtgtct gtcgtgatgt

20

<210> 65
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65
cagagccttt gctggtccat

20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66
tgtacagaat cttaaagggc

20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67
ggtttagtaa gccccggtag

20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68
cactggtagc tcaagtccgg

20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69
ggtccttttc cttttgaaca

20

<210> 70
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70
tggccgtgcg ctgttcccac

20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71
gtcacctgaa taaggccaca

20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72
tcatccgctc caacatggca

20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73
atcgcatgca ggtcacgtgg

20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74
tctgtgatcg catgcaggtc

20

<210> 75
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75
ccgtgatagg cccatcctgt 20

<210> 76
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76
agcggtagtt acgttgcata 20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77
caatgttctg tccttcagca 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78
aagccaggct ctgtgggccc 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79
agccacgccc tcatagcgca 20

<210> 80
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80
ggtcactcac cgcctatcca

20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81
aactcccggg taactccctt

20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82
agaggcccag agaggttaag

20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83
actcaatgac ctgtcagagg

20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84
ttgatcctcc caagagcccc

20

<210> 85
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85
gcactgccta ccgtcctcat 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86
tccaggacga tgctcagagt 20

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 87
aacatgtcga ccacgccctc 20

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88
tctgcgttac ctctgtctgc 20

<210> 89
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89
gatactggtc ctgccaggat 20

<210> 90
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 90
ctgtccttca gcagaagtca 20

<210> 91
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91
tgaaaggcca gccacgcccc 20

<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92
gctgggagct gactttcttc 20

<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93
gctgcactcg taatggctgg 20

<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94
acttaccgga accgtggtgg 20

<210> 95
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 95
acc caactta cccggaccgt

20

<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 96
tgctcacggc tgatgccatc

20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 97
agacatgcac agcagtggag

20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 98
cttggcaaac acttgctcca

20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 99
tcccgccac acggtcaatg

20

<210> 100
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 100
gcggtagctc ttcttgctcc 20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 101
ccaggaacac catcaatgga 20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 102
ctccagaaat cgcccatggt 20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 103
cacacttcac ccgggatttc 20

<210> 104
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 104
tggagccact cttatggagg 20

<210> 105
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 105
gtcacgtggc catagatgtc

20

<210> 106
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 106
cccgaagctt ggtcagcatg

20

<210> 107
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 107
ctgcccattt cccgaagctt

20

<210> 108
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 108
cggattgtcc ttgactgccc

20

<210> 109
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 109
tccagggccg cacggtagca

20

<210> 110
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 110
agcagtagtt acgttgcata 20

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 111
ggtatggctc agaggagctg 20

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 112
ggctctctga ctggtgtggc 20

<210> 113
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 113
cacttggccg ggtggacgag 20

<210> 114
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 114
gagaagcatg agaacgcgga 20

<210> 115
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 115
tccttccgca gaagttgtac

20

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 116
cacaaggaag gcgagttact

20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 117
agtcacgctg cctcccgggc

20

<210> 118
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 118
ggacagcagg agtcacgctg

20

<210> 119
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 119
ccccagacac gtctgtggtt

20

<210> 120
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 120
cccgaggtgg ccagaaccca

20

<210> 121
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 121
tcacctgtgc cattcatttc

20

<210> 122
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 122
cagacatgtg ctaccaggcc

20

<210> 123
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 123
ctgaggacag acatgtgcta

20

<210> 124
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 124
agctgcaaac caggagagaa

20

<210> 125
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 125
aagtcagta gtcttgccac

20

<210> 126
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 126
tgcccagagg aagagaccct

20

<210> 127
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 127
aacagctatg cacccttccc

20

<210> 128
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 128
gcatccacaa ggtaaaaatg

20

<210> 129
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 129
acagtgaact ctacagcact

20

<210> 130
<211> 20

<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 130
catgatcgct gtagtttttc

20

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 131
agatacacag ctgagacaga

20

<210> 132
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 132
ggctcacccc cttgggagga

20

<210> 133
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 133
cgtggctcct cgtttctcca

20

<210> 134
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 134
gggctccacc acggtccggg

20

<210> 135
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 135
ttatcaccca gtactccgtg

20

<210> 136
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 136
tgtgggtgcg ggcacacaca

20

<210> 137
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 137
ctgaactcca ctgctgtgca

20

<210> 138
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 138
catccagtcc cggaccatgc

20

<210> 139
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 139
cacctggtgt ccatccgcac

20

<210> 140
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 140
aacccatgga ccagaagcgc

20

<210> 141
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 141
tcattgtcat cgccatcctc

20

<210> 142
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 142
cccaggatg cgagaccacc

20

<210> 143
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 143
cgctcaaag ccaacgatgg

20

<210> 144
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 144
ctgcccgaga ccatgggcga

20

<210> 145
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 145
atgaagcacg agaagacggt

20

<210> 146
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 146
accatcatcg tcatgctgac

20

<210> 147
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 147
gggatgggca gtcaaggaca

20

<210> 148
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 148
tcacggtgca ctgcagtgct

20

<210> 149
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 149
tcctggagcg catgcgctat

20

<210> 150
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 150
cagctgtgct accgtgcggc

20

<210> 151
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 151
gggacccagc tcctctgagc

20

<210> 152
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 152
cccgttcaa gctctctgtt

20

<210> 153
<211> 20
<212> DNA

<213> H. sapiens

<220>

<400> 153
accatcgtgt ttgcaaaggt

20

<210> 154
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 154
cctcagggcc aagcgggggc

20

<210> 155
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 155
aaaccaatgt ggcaagacta

20

<210> 156
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 156
ctatctagat aggtaagtgg

20

<210> 157
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 157
tagctaggct aagtcaagat

20

<210> 158
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 158
gatgaaacat tcatttttac

20

<210> 159
<211> 20

<212> DNA
<213> H. sapiens

<220>

<400> 159
tgtggatgct agtgctgtag

20

<210> 160
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 160
cagggaggac gatggtgccc

20

<210> 161
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 161
ggtgcagcga gatgaagcca

20

<210> 162
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 162
gatgccagtt ggccgcaacg

20

<210> 163
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 163
aggtcacctt cgacccaacc

20

<210> 164
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 164
cgttactgtt gctgcctata

20

<210> 165

<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 165
acatcacgac agacacccgc

20

<210> 166
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 166
atggaccagc aaaggctctg

20

<210> 167
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 167
ctaccggggc ttctacaacc

20

<210> 168
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 168
ccggacttga gctaccagtg

20

<210> 169
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 169
tggtcaaaag gaaaaggacc

20

<210> 170
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 170
gtgggaacag cgcacggcca

20

<210> 171
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 171
tgtggcctta ttcaggtgac

20

<210> 172
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 172
tgccatgttg gagcggatga

20

<210> 173
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 173
ccacgtgacc tgcattgcgat

20

<210> 174
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 174
gacctgcatg cgatcacaga

20

<210> 175
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 175
acaggatggg cctatcacgg

20

<210> 176
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 176
tatgcaacgt aactaccgct

20

<210> 177
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 177
tgctgaagga cagaacattg

20

<210> 178
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 178
gggcccacag agcctggctt

20

<210> 179
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 179
tgcgctatga gggcgtggct

20

<210> 180
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 180
aagggaagtta cccgggagtt

20

<210> 181
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 181
atgaggacgg taggcagtgc

20

<210> 182
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 182
actctgagca tcgtcctgga

20

<210> 183
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 183
tgactttctgc tgaaggacag 20

<210> 184
<211> 20
<212> DNA
<213> H. sapiens

<220>

<400> 184
ggggcgtggc tggcctttca 20

<210> 185
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 185
acgggtccggg taagttgggt 20

<210> 186
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 186
tggagcaagt gtttgccaag 20

<210> 187
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 187
cattgaccgt gtgggcggga 20

<210> 188
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 188

aagcttcggg agatgggcag

20

<210> 189
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 189
gggcagtcaa ggacaatccg

20

<210> 190
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 190
tatgcaacgt aactactgct

20

<210> 191
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 191
cagctcctct gagccatacc

20

<210> 192
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 192
gccacaccag tcagagagcc

20

<210> 193
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 193
tccgcgttct catgcttctc

20

<210> 194
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 194
gtacaacttc tgcggaagga

20

<210> 195
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 195
tgggttcttg ccacctcggg

20

<210> 196
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 196
gtggcaagac tactggactt

20

<210> 197
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 197
agggtctctt cctctgggca

20

<210> 198
<211> 20
<212> DNA
<213> M. musculus

<220>

<400> 198
agtgtgttag agttcactgt

20